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ABSTRACT 
 
ANALYSIS OF 45S rDNA PROMOTER METHYLATION AND 
EXPRESSION OF rRNA TRANSCRIPTS IN BREAST CANCER 
 
Gurbet Karahan 
Ph.D. in Molecular Biology and Genetics 
Advisor: Assoc. Prof. Dr. I!ık Yulu" 
July, 2015 
 
Ribosome biogenesis has a central role in cell growth and proliferation that is usually 
disrupted in tumor cells by the inactivation of tumor suppressor genes and activation 
of oncogenes. Ribosomal RNA (rRNA) gene expression is one of the most important 
factors regulating ribosome production, which is controlled by CG rich 45S 
ribosomal DNA (rDNA) promoter. The effect of DNA methylation at 45S rDNA 
promoter on rRNA gene expression is a subject of controversy in the literature. In 
this thesis, a 434 bp region (-380 bp to +54 bp) spanning both upstream control 
element (UCE) and core promoter located in 45S rDNA promoter containing 54 
CpGs was analysed in breast cancer. We also analysed the related rRNA expression 
levels in the same samples in order to clarify the role of 45S rDNA promoter 
methylation on rRNA gene expression.  
45S rDNA promoter region was highly methylated (74%-96%) in all cell lines 
including non-tumorigenic breast cell line (MCF10A). Even though 45S rDNA 
promoter region of breast cancer cell lines are extensively methylated, rRNAs (18S, 
28S, 5.8S and 45S ETS) were expressed independent of the heavy methylation. 
Expression levels of rRNAs are assessed either using housekeeping genes (ACTB, 
TBP, ACTB&TBP) or geometric mean of rRNAs (GM-rRNAs). We propose GM-
rRNA normalization as a new method to identify relative expression differences 
between rRNA transcripts. 
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Epigenetic drugs 5-Aza-2’-deoxycytidine (5-AZA) and Trichostatin A (TSA) were 
used to determine the effect of DNA methylation and histone acetylation on rRNA 
expression. Demethylation with 5-AZA resulted in an unexpected decrease in the 
expression of all rRNA. TSA treatment did not lead to any significant expression 
difference in cell lines. 
To better evaluate the effect of DNA methylation on the expression of rRNA 
transcripts we analysed the methylation status of 19 breast tumor and matched 
normal frozen tissue samples. The results showed that majority of the tumors (13/19) 
have significantly higher methylation levels than their normal pairs. Using the GM-
rRNA as reference helped us to determine significant differences in the proportionate 
expression of rRNAs in these tissue samples. The 5.8S rRNA ratio was significantly 
lower whereas the 18S rRNA ratio was significantly higher in breast tumor samples. 
Furthermore, the 45S rDNA promoter methylation levels in normal breast tissue 
samples were negatively correlated with the18S rRNA ratio but this correlation was 
disrupted in breast tumors. Similarly, rRNA transcript levels were significantly 
correlated with each other in normal samples, were lost in tumor samples. It is clear 
that, there is a dysregulation both in rDNA methylation levels and spliced rRNA 
transcripts specific to breast tumor samples, which was not observed in normal breast 
tissues. rRNA gene expression is controlled by mechanisms other than promoter 
DNA methylation. Tumorigenesis may cause disruption of many control mechanisms 
that are required for proper rRNA expression, splicing and maturation, resulting in a 
dysregulation of the correlation between spliced rRNA expression levels, which 
should be investigated further. 
 
Keywords: Breast Cancer, DNA methylation, 45S rDNA promoter, rRNA gene 
expression 
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ÖZET 
 
MEME KANSER#NDE 45S rDNA PROMOTÖR MET#LASYON 
VE rRNA TRANSKR#PTLER#N#N #FADE ANAL#Z#  
 
Gurbet Karahan 
Moleküler Biyoloji ve Genetik Doktora Tezi 
Danı!man: Doç. Dr. I!ık Yulu" 
Temmuz, 2015 
 
Tümör hücrelerinde genellikle tümör baskılayıcı genlerin inaktivasyonu ve 
onkogenlerin aktifle!tirilmesi ile bozulan ribozom biyogenezi hücre büyümesi ve 
bölünmesinde merkezi bir rol oynar. Ribozomal RNA (rRNA) gen ifadesi ribozom 
üretimini düzenleyen en önemli faktörlerden biridir ve CG’ler bakımından zengin 
45S ribozomal DNA (45S rDNA) promotörü tarafından kontrol edilir. 45S rDNA 
promotörünün rRNA ifadesi üzerindeki etkisi literatürde tartı!malı bir konudur. Bu 
tezde, 54 CpG içeren, 45S rDNA promotöründe bulunan yukarı kontrol elementini 
(Upstream control element, UCE) ve çekirdek promotörü (Core promoter, CP) 
kapsayan 434 bç lik bir bölge meme kanserinde bisülfit dizileme yöntemi 
kullanılarak analiz edilmi!tir. 45S rDNA promotör metilasyonunun rRNA gen 
ifadesindeki rolünü netle!tirmek için aynı örneklerde ilgili rRNA ifade düzeylerini de 
analiz ettik.  
45S rDNA promotör bölgesi tümörijenik olmayan meme hücre hattı (MCF10A) da 
dahil olmak üzere tüm meme kanseri hücre hatlarında oldukça metillenmi!tir. Her ne 
kadar 45S rDNA promotör bölgesi hücre hatlarında yo"un biçimde metillenmi! olsa 
da rRNA’lar (18S, 28S, 5.8S ve 45S ETS) bu a"ır metilasyondan ba"ımsız olarak 
ifade olmu!lardır. rRNA’ların ifade düzeyleri ya referans genleri (ACTB, TBP, 
ACTB&TBP) yada rRNA’ların geometrik ortalaması (GM-rRNAs) kullanılarak 
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de"erlendirilmi!tir. GM-rRNA normalizasyonunu rRNA’lar arasındaki göreceli 
farklılıkları tanımlamak için yeni bir yöntem olarak öneriyoruz. 
DNA metilasyonu ve histon asetilasyonunun rRNA ifadesi üzerindeki etkisini 
belirlemek için epigenetik ilaçlar 5-Aza-2’-deoksisitidin (5-AZA) ve Trikostatin A 
(TSA) kullanılmı!tır. 5-AZA ile demetilasyon TBP, ACTB veya ACTB&TBP 
normalizasyonları ile tüm rRNA türlerinde beklenmedik bir azalmayla 
sonuçlanmı!tır. TSA muamelesi hücre hatlarında anlamlı bir ifade farkına sebep 
olmadı. 
DNA metilasyonunun rRNA transkriptlerinin ifadesi üzerindeki etkisini daha iyi 
de"erlendirmek için 19 dondurulmu! meme tümörü ve e! normal doku örneklerinin 
metilasyon durumları analiz edildi. Sonuçlar tümörlerin ço"unun (13/19) normal e! 
dokularına göre metilasyon seviyelerinin anlamlı olarak daha yüksek oldu"unu 
gösterdi. Referans gen olarak GM-rRNA’yı kullanmamız bu doku örneklerinde 
rRNA‘ların ifadesindeki anlamlı oransal farklılıkları belirlemek için bize yardımcı 
olmu!tur. Meme kanseri örneklerinde 5.8S rRNA oranı anlamlı olarak dü!ük iken 
18S rRNA oranı anlamlı olarak yüksektir. Ayrıca normal meme dokularında 45S 
rDNA promotör metilasyon seviyeleri ile 18S rRNA oranı negatif olarak korele 
ederken bu korelasyon meme tümörlerinde bozulmu!tur. Benzer !ekilde normal doku 
örneklerindeki rRNA transkriptlerinin seviyeleri birbirleri ile korele ederken tumor 
hücrelerinde bu kaybolmu!tur. Hem rDNA promotör metilasyon seviyelerinde hem 
de kırpılan rRNA transkriptlerinde meme tümör örneklerine özgü normal meme 
dokularında gözlemlenmeyen bir bozulma oldu"u açıktır. rRNA gen ifadesinin 
meme kanserinde promotör DNA metilasyonundan ba!ka mekanizmalar tarafından 
kontrol edilmektedir. Tümörigenez, düzgün rRNA ifadesi, kırpılması ve 
olgunla!ması için gerekli birçok kontrol mekanizmasının bozulmasına neden olabilir 
ve bu kırpılmı! rRNA ifade seviyelerindeki korelasyonun bozulmasıyla sonuçlanan 
durumun daha iyi ara!tırılması gerekir. 
 
Anahtar sözcükler: Meme kanseri, DNA metilasyonu, 45S rDNA promotörü, rRNA 
genlerinin ifadesi 
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DNMT  DNA methyltransferases 
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1 INTRODUCTION 
1.1 Breast Cancer 
 
Breast cancer is a type of cancer that develops in breast tissue. Remarkable advances 
have been made in the diagnosis, prevention and treatment of breast cancer through the 
clinical application of scientific developments in recent years. Yet breast cancer still 
affecting the lives of millions worldwide. 
Breast cancer is the most common type of cancer among women and is responsible for 
25% of all new cases. It was the most frequent cause of cancer deaths in women living in 
less developed regions (14.3 % of all cancer deaths) and the second most common cause 
of cancer deaths in more developed regions (15.4% after lung cancer) in 2012 (Figure 
1.1) (Ferlay J et al. 2013). Breast cancer is derived either from the lining of ducts 
carrying milk (ductal carcinoma) or from the milk glands called lobules (lobular 
carcinoma). Breast carcinoma more frequently arises from ductal tissue and is then called 
ductal carcinoma (invasive and in situ). Breast cancer occurs in both genders but male 
breast cancer is very uncommon (http://www.cancer.gov/cancertopics/types/breast).  
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Figure 1.1. Estimated age-standardized incidence and mortality rates of different cancer 
types in women according to the Globocan 2012 (Ferlay J et al. 2013). Figure taken from 
(Ferlay J et al. 2013), Copyright (2015) IARC. 
 
1.1.1 Epidemiology and Risk Factors of Breast Cancer 
 
Breast cancer is associated with several risk factors such as age, age of menarche and 
menopause, age of first pregnancy, life style and family history. The breast cancer 
incidence increases with age (McPherson et al. 2000).  
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Menarche at young age and late menopause increase the time of exposure to estrogen as 
well as the risk of getting breast cancer. Parity and age at first childbirth are also 
important factors. The breast cancer risk is twice as high in women who had their first 
child after the age of 30 compared to women who had their first child before the age of 
20 (McPherson et al. 2000). Breastfeeding was suggested to have a protective role against 
breast cancer, breastfeeding for one year is estimated to lead to a 4.3% reduction in breast 
cancer risk (Anon 2002). Exposure to estrogen is an important regulator of cell 
proliferation of breast cells but breast cancer pathogenesis does not solely depend on 
estrogen and estrogen receptors. Some of the patients are ER (estrogen receptor) positive 
but do not respond to anti-estrogen treatment (Higa 2009). Patients with proliferative 
breast disease also have a higher risk of breast cancer compared to the general population 
(Hartmann et al. 2005).  
Lifestyle risk factors of breast cancer includes alcohol consumption, obesity, physical 
inactivity and radiation exposure (Danaei et al. 2005). 
Familial or somatic mutations of BRCA1 and BRCA2 are well-known high risk factors for 
breast cancer formation (Lalloo & Evans 2012). Breast cancer history in the first degree 
relatives increase the risk of breast cancer (Higa 2009) and familial cases constitute 10% 
of all the breast cancer cases (McPherson et al. 2000). Hereditary breast and ovarian 
cancers can arise from constitutional mutations in BRCA1 gene. BRCA1 gene is involved 
in double-strand break recognition mechanism during DNA repair but also implicated in 
several other cellular functions such as; chromatin remodelling, transcriptional 
regulation, cell cycle checkpoint control and genomic stability (Campeau et al. 2008). 
The initial studies claimed that BRCA1 and BRCA2 mutations are the main cause of the 
familial cases, however recent studies identified that mutations at these two genes consist 
only 25-28% of the hereditary cases (Gerdes et al. 2006; Melchor & Benítez 2013). Other 
genes are also implicated in increased risk factors for breast cancer such as TP53, CDH1, 
PTEN, RAD51C, STK11 and RAD51D with high penetrance and CHEK2, ATM, PALB2 
and BRIP1 low or moderate penetrance (reviewed in (Vargas et al. 2011)). Mutations in 
TP53 and PTEN genes, both of which encode proteins that function as key regulators of 
cell division, account for only a minority of inherited breast cancers (Higa 2009). 
Genome-wide association studies (GWAS) identified breast cancer susceptibility loci 
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including 2q33, 2q35, 5q11, 5p12, 8q24, 10q26, 11p15 and 16q12 (Cox et al. 2007; 
Easton et al. 2007; Stacey et al. 2007). Despite intensive studies performed with GWAS 
and next generation exome sequencing, no single high penetrance allele was identified to 
explain remaining large fraction of breast cancer cases (Smith et al. 2006; Rosa-Rosa et 
al. 2008; Snape et al. 2012; Gracia-Aznarez et al. 2013). Remaining susceptibility is more 
likely to depend on the involvement of multiple low penetrance genes. 
 
1.1.2 Breast Cancer Progression 
Progression of breast cancer is similar to Vogelstein’s model for colon cancer 
development (Vogelstein et al. 1988), a multi-step process including changes from 
normal (terminal duct lobular unit) to hyperplasia, carcinoma in situ, invasive carcinoma 
and metastasis (Figure 1.2) (Wellings et al. 1975). The traditionally accepted multi-step 
progression of breast cancer schematized in Figure 1.2, is only based on morphological 
and epidemiological studies. 
 
 
Figure 1.2. Breast cancer progression model (Polyak 2007). Figure taken from (Polyak 
2007), Copyright (2015), The Journal of Clinical Investigation.  
 
The improvements in molecular biology, immunohistochemistry, microarray technology 
and next-generation sequencing have changed our understanding about this progressive 
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breast cancer model. Now we know that progression is not a very straight path but it is 
rather complex and cumulative events in different pathways towards the invasive breast 
cancer (Simpson et al. 2005).  
The molecular mechanisms involved in tumor initiation and progression constitute an 
important challenge in the breast cancer field. Developmental signalling pathways 
regulating mammary development have found to be disrupted in cancer. Developmental 
signalling pathways such as IGF, integrin, Notch, NF-#B, STAT, TGF-$ and Wnt 
pathways are deregulated in breast cancer. Development and branching of the ductal 
epithelial tree during puberty requires amphiregulin/EGFR signalling, while 
overexpression of both the ligand and the related receptor ErbB2, is associated with poor 
prognosis in breast cancer. Estrogen is an important factor in breast cancer initiation and 
progression, and is also implicated as a risk factor. ER % together with ER $ and several 
different signalling factors are central operators of breast cancers (Thompson et al. 2008). 
 
1.1.3 Clinical Grading and Staging of Breast Cancer 
 
Grading of breast cancer is the first most important step that helps clinicians to decide the 
treatment options of the patients because it is a measure of tumor aggressiveness. Grading 
refers to the appearance of the cancer cells under the microscope. “Low grade” tumors 
are less aggressive than “high grade” tumors.  Breast cancer grading depends on three 
factors: nuclear grade (change in the cell size, shape and uniformity), tubule formation 
(percent of the cells with the tubular formation) and mitotic rate (rate of cell division) 
(Rank et al. 1987). Each variable is scored from 1 to 3 (1 is given for the best and 3 for 
the worst). Scores from each component are added together to determine the “grade”. 
This grading system is called the Scarff-Bloom-Richardson (SBR) grading system. The 
lowest possible score is 3 and given to the tumors with low cell proliferation rate and 
higher level of differentiation, the highest possible score is 9 and given to the highly 
proliferative and undifferentiated tumors. There are three grades in this system; grade 1 
(low-grade, score: 3-5), grade 2 (moderate or intermediate grade, score: 6,7) and grade 3 
(high-grade, score: 8,9) (Bloom & Richardson 1957).  
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Cancer stage is scored based on the spreading state of the tumor. TNM (Tumor-Node-
Metastasis) staging considers three aspects of tumor: tumor size, lymph node 
involvement and invasiveness of the tumor and whether it has spread away from the 
breast. Staging helps to classify cancer into groups depending on the different variables 
and characteristics of the cancer, which further improves the treatment decision. Early 
stages are stage 0, stage I, stage II, some stages of stage III and late or advanced stages 
are stage III and IV (Elston & Ellis 1991). Stage II is divided into two groups as IIA and 
IIB, while stage III is divided into three groups as IIIA, IIIB and IIIC.  
Breast cancer is a complex disease with different subtypes having different properties and 
various clinical outcomes are associated with these different subtypes (Elston & Ellis 
1991). The most important determinants of these subtypes are ER and progesterone 
receptor (PR) status of tumor cells and the amplification, overexpression of the HER2 
oncogene. Classification of this heterogeneous disease required for preventive and 
therapeutic approaches. Many genes play crucial roles in breast cancer and the 
heterogeneous nature of the disease interferes with grouping of these subtypes. Recent 
molecular studies using microarray technology with large group of tumor sets clustered 
breast cancer depending on the gene expression profiles into five major molecular 
subtypes: luminal A, basal-like, normal breast-like, luminal B and HER2+/ER- (Sørlie et 
al. 2001; Perou et al. 2000; Hu et al. 2006). 
 
Figure 1.3. Hierarchical clustering of 85 samples (78 carcinomas, 4 normal tissues and 3 
benign tumors) depending on the gene signatures acquired using microarray data (Perou et 
al. 2000). Figure taken from (Perou et al. 2000), Copyright (2015) Macmillan Publishers 
Limited. 
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As seen in Figure 1.3 tumors are clustered into two main groups. The first group contains 
already characterized basal-like, ErbB2+ and normal-breast like subgroups with low or 
no expression of ER. Basal-like subtype defined by high expression of certain keratins (5 
and 17), laminin and fatty acid binding protein 7, while ErbB2 characterized by high 
expression of ErbB2 and GRB7 and normal-like breast showed a similar expression 
pattern to adipose tissue and non-epithelial cell types. The second branch of the 
dendogram contains luminal ER+ subtypes (two or possibly three different groups). 
Luminal subtype A is defined with the highest expression of ER % gene GATA binding 
protein 3, X-box binding protein 1, trefoil factor 3, hepatocyte nuclear factor 3 a, and 
estrogen-regulated LIV-1. The other two groups, luminal subtype B and C, both show 
expression of genes including the ER cluster and those that are specific to the luminal 
phenotype. Luminal C subtype also shows expression of a novel set of genes with 
unknown functions (Perou et al. 2000).  
The classification of breast cancer using new strategies is important for finding the 
missing pieces between genotype and phenotype. It can provide insights into the 
progression of disease from normal to invasive carcinoma. Identification of new subtypes 
can provide new prognostic parameters and personalized care for the patients.  
 
1.2 Ribosomal RNA Genes 
 
Ribosomes are essential organelles that are required to support cell growth. rDNA 
transcription regulates the ribosome biogenesis that has a central role in cell cycle 
progression (Brown & Szyf 2008). Ribosome synthesis is a very complex process that is 
closely related to cell metabolism. Nucleoli form in the nucleus wherever the rRNA 
genes are transcribed. Ribosome biogenesis is tightly correlated with rRNA synthesis. 
The human genome contains about 300-400 copies of rRNA genes but only a fraction of 
these genes are actively transcribed depending on the cell type, external signals and cell 
stage while the rest of the genes remain inactive (McKnight & Miller 1976). 
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1.2.1 Organization of rDNA Genes 
 
rRNA genes are organized as tandemly repeated arrays within the nucleolar organizing 
regions (NORs), located on the short arms of five human acrocentric chromosomes 13, 
14, 15, 21 and 22 NORs can be observed as secondary constrictions in the chromosomes 
during metaphase (Schmickel 1973; Henderson et al. 1972) (Figure 1.4). Location of 
rDNA genes on the short arms of chromosomes insulate rDNA genes from Pol II and Pol 
III transcribed genes, this isolation was further reinforced by surrounding repetitive 
satellite DNA. 
 
 
Figure 1.4. NORs are located at secondary constrictions of five human acrocentric 
chromosomes (Henderson et al. 1972). Figure adapted from (McStay & Grummt 2008). 
Ideograms were taken from the University of Washington, Department of Pathology 
website (http://www.pathology.washington.edu/research/cytopages/idiograms/human/). 
Copyright (1994) David Adler.  
 
rDNA repeats were thought to organized as only head to tail direction, but recently the 
molecular combing technique has revealed that rDNA repeats exist in both head to tail 
and tail to head direction in the NORs (Caburet et al. 2005). 
Mammalian rDNA transcription units are approximately 43 kb long and each rDNA 
repeat is interrupted with long (~ 30kb) intergenic spacer region (IGS) (Gonzalez & 
Sylvester 1997). The entire promoter region of rRNA genes is contained in the IGS 
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region. The promoter region of rRNA consists of two important elements; core promoter 
(CP) and upstream control element (UCE). CP is located between -50 bp to +20 bp and is 
essential for basal transcription whereas UCE is located 150-200 bp upstream of the 
transcription start site and required for efficient pre-initiation complex formation (Paule 
& White 2000; Learned et al. 1986) (Figure 1.5). 
 
 
Figure 1.5. Structural organization of mammalian rDNA transcription unit. Adapted from 
(Paule & White 2000; McStay & Grummt 2008). IGS: Intergenic spacer, UCE: Upstream 
control element, CP: Core promoter, ETS: External transcribed spacer, ITS: Internal 
transcribed spacer. 
 
rRNA genes (except 5S, which is transcribed by RNA Polymerase III) are transcribed 
from 45S rDNA promoter by RNA polymerase I (Pol I) as a long precursor known as 45S 
pre-RNA that is rapidly spliced into the 18S, 28S and 5.8S rRNA transcripts.  
These rRNA transcripts are the catalytic and structural components of the ribosomes and 
are processed, modified and assembled into respective ribosomal subunits in the 
nucleolus.  
 
1.2.2 Regulation of rDNA genes 
 
Since approximately 80% of the total RNA of a proliferating cell consists of Pol I 
products, rRNA gene expression should be tightly regulated in order to avoid energy loss 
or unwanted growth of the cell. Therefore, the transcription of rRNA genes is regulated at 
every step of the road; pre-initiation complex (PIC) formation, initiation, promoter 
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escape, elongation, termination, re-initiation, RNA processing and post-transcriptional 
modifications (Russell & Zomerdijk 2005).  
There are two essential transcription factors identified in mammals; upstream binding 
factor (UBF) and the selectivity factor (SL1 in humans and TIF-IB in mouse), 
cooperative binding of these two factors to the promoter region is required for Pol I 
recruitment (Learned et al. 1986; Clos et al. 1986). UBF contains several HMG boxes 
and this motif is known to bend DNA and enable UBF interaction with the minor groove 
of DNA (Putnam et al. 1994). UBF has two major roles in the rDNA transcription: 
stabilizing SL1/TIF-IB on the rDNA promoter and competing with non-specific DNA 
binding proteins such as H1, which prevents the binding of SL1/TIF-IB (Kuhn & 
Grummt 1992). SL1/TIF-IB is a protein complex, which contains TATA-binding protein 
(TBP) and five Pol I specific TBP-associated factors (TAFI 48, TAFI 68, TAFI 35, TAFI 
12 and TAFI 95/110), TAFIs are responsible for the promoter recognition (Comai et al. 
1992; Heix et al. 1997; Zomerdijk et al. 1994; Gorski et al. 2007; Denissov et al. 2007). 
TAFIs also interact with a basal regulatory factor TIF-IA which associate with 
transcriptionally active Pol I subpopulation (Pol I$) (Miller et al. 2001; Yuan et al. 2002). 
 
 
Figure 1.6. Recruitment of Pol I to the pre-initiation complex by UBF and SL1. Figure 
taken from (Moss 2004), Copyright (2004) Elsevier Limited. 
 
Transcription from 45S rDNA promoter by Pol I was found to be a dynamic process. 
Components of transcription machinery are rapidly shuffled between nucleoplasm and 
fibrillar centers (rDNA transcription centers) while subunits of transcription machinery 
all suggest that a mammalianUAF-like complexmust still
be found. The PolII basal and transcription coupled
repair factor TFIIH may also play a role in PolI transcrip-
tion [20,21]. However, doubt still exists as to whether
TFIIH loss affects PolI transcription directly or via the
transcription of PolII genes [22].
In mammals, it is believed that UBF aids SL1 in its ability
to recognise the promoter, possibly via DNA looping [23].
UBF binds throughout the PolI promoter via at least three
of its HMG1-boxes, which bind and kink the DNA.
However, a post-initiation role for UBF has also been
demonstrated [24]. Hmo1p, a single HMG1-box nucleo-
lar protein vaguely resembling UBF, strongly enhances
rRNA gene transcription and cell growth in yeast [25].
Both UBF andHmo1 belong to the sequence non-specific
class of HMG1-box proteins [26]. Consistent with this
and with its high abundance, UBF is found bound
throughout the rRNA genes [27!!]. Thus, both UBF
andHmoIpmay define an rRNA gene-specific chromatin.
Gene activation — regulation by numbers?
Typically 100s to 1000s of copies of the rRNA genes exist
as tandem repeats at either one or several NORs. Reg-
ulation of rRNA gene transcription could then logically
occur by modulating the activity of the transcription
machinery, by changing the number of active genes or
both. But, although changes in the number of active genes
have been observed, several lines of evidence suggest
that they are in fact not important in regulating pre-rRNA
transcription rates. Differential accessibility of the rRNA
genes to the DNA crosslinker psoralen led to the surpris-
ing conclusion that, in both higher and lower eukaryotes,
no more than "50% of chromosomal ribosomal genes are
active at any given time [28!!,29]. Consistent with this,
both yeast and Drosophila require less than half of their
normal rRNA gene complement to survive [30,31]. On
the other hand, in yeast cells carrying theminimum viable
number of rRNA genes, most if not all genes are tran-
scribed [32]. When grown into stationary phase, yeast
reduces pre-rRNA synthesis by 10 or more times. Con-
comitantly it also reduces the proportion of its rRNA
genes that are actively transcribed [33!!]. Modification of
chromatin has become a key theme in our understanding
of gene regulation [34]. Thus, it was not surprising to find
that loss of histone acetylation, in this case at lysines (K)
-5 and -12 of H4, was correlated with yeast rRNA gene
inactivation. This data implicates the histone deacetylase
Rpd3p (homolog of HDAC1,2) and perhaps the oppos-
ing acetyl-transferase Esa1p (TIP60) [35!!]. However,
although loss of Rpd3p does prevent inactivation of rRNA
genes, it does not prevent the normal down-regulation of
transcription associated with stationary phase [33!!].
Thus, althoughH4–K5 and –K12 deacetylation correlates
with gene inactivation and Rpd3 is essential for this
inactivation, neither are necessary to down-regulate tran-
scription in stationary phase. A more rapid 5–10 times
down-regulation of yeast rRNA gene transcription is
observed when the TOR (target of rapamycin) nutrient
sensing pathway is inactivated [2]. This down-regulation
is also accompanied by a deacetylation of H4–K5 and
-K12 [35!!]. However, whereas rapamycin down-regula-
tion of pre-rRNA synthesis was claimed to be Rpd3p-
dependent in one study [35!!], in another it was not
accompanied by gene inactivation, the apparent function
of Rpd3 [36!!]. Left out of this picture is the role of the
UBF-like small HMG-box protein HmoI. Mammalian
UBF activity is, in fact, directly regulated by an acetyla-
tion–deacetylation cycle implicating acetyl-transferase
CBP and deacetylase HDAC1 [37]. Could then the key
target of Rpd3p be HmoI and not H4? Whatever the
mechanism of gene inactivation in yeast, it does not
appear to play a role in down-regulating the global level
of pre-rRNA gene transcription.
Silencing in yeast — keeping PolI on but
PolII off
Gene ‘silencing’ at the yeast NOR refers not to the
inactivation of rRNA genes but rather to the suppression
of recombination, to the inactivation of PolII genes
transposed into the NOR and to the inhibition of PolII
Figure 1
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enter the nucleolus apart from each other rather than as a preassembled protein complex 
(Dundr et al. 2002). Transcription terminator sequences are found both the 5’and 3’end of 
the rDNA transcription unit. Termination sequences at the 3’end are obviously important 
for transcriptional termination and are bound by TTF-I (transcription termination factor) 
and PTRF (polymerase and transcript release factor) for proper transcription termination 
but terminator sequence at the 5’end serves for a different function (Jansa & Grummt 
1999; Grummt et al. 1986; Grummt et al. 1985; Bartsch et al. 1987). It is bound by TTF-I 
and required for transcription initiation and recruitment of chromatin remodelling 
complexes such as NuRD, NuRC and CSB (Strohner et al. 2001; Santoro et al. 2002; 
Yuan et al. 2007; Xie et al. 2012). 
Psoralen crosslinking experiments revealed that rDNA clusters exist in two distinct 
configurations in the nucleolus, active NORs are uncondensed (Heliot et al. 1997) and are 
occupied by Pol I and Pol I-specific transcription factors (UBF, SL1 and TTF-I) during 
mitosis (Roussel et al. 1993; Roussel et al. 1996). Meanwhile inactive NORs are 
packaged into a heterochromatin structure and lack Pol I as well as specific transcription 
factors.  
rRNA synthesis is thought to be controlled either by changing the number of active rRNA 
copies or changing the Pol I activity and regulating the initiation frequency on already 
active genes (Grummt 2003; Moss 2004). Both mechanisms are shown to be operating 
under different circumstances in yeast but similar to vertebrates proliferating yeast cells 
increase the transcription initiation on already active rDNA genes instead of transforming 
inactive copies to active copies (Reeder 1999). Active and inactive rDNA copies are 
maintained through the cell cycle and are independent from rRNA levels (Conconi et al. 
1989). Epigenetic modifications also support active and inactive rDNA states but will be 
discussed in a further section. 
rDNA synthesis can be regulated by any protein that is essential for Pol I transcription, 
such as phosphorylation of UBF C terminus at different serine residues by casein kinase 
II is required for UBF transactivation and its hypophoshorylation is associated with 
transcriptional inactivity in terminally differentiated cells (O’Mahony et al. 1992; Voit et 
al. 1992; Voit et al. 1995; Tuan et al. 1999).  
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Post-transcriptional modifications also have very important regulatory roles. As 
previously mentioned, rRNA genes are transcribed as 45S pre-RNA which then is rapidly 
spliced into the 18S, 28S and 5.8S rRNA transcripts (Eichler & Craig 1994). These 
transcripts undergo extensive chemical modification, sometimes even before they are 
cleaved. There are three major types of rRNA modifications: 2’-O-methylation (Nm), 
pseudouridylation (&) and base methylation at various positions (Smith & Dunn 1959; 
Davis & Allen 1957; Wagner et al. 1967). Small nucleolar RNA-protein complexes 
(snoRNPs) direct the modification of rRNAs in eukaryotes. Two families of snoRNPs; 
box C/D and H/ACA are assigned for most prevalent modifications of rRNAs; 2’-O-
methylation and pseudouridylation, respectively (Tyc & Steitz 1989; Balakin et al. 1996; 
Kiss et al. 1996; Tycowski et al. 1998; Ganot et al. 1997). RNA component of the 
snoRNPs selects the site for modification through base pairing (Bachellerie et al. 1995). 
Protein component of box C/D fibrillarin and pseudouridine synthase of box H/ACA 
snoRNPs dyskerin catalyse the modification reaction (Tollervey et al. 1993; Zebarjadian 
et al. 1999). Besides their role in chemical modification of rRNAs both family of 
snoRNPs play role in rRNA processing and also help rRNA folding (Henras et al. 2008; 
Phipps et al. 2011). Processed and modified rRNA transcripts assembled into respective 
ribosomal subunits in the nucleolus (Trapman et al. 1975; Venema & Tollervey 1999). 
 
1.2.3 rRNA Genes and Cancer 
 
The association of nucleolus and cancer has been long known. Abnormal morphology of 
the nucleolus in cancer cells has drawn attention of tumor pathologists as early as the 19th 
century. However the molecular biology of rRNA synthesis and ribosome biogenesis of 
cancers cells have recently begun to be explored.  
Nucleoli is visible as a result of numerous macromolecules that are required for rRNA 
transcription, nucleoli disappears if rRNA synthesis is reduced whereas enlarges if Pol I 
activity is increased as observed in cancer cells.  
The cell growth defines an increase in the cell mass whereas proliferation is an indicator 
of increase in cell number. Cell division can not occur without a proper cell growth 
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(Killander & Zetterberg 1965; Johnston et al. 1977). Ribosome biogenesis is highly 
correlated with both of the processes.  
Several tumor suppressors and oncogenes have been demonstrated to affect Pol I 
dependent transcription (Zhai & Comai 2000; Poortinga et al. 2004; Arabi et al. 2005; 
Voit et al. 1997). There are number of pathways known to regulate rRNA synthesis such 
as mammalian target of Rapamycin (mTOR), phosphatidyl inositol-3 kinase (PI3K) and 
mitogen-activated protein kinase (MAPK) which are usually deregulated in cancer cells 
(Grummt 2003; Moss 2004). c-Myc, overexpressed in various cancers, is essential for 
cell cycle entry and directly enhances Pol I activity by recruiting SL1 to the rDNA 
promoter (Arabi et al. 2005; Grandori et al. 2005). However, only a part of the rRNA 
genes are transcribed even in the highly proliferative cancer cells. This fact illustrates that 
various epigenetic mechanisms in addition to the signalling pathways take part in the 
regulation of rRNA genes.  
 
1.2.4 Normalization of rRNA gene expression in cancer 
 
For interpretation of quantitative gene expression measurements in clinical tumor 
samples, a normalizer is necessary to correct expression data for differences in cellular 
input, RNA quality, and RT efficiency between samples. In the literature, rRNA gene 
expression is usually determined by normalizing to genes such as; GAPDH, TBP, ARPP 
P0 (acidic ribosomal phosphoprotein) and TFIIB (Raval et al. 2012; Uemura et al. 2011; 
Grandori et al. 2005) yet all these reference genes are transcribed by Polymerase II. 
However the output of such analysis is only help the researcher to identify rRNA 
expression levels relative to the polymerase II transcribed mRNA levels. Total RNA is 
represented mostly by rRNA (>80%), even a small decrease in rRNA expression may 
lead to a disproportional increase in the assessment of mRNA levels. We propose using 
geometric mean of four rRNA transcripts (18S, 28S, 5.8S and 45S ETS) to eliminate any 
bias introduced by using mRNA levels. This novel approach is also essential for 
identification of relative changes of rRNAs with regard to each other within a total rRNA 
pool. 
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1.3 Epigenetics 
 
“The branch of biology which studies the causal interactions between genes and their 
products, which brings the phenotype into being” said Conrad Waddington (1905-1975) 
who is attributed to have created the term of epigenetics in 1942 
(http://epigenome.eu/en/1,1,0). Epigenetic, as its name implies (epi- means over, above in 
Greek), does not involve changes in the DNA sequence itself but rather effects the gene 
expression or phenotype. Non-genetic factors effect the gene expression differently 
without effecting the DNA sequence (Bird 2007). 
DNA methylation, histone modifications and nucleosomal remodelling constitute 
interacting branches of epigenetic regulation. These processes regulate chromatin 
structure to form euchromatin or heterochromatin, and in turn activate or silence the gene 
expression. Micro RNAs (miRNAs) are also accepted as epigenetic regulators of gene 
expression but in contrast to other mechanisms miRNAs do not affect the chromatin 
structure and rather affect the mRNAs levels. 
 
1.3.1 DNA Methylation 
 
DNA methylation is the covalent addition of a methyl group to the 5th carbon of the 
cytosine ring. Even though mammalian DNA methylation is thought to be restricted to 
the cytosine followed by a guanine (CpG sites), recent studies have revealed that 
embryonic stem cells have methylation at non-CpG sites (Lister et al. 2009; Ramsahoye 
et al. 2000; Woodcock et al. 1987). CpG frequency of the human genome (2-5%) is less 
than expected (Josse et al. 1961; Swartz et al. 1962), since they are hotspots for mutation 
(Coulondre et al. 1978) thus CG dinucleotides are decreased during evolution. They are 
not randomly dispersed through the genome but mostly found as clusters either at 
promoter regions of the genes (known as CpG islands) or at the repetitive sequences 
(such as rDNA, satellite sequences, or centromeric repeats). The formal definition of a 
CpG island (CGI) is “a region with at least 200 bp and with a GC percentage that is 
greater than 50% and with an observed/expected CpG ratio that is greater than 60%” 
(Gardiner-Garden & Frommer 1987). More than 70% of the CpGs sites in the vertebrate 
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genome are methylated (Cooper & Krawczak 1989). CGIs are usually located around 
transcription start sites of genes (Takai & Jones 2002). DNA methylation at the promoter 
region is associated with gene silencing (Bird 2002).   
The best-known DNA methylation instance is found at the X chromosomes of females. 
One of the X chromosomes (randomly selected in each cell) is hypermethylated during 
early development and enables monoallelic gene expression while providing dosage 
compensation (Panning & Jaenisch 1998). Imprinting is also ensured by DNA 
methylation. Some of the genes should be expressed maternally or paternally, one of the 
allele from the other parent should be silenced for normal development of the organism 
(Feil 1999). CGI methylation is also important in carcinogenesis as well as silencing of 
intragenomic mobile elements (Yoder et al. 1997). 
DNA methyltransferases (DNMTs) mediate the transfer of the methyl group from S-
adenosyl L-methionine (SAM) to cytosine of CpG dinucleotide and generation of 5-
methylcytosine (Brenner & Fuks 2006). Known DNMTs are DNMT1, DNMT2, 
DNMT3a, DNMT3b and DNMT3L. DNMT3a, DNMT3b and DNMT3L are responsible 
for the de novo methylation whereas DNMT1 is required for maintenance of methylation 
pattern during cell division (Okano et al. 1999; Tajima & Suetake 1998). 
 
1.3.2 Histone Modifications and Chromatin Remodelling 
 
The chromatin consists of nucleosomes. A nucleosome is a protein-DNA complex 
containing an octamer of core histone proteins (H2A, H2B, H3 and H4) wrapped with 
146 bp long DNA (Kornberg & Thomas 1974). N-tails of core histones exposed to 
different covalent modifications such as acetylation, methylation, sumoylation, 
ubiquitination, phosphorylation and ADP-ribosylation. These modifications regulate 
chromatin structure as well as gene expression at the affected regions which in turn can 
alter the cell behaviour (Shiio & Eisenman 2003; Schübeler et al. 2004; Shilatifard 2006; 
Bradbury 1989).  
Histone modifications first started to draw attention by the identification of first histone 
deacetylase (HDAC) and histone acetyltransferase (HAT) as transcriptional coactivator 
and corepressor, respectively (Brownell et al. 1996; Taunton et al. 1996). Histone 
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acetylation mainly occurs in lysine residues of H3 and H4. Acetylation of lysine residues 
are associated with open chromatin structure and active gene expression whereas 
deacetylation causes condensation of chromatin (Schübeler et al. 2004). Histone 
phosphorylation is observed in different histone residues such as serines, tyrosines, 
threonines and phosphorylation is not limited to the N-terminus of histones (Banerjee & 
Chakravarti 2011). Phosphorylation and dephosphorylation reactions are catalysed by 
kinases and phosphatases which are also regulated by phosphorylations (Bodenmiller et 
al. 2010; Zorina et al. 2011). Both histone acetylation and phosphorylation modifications 
are changeable and dynamic events (Jackson et al. 1975; Barth & Imhof 2010). Histone 
methylation can occur on lysine and arginine residues as mono-, di-, tri-methylation and 
is regulated by histone methyltransferases (HMTs) and their action balanced by histone 
demethylases (Rice et al. 2003; Tsukada et al. 2006).  
Histone modifications have been considered to affect the chromatin structure through 
changes in histone-histone and histone-DNA interactions for a long time (Wolffe & 
Hayes 1999; Hansen et al. 1998). However, the vast variety of modifications and 
association of histone patterns with specific biological functions have led to the idea that 
histone modifications might be referred as a “histone code” and this code is read by other 
proteins and protein complexes (Mizzen et al. 1998; Turner 1993; López-Rodas et al. 
1993; Loidl 1994; Tordera et al. 1993).  
Chromatin associated proteins recognize and bind to the sites of histone modifications 
with their dedicated domains (acetylated lysine residues recognized by bromodomains, 
methylated lysine residues recognized by chromodomains) and mediate chromatin 
remodelling and regulate gene expression (Zeng & Zhou 2002; Daniel et al. 2005; Martin 
& Zhang 2005). 
Some of the aforementioned histone modification enzymes are also parts of chromatin 
remodelling complexes, which together regulate chromatin configuration as well as gene 
expression. 
Profiling histone modifications revealed that cancer cells display loss of mono- and tri- 
methylated forms of H4 and a general deacetylation of histones observed as a result of 
inactivation of HATs (Jones & Baylin 2002). Deregulation of histone modifications at 
tumor suppressor genes and proto-oncogenes has great effect on the cancer progression. 
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DNA methylation and chromatin modifications are closely associated with each other 
during the packaging of DNA. Recent studies have revealed that methyl-CpG binding 
proteins associate with HDACs, DNMTs and HMTs to alter chromatin structure and 
cause gene silencing. Nucleosomal remodelling complexes such as Sin3A, NuRD, 
SUV39H, NCoR/SMRT, CoREST, and SWI/SNF have also been found to be partners 
with methyl-CpG binding proteins. Epigenetic cancer studies have revealed that methyl-
CpG binding proteins are found mostly at hypermethylated promoters of cancer related 
genes. Nucleosomal remodelling complexes are recruited to the methylated DNA bound 
by methyl-CpG binding proteins to reorganize chromatin to the repressive 
heterochromatin state causing gene silencing. Moreover, chromatin-remodelling 
complexes can further alleviate binding of the methyl-CpG binding proteins to the 
methylated DNA, generating a never-ending cycle between two mechanisms. Methyl-
CpG binding proteins link the DNA methylation to repressive chromatin modification 
and remodelling by interacting multiple chromatin related proteins (reviewed in (Lo & 
Sukumar 2008)). There are many intersecting pathways that are engaged in the epigenetic 
regulation of gene expression in this emerging field, yet many others remain to be 
uncovered.  
 
1.3.3 DNA Methylation and Cancer 
 
CpG islands at the promoter regions of genes are unmethylated and they are actively 
expressed in normal cells. Genes with CpG islands became susceptible to methylation 
when cell start to transform from normal cell to cancer cell. Methylation patterns are 
inverted in the genome of cancer cells compared to normal cells (Baylin & Ohm 2006). 
For example: repetitive sequences normally methylated to protect the genome from 
mobile elements become unmethylated in transformed cells whereas normally 
unmethylated CpG islands at the promoter regions of the genes become methylated in 
cancer cells (Manel Esteller 2007; Jones & Baylin 2002). Both of the mechanisms are 
advantageous for cancer cells to survive; hypermethylation of the CpG islands at 
promoters of the tumor suppressor genes lead to the survival of the cancer cells whereas 
hypomethylation of the repetitive elements increase genomic instability in cancer cells 
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and so they can accumulate more genomic aberrations (Manel Esteller 2007). Change in 
the DNA methylation profile is one of the characteristics of almost all human cancers, 
including breast cancer. 
The two-hit model was purposed by Knudson states that inactivation of a tumor 
suppressor gene requires both of the copies to lose their function (Knudson 2000). 
Methylation of a tumor suppressor gene can be the second hit to an already mutated 
tumor suppressor gene. p16INK4a, APC and BRCA1 are, well-known tumor suppressor 
genes, inactivated in the germ line by mutations and functional allele is inactivated 
through hypermethylation of the DNA (Foster et al. 1998; Virmani et al. 2001; 
Birgisdottir et al. 2006). Hypermethylated tumor suppressor can be related to many 
biological functions and many of them have already been identified. Examples include 
genes playing role in cell cycle regulation, angiogenesis, cell adhesion, apoptosis, DNA 
repair, invasion, hormone regulation, and cellular growth-inhibitory signalling and the list 
is growing everyday (Szyf et al. 2004). 
 
1.3.4 rDNA Methylation and Cancer 
 
As mentioned earlier, psoralen crosslinking experiments revealed that rDNA clusters 
exist in two distinct configurations in the nucleolus as active and inactive (Heliot et al. 
1997). Epigenetic modifications support the active and inactive states of rDNA gene 
clusters. Increase in histone acetylation levels are known to associated with active genes 
(Tazi & Bird 1990). MeCP2 protein is known to associate with histone deacetylases, has 
also high affinity towards methylated DNA (Meehan et al. 1992). DNA methylation and 
histone acetylation as well as other histone marks are together involved in epigenetic 
regulation of gene expression and chromatin structure. 
Methylation of CpGs at the promoter (Stancheva et al. 1997), repressive histone codes 
such as; methylated H3K9me3, H4K20 and H3K27me3 are indicators of inactive rRNA 
copies (Santoro et al. 2002), whereas acetylated histones H4, H3 and H3K4me3 and 
unmethylated rDNA promoter region associates with active copies of rDNA (Earley et al. 
2006; Lawrence et al. 2004; Zhou et al. 2002).  
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45S rDNA promoter region and transcribed regions have an unusual CpG composition, 
they are very rich in CG dinucleotides however much longer than a regular CpG island 
(Worton et al. 1988). CpG islands in the genome of cancer cells are known to be 
subjected to hypermethylation and eventually loose the gene expression. Several studies 
have been reported about rDNA promoter methylation status in cancer in the literature 
but rRNA expression levels and their relations with rDNA promoter methylation have 
been overlooked in these studies. 
Bisulfite sequencing of clonal DNA is frequently used in rDNA promoter methylation 
studies. It has been reported that 45S rDNA promoter region methylation decreases 
rRNA gene expression in hepatocellular carcinoma (Ghoshal et al. 2004) and similar 
results were reported in the CD34+ cells of patients with myelodysplastic syndromes 
(Raval et al. 2012) . Some other studies showed no relation or positive correlation 
between promoter methylation and rRNA transcription.!Loss of rRNA promoter 
methylation was shown to inhibit both the synthesis and the processing of rRNA proved a 
contrary effect of rDNA methylation on rRNA production. Further investigation in the 
same study suggested that this inhibition was the result of cryptic RNA polymerase II 
transcription of the rRNA genes (Gagnon-Kugler et al. 2009). In another study, the 
authors demonstrated that in prostate cancer specimens and prostate cancer cell lines 
increased rRNA levels do not correlate with hypomethylation of rDNA promoter 
(Uemura et al. 2011; Yan et al. 2000). A more recent study showed that 45S rDNA 
promoter including 5’ regions of 18S and 28S rDNA were hypermethylated in breast 
cancer tissues compared to paired normal tissues and identified a correlation between 
methylation levels of these regions and nuclear grade and nuclear size (Bacalini et al. 
2014). 
In addition to bisulfite sequencing of clonal rDNA promoters, CpG methylation of rDNA 
promoter was also evaluated using methylation specific restriction techniques. Three 
studies have identified CpG methylation of rDNA promoters as a prognostic factor in 
ovarian cancer, endometrial cancer and breast cancer using this technique (Chan et al. 
2005; Yan et al. 2000; Powell et al. 2002).  
Our motivation to analyse 45S rDNA promoter methylation region came from the study 
of a former lab member. The aim of the study was to find suitable reference genes for 
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breast cancer by using matched breast tumor and normal samples. All of the reference 
gene candidates showed a relatively higher expression in tumor samples than in normal 
counterparts (Gur-Dedeoglu et al. 2009). Since 80% of the total RNA from a sample is 
rRNAs, even the small changes with regard to rRNA expression can influence the mRNA 
ratio of the total sample. Differential expression of reference genes drove our attention to 
mRNA/rRNA ratio. Quantification of 18S rRNA with reference genes ACTB and SDHA 
in 13 tumor and normal pairs revealed that 18S rRNA was down regulated in most of the 
tumor samples (9/13) whereas ACTB and SDHA expressions were higher in tumor 
samples (Gur-Dedeoglu et al. 2009). 
In our knowledge, although many studies have been conducted to analyse rDNA 
promoter methylation levels in cancer, the relationship between rRNA transcript levels 
and rDNA promoter methylation levels have not been investigated in breast cancer. 
 
1.4 Aim and Hypothesis 
 
rRNA genes are the one of the most important genes for a cell to grow, proliferate and 
survive since they are the core elements of protein factories of the cells, ribosomes. Since 
cancer cells harbor mutations to overcome proliferation restricting mechanism they have 
to alter the ribosome biogenesis in order to keep growing and dividing. Many tumors are 
known to increase ribosome biogenesis through increasing the transcription level of 
rRNA genes. However expression of rRNA transcripts remain largely unexplored in 
breast cancer.  
18S and 28S rRNA genes had been used as housekeeping genes along with the classical 
housekeeping genes such as GAPDH and $-actin because they are thought to have stable 
expression (Murthi et al. 2008; Pérez et al. 2008). In contrast to common belief about the 
stable expression of rRNA genes, in recent studies it has been shown that 18S rRNA is 
differentially expressed in breast tumor and normal samples and it is not an appropriate 
reference gene (Gur-Dedeoglu et al. 2009; Tricarico et al. 2002; de Kok et al. 2005). 
Underlying mechanism for this differential expression was recently identified to be 
rDNA methylation in some cancer types such as hepatocellular carcinoma, patients with 
myelodysplastic syndromes (Ghoshal et al. 2004; Raval et al. 2012) although some other 
 21 
studies found an opposite or no correlation between rDNA methylation and rRNA gene 
expression. rRNA gene regulation through 45S rDNA methylation is controversial in the 
literature. 
rRNA transcripts (18S, 28S and 5.8S) are transcribed from the same promoter and more 
than 80% of the total RNA in a cell is comprised from these essential transcripts. Any 
dysregulation regarding to the expression or splicing of these transcripts might have 
major impact on cancer development and progression. rRNA gene expression is 
commonly analysed by using reference genes such as; ACTB, TBP and GAPDH. 
However, using mRNA levels for rRNA expression analysis do not identify whether the 
ratios of spliced products of the 45S precursor were differentially expressed between 
tumor and normal pairs in breast cancer. We purpose using geometric mean of all four 
rRNA products (18S, 28S, 5.8S and 45S ETS) to normalize rRNA gene expression to 
identify relative changes of rRNAs within a pool of rRNA transcripts.  
DNA methylation is one of the important mechanisms contributing to the tumorigenesis. 
Our aim was to find whether abnormal DNA methylation extends to an essential gene 
promoter, 45S rDNA promoter and how the level of rDNA methylation affects the rRNA 
expression and proportions of different rRNA trasncripts in the rRNA pool in breast 
cancer and normal breast tissues.  
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 General Laboratory Reagents and Kits 
 
General chemicals (such as ethanol, methanol, isopropanol, chloroform…) were all 
analytical grade and mainly purchased from Sigma Aldrich Sigma-Aldrich (St. Louis, 
MO, USA) or Merck (Darmstadt, Germany). A full list of reagents, chemicals and kits 
are catalogued in Table 2-1. 
  
Table 2-1. List of reagents and kits used in this study 
Reagents Catalogue No Company 
4-Bromoanisole  BN 191 
Molecular Research 
Center, USA 
Agar (microbiology grade) 05039-500G 
Fluka, Sigma Aldrich, 
USA 
Agarose-Basica Le BHE500 Prona, Spain 
Ampicillin A0839.0025 Applichem, Germany 
Bacto-tryptone 1612 Conda, Spain 
CaCl2. 2H2O 
433381 
 
Carlo Erba, Italy 
D(+)-Glucose  16325 
Riedel-de Haen, Sigma 
Aldrich, USA 
DEPC A0881.0100 Applichem, Germany 
dNTP Set R0182 Fermentas, Thermo 
 23 
Scientific, USA 
DyNAmo HS SYBR 
Green qPCR Kit  
F-410L Thermo Scientific, USA 
EDTA  A3562.1000 Applichem, Germany 
EpiTect Bisulfite Kit  59104 Qiagen, Germany  
Etidium Bromide 17898 Thermo Scientific, USA 
Gene ruler 50 bp ladder SM373 Thermo Scientific, USA 
Glacial acetic acid 27225-2.5L-R Sigma Aldrich, USA 
HyPure Molecular Biology 
Grade water 
SH30538.01 
Hyclone, Thermo 
Scientific, USA 
IPTG A4773.0005 Applichem, Germany 
KCl 12636.1KG Sigma Aldrich, USA 
KOH 1.05012.1000 Merck, USA 
MessageClean Kit  M601 GenHunter, USA 
MnCl2. 4H2O M3634-100G Sigma Aldrich, USA 
NaCl 31434 Sigma Aldrich, USA 
NaOH 6203 Sigma Aldrich, USA 
Nucleospin RNA 740955.5 
Macherey Nagel, 
Germany 
Nucleospin Tissue 740952.5 
Macherey Nagel, 
Germany 
pGEM-T Easy vector 
system  
A1360 Promega, USA 
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Phenol: Chloroform: 
Isoamyl alcohol, 25:24:1, 
pH 6.6 
AM9730 
Ambion by Life 
Sciences, USA 
Pipes A1079.0100 Applichem, Germany 
PureLink Quick Plasmid 
Miniprep Kit 
K210011 
Invitrogen, Thermo 
Scientific, USA 
QIAquick Gel Extraction 
kit  
28704 Qiagen, Germany  
RevertAid First Strand 
cDNA Synthesis Kit  
K1622 Thermo Scientific, USA 
Taq DNA Polymerase  EP0402 
Fermentas, Thermo 
Scientific, USA 
TRI Reagent RT  RT 111 
Molecular Research 
Center, USA 
Trizma Base T1503-1KG Sigma Aldrich, USA 
X-Gal R0404 
Fermentas, Thermo 
Scientific, USA 
Yeast extract 1702 Conda, Spain 
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2.1.2 Tissue Culture Reagents 
 
All reagents used in tissue culture are listed in Table 2-2. 
Table 2-2. List of reagents and chemicals used in tissue culture 
 
Catalogue No Company 
5-aza-2' deoxycytidine A3656 Sigma Aldrich, USA 
DMEM HIGH Glucose  SH30243.01 
Hyclone, Thermo 
Scientific, USA 
DMEM Low Glucose SH30021.01 
Hyclone, Thermo 
Scientific, USA 
DMEM/F-12 SH3002301  
Hyclone, Thermo 
Scientific, USA 
DMEM/Low Glucose SH30021.01 
Hyclone, Thermo 
Scientific, USA 
EGF E9644 Sigma Aldrich, USA 
FBS CH30160.03 
Hyclone, Thermo 
Scientific, USA 
Hydrocortisone H4001 Sigma Aldrich, USA 
Insulin I9278 Sigma Aldrich, USA 
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L-glutamine SH3003401 
Hyclone, Thermo 
Scientific, USA 
McCoy’s 5A  SH30200.01 
Hyclone, Thermo 
Scientific, USA 
Non-Essential Amino 
Acids 
SH30238.01 
Hyclone, Thermo 
Scientific, USA 
PBS SH30256 
Hyclone, Thermo 
Scientific, USA 
PBS (Ca -Mg free) SH30256.01 
Hyclone, Thermo 
Scientific, USA 
Penicillin/Streptomycin SV30010 
Hyclone, Thermo 
Scientific, USA 
RPMI 1640 SH30027.01 
Hyclone, Thermo 
Scientific, USA 
Sodium Pyruvate 11360-070 
Gibco, Thermo 
Scientific, USA 
Trichostatin A T8552 Sigma Aldrich, USA 
DMSO A1584.0100 Applichem, Germany 
Trypsin/EDTA SV3003101 
Hyclone, Thermo 
Scientific, USA 
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2.1.3 Instruments 
 
All equipment used in this study are listed in Table 2-3. 
 
Table 2-3. List of instruments used in this study 
!Name Company 
Applied Biosystem PCR Machine 
Applied Biosystems, Life 
Sciences, USA 
AutoFlow NU-8500 Water Jacket CO2 
Incubator 
NuAire, USA 
AxioCam MRc5 image capture device Carl Zeiss, Germany 
Centrifuges 5810 and 5810 R Eppendorf, Germany 
Stratagene Mx3005P Real-Time PCR System Agilent, USA 
 
2.1.4 Primers 
 
All primers used in this study are listed in Table 2-4. 
Table 2-4. Primers used in this study 
Primers Sequence 
Product 
Size 
(bp) 
Efficiency 
Value 
45S 
BSP 
forward 
5’-GAGTCGGAGAGCGCTCCCTGAG -’3 434 - 
45S 
BSP 
reverse 
5’-CTGGAGAGGTTGGGCCTCCG-’3    
 28 
18S 
rRNA 
forward 
5’-AAACGGCTACCACATCCAAG-’3  154 1.95 
18S 
rRNA 
reverse 
5’-CCTCCAATGGATCCTCGTTA-’3    
28S 
rRNA 
forward 
5’-CAGGGGAATCCGACTGTTTA-’3  151 1.85 
28SS 
rRNA 
reverse 
5’-ATGACGAGGCATTTGGCTAC-’3   
5.8S 
rRNA 
forward 
5’-CTCTTAGCGGTGGATCACTC-’3 155 2.0 
5.8S 
rRNA 
reverse 
5’-GACGCTCAGACAGGCGTAG-’3    
45S 
ETS 
forward  
5’-CGATCTGAGAGGCGTGCCTT-’3 87 1.93 
45S 
ETS 
reverse 
5’-GGCAGCGCTACCATAACGGA-’3   
ACTB 
forward 5’-!CCAACCGCGAGACGATGACC-’3 124 2.03 
ACTB 
reverse 5’- GAGTCCATCACGATGCCAG-3   
TBP 
forward  5’-TGCACAGGAGCCAAGAGTGAAAT-’3 134 2.2 
TBP 
reverse 5’-CACATCACAGCTCCCCACCA-’3   
    BSP: Bisulfite Sequencing Primers 
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2.2 Solutions and Media 
2.2.1 General Solutions 
 
50X Tris-Acetate-EDTA (TAE) Buffer 
242 g Trizma base 
18.61 g Disodium EDTA 
57.1 ml Glacial Acetic Acid  
Bring volume up to 1 litre with double distilled water (ddH2O). 
 
Lysogeny Broth (LB) Medium 
10 g tryptone 
 5 g yeast extract 
10 g NaCl in 950 mL double distilled water 
pH of the medium is adjusted to 7.0 using 1N NaOH and volume is brought up to 1 litre 
with ddH2O and autoclaved.  
Add Ampicillin (to a final concentration of 100 µg/ml) when LB is cooled down to 55°C. 
 
LB Agar plates with IPTG/X-Gal/ Ampicillin 
10 g tryptone 
 5 g yeast extract 
10 g NaCl 
15 g Microbiology grade Agar in 950 mL ddH2O 
pH of the medium is adjusted to 7.0 using 1N NaOH and volume is brought up to 1 litre 
with ddH2O and autoclaved.  
Add Ampicillin (100 µg/ml) IPTG (0.5 mM) and X-Gal (80 µg/ml) when LB is cooled 
down to 55°C and pour into sterile petri dishes. Let them cool down, then invert and store 
at +4°C. 
 
Transformation Buffer 
10.88 g MnCl2.4H2O 
2.2 g CaCl2.2H2O 
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18.65 g KCl 
20 ml 0.5M Pipes (pH 6.7 adjusted with KOH) and the volume is adjusted to 1 litre with 
ddH2O. Transformation buffer is filter sterilized and stored +4°C. 
 
SOC Medium 
20 g tryptone 
5 g yeast extract  
2 ml of 5M NaCl 
2.5 ml of KCl 
10 ml of 1M MgCl2 
10 ml of 1M MgSO4 
20 ml of 1M glucose 
Adjust the volume to 1liter with ddH2O and autoclave.  
 
2.3 Methods 
2.3.1 Cell Culture Techniques 
 
Growth conditions of breast cancer cell lines and non-tumorigenic cell line MCF-10A are 
listed in Table 2-5. 
 
Table 2-5. Growth medium ingredients of cell lines used in this study 
Cell line Growth Medium 
MCF7 10% FBS (Hyclone, Thermo Scientific, USA) and 1% 
Penicillin / Streptomycin (P/S) (Hyclone) supplemented low 
glucose Dulbecco’s Modified Eagle Medium (DMEM) 
(Hyclone)  
MDA-MB-453 10% FBS and 1% Penicillin / Streptomycin (P/S) supplemented 
low glucose DMEM 
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MDA-MB-468 10% FBS and 1% Penicillin / Streptomycin (P/S) supplemented 
low glucose DMEM 
BT20 10% FBS and 1% Penicillin / Streptomycin (P/S) supplemented 
low glucose DMEM 
MDA-MB-231 10% FBS and 1% Penicillin / Streptomycin (P/S) supplemented 
low glucose DMEM 
CAMA-1 10% FBS and 1% Penicillin / Streptomycin (P/S) supplemented 
low glucose DMEM 
ZR-75-1  10% FBS, 1% P/S and 2mM glucose (Sigma-Aldrich, USA) 
supplemented RPMI-1640 medium (Hyclone)  
BT474 10% FBS, 1% P/S and 10µg/ml insulin (Sigma-Aldrich)  
MDA-MB-157  10% FBS, 1mM sodium pyruvate (Gibco, Invitrogen, USA) 
and 1% P/S supplemented low glucose DMEM 
MDA-MB-361  10% FBS, 1mM sodium pyruvate and 1% P/S supplemented 
low glucose DMEM 
HCC-1937  10% FBS, 1% P/S and 1mM sodium pyruvate supplemented 
RPMI-1640 medium 
MCF10A 10% FBS, 1% P/S, 10µg/ml insulin, 20 ng/ml EGF (Sigma-
Aldrich) and 0.5 mg/ml hydrocortisone (Sigma-Aldrich) 
supplemented DMEM/Ham’s F-12 (1:1) medium (Biochrome, 
Merck Millipore, Germany) 
SKBR-3  10% FBS and 1% P/S supplemented McCoy’s 5A medium 
(Hyclone) 
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CAL-51  20% FBS and 1% P/S supplemented high glucose DMEM 
All cells were grown in 5% CO2 and 95% air at 37°C cell culture incubator. 
 
All cell lines except MCF-10A were purchased from ATCC while MCF-10A was kindly 
provided by Assist. Prof. Dr. A. Elif Erson (Middle East Technical University). 
 
2.3.1.1 Passaging of cell lines 
 
All cell lines used in this study were adherent cell lines. Cell lines were passaged every 2-
3 days before they became confluent, depending on the growth rate of the cell line. 
Growth medium was discarded using a sterile glass pipette and cells were washed with 
1X PBS (Hyclone). After discarding PBS, Trypsin/EDTA solution (Hyclone) was added 
onto cells until it covers the surface of the cell monolayer. In order to increase the 
enzymatic activity of the Trypsin/EDTA solution, the cell culture dish was placed in a 
cell culture incubator at 37°C for 3-5 minutes. When cells dissociated from the flask, 
cells were diluted with fresh medium and transferred to new flasks.  
 
2.3.1.2 Cryopreservation and thawing of the cells 
 
Cells were passaged one day prior to cryopreservation to increase the viability of the cells 
during cryopreservation process. Similar to passaging, old medium was discarded and 
cells were washed with 1X PBS. Trypsinization was performed; cells were collected with 
fresh medium and placed into a 15 ml falcon tube. Cells were centrifuged at 1500 rpm for 
5 minutes. The medium was discarded and the cell pellet was gently resuspended with 1.5 
ml freezing medium (10% DMSO and 90% FBS). Cells were transferred into properly 
labelled cryotube vials and left in -20°C for 1-2 hours. Then cryotube vials were taken 
from -20°C and replaced into -80°C for overnight. After overnight at -80°C, vials are 
placed in liquid nitrogen for long-term storage.  
For thawing of the cells, vials were taken from liquid nitrogen tanks and transported the 
cell culture room in a liquid nitrogen container. Vials were taken from the liquid nitrogen 
 33 
and immediately put in 37°C water bath. Vials were allowed to stand until half of the cell 
mixture was thawed. Half defrosted cells were added on top of 5 ml of medium in 15 ml 
of falcon tube and centrifuged at 1500 rpm for 5 minutes. Supernatant was discarded to 
get rid of the unwanted DMSO, cell pellet was gently resuspended in 5 ml of fresh 
medium and transferred to sterile T25 tissue culture flask and placed into the cell culture 
incubator.  
 
2.3.1.3 Collection of the cells for RNA or DNA isolation 
 
Cells were either collected before becoming confluent or after a particular treatment (5-
AZA, TSA etc.). First, used medium was discarded and cells were washed with 1X PBS. 
After trypsinization, cells were collected with fresh medium into a 15 ml falcon. Falcon 
tubes were immediately placed into ice and centrifuged at 1500 rpm for 5 minutes at 
+4°C. After discarding the medium, pellet was washed with cold 1X PBS and replaced 
back into centrifuge and centrifuged at the same conditions. PBS was discarded; tubes 
were snap frozen in liquid nitrogen and stored at -80°C until use. 
 
2.3.1.4 Treatment of cell lines with 5-AZA and/or TSA 
 
MCF7, MDA-MB-231, MDA-MB-453, MDA-MB-468, BT-474, ZR-75-1, BT-20, 
MDA-MD-361, SKBR-3, CAL-51 and MCF-10A cell lines were treated with 5-AZA and 
TSA separately.  
750.000 cells were plated in 100 mm cell culture dish and treated with 5µM 5-AZA 
(Sigma-Aldrich) or DMSO (at the same amount used to solubilize 5-AZA). 5-
AZA/DMSO and medium changed everyday for four days and cells were collected at the 
end of day four. For TSA treatment, cells were treated with either 400 nM TSA or DMSO 
(at the same amount used to solubilize TSA) 24 hour after the cell seeding and collected 
at the end of 48th hour.  
MCF7, MDA-MB-231, MDA-MB-453, MDA-MB-468, BT-474, ZR-75-1, BT-20, 
SKBR-3, CAL-51 and MCF-10A were treated with both 5-AZA and TSA together. 
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Similar to single treatments, 5µM of 5-AZA put into the medium at the day of seeding 
and 5-AZA was changed along with the medium everyday. 400nM TSA was added three 
days after the seeding (24 hours before the collection of cells) cells were collected at day 
four to analyze the effect of 5-AZA and TSA together.  
 
2.3.2 Patients and Tissue Samples 
 
19 primary breast tumors and matched normal tissues were collected from Ankara 
Numune Research and Teaching Hospital (see Table 2-6). The Research Ethics 
Committee of Ankara Numune Research and Teaching Hospital approved the use of 
collected clinical tissue samples and patient consent was obtained in agreement with the 
Helsinki Declaration. 
Both breast tissues and matched normal tissues resected during surgery and were 
immediately frozen in liquid nitrogen and stored at -80°C. Hematoxylin and eosin 
staining was used for determining the pathological characteristics. For tumor samples, 
only samples compromised of more than 80-90% of tumor cells were involved in the 
study.  
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Table 2-6. Clinical/Pathological characteristics of patient samples 
Patients Age ER  PR  Diagnosis  Lym. 
Node  
Gr
ade  
Stage  DM Month 
of the 
DM 
113  63 +  - IDC +  1 IIIB +  20 
115  57     Papillary 
carcinoma 
-  3 IIA -    
96  39 -  +  IDC -  2 IIA -    
116  74 -  -  IDC +  2 IIA -    
137  42 -  +  Medullary  -  3 IIB -    
146 49 +  +  ILC +    IIB -    
148  70 +  -  IDC +  2 IIIA +  15 
154  32 -  -  IDC +  3 IIIB -    
159  30 -  +  Metaplastic  -  2 IIA -    
161  41 -  -  IDC -  2 IIB +  47 
164 74 +  +  IDC -  2 IIB -    
166  55 -  +  IDC +  2 IIA -    
168  44 -  +  IDC +  2 IIB -    
170  60 -  -  IDC +  2 IIIB -    
176  49 +  +  IDC +  2 IIA -    
177  47 -  +  IDC +  2 IIIA +  48 
181  44 -  -  IDC +  2 I -    
133*                   
173*                   
* Patients with missing information 
ER: Estrogen receptor status, PR: Progesterone receptor status, IDC: Infiltrating ductal 
carcinoma, Lym. Node: Lymph node status, DM: Distant metastasis status. 
 
2.3.3 DNA Extraction 
 
Breast cancer cell lines as well as clinical breast cancer and matched normal tissue 
samples were resuspended in Proteinase K containing solution and placed onto a heat 
block at 56°C overnight in order to increase the DNA yield of the isolation. The 
manufacturer’s instructions of the Nucleospin Tissue (Macherey Nagel, Germany) DNA 
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extraction kit was followed. Extracted DNA samples were measured with Nanodrop 
Spectrophotometer (Thermo Scientific). 
 
2.3.4 Generation of Competent E. coli DH5$ 
 
E. coli DH5% glycerol stock was streaked on an agar plate (without antibiotics) using a 
sterile loop and left in 37°C bacteria incubator overnight. 2-3 colonies were selected and 
grown in 15 ml LB overnight in a shaker incubator at 37°C. Overnight culture from one 
colony was added into 200 ml LB in a 1000 ml flask until the optical density (OD) 
reaches 0.2. The bacteria mixture was placed in a shaker incubator at 25°C and grown 
until the OD at 600 nm becomes 0.5-0.6. The bacteria mixture was transferred into a 465 
ml ultracentrifugation tube and left on ice 10 minutes. Tubes were centrifuged at 2500 g 
for 10 minutes at +4°C. The supernatant was discarded and bacteria pellet is resuspended 
with 64 ml ice-cold transfer buffer. The mixture was transferred into two cold 30 ml 
ultracentrifugation tubes and left on ice for 10 minutes. The tubes were centrifuged again 
at 2500 g for 10 minutes at +4°C. The supernatant was discarded and bacteria were 
resuspended in 8 ml ice-cold transfer buffer containing 7% DMSO. This mixture was 
aliquotted as 200 µl per 1.5 ml eppendorf tube, frozen immediately with liquid nitrogen 
and stored at -80°C until use. 
 
2.3.5 Bisulfite Sequencing 
2.3.5.1 Bisulfite treatment of genomic DNA 
 
1 µg of genomic DNA was used for sodium bisulfite treatment of DNA, which was used 
to convert unmethylated cytosine residues to uracil and leaves methylated cytosine 
residues as cytosine. EpiTect Bisulfite Kit (Qiagen, Germany) was used to perform 
sodium bisulfite treatment of DNA. Manufacturer’s instructions were followed. Elution 
was performed using 20 µl of elution buffer. 
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2.3.5.2 Bisulfite specific PCR for 45S rDNA promoter region 
 
Bisulfite converted DNA (1µl) was amplified with Taq DNA Polymerase (Fermentas, 
Thermo Scientific, USA) using bisulfite DNA specific primers targeting 45S promoter 
(sequences of 45S BSP forward and reverse were listed in Table 2-4. 
45S BSP PCR reaction mixture was prepared as follows: 
 
 10X Taq Buffer   2.5 µl 
 MgCl2 (25 mM)   3 µl 
 dNTP (10 mM)   1.5 µl 
 45S BSP Forward Primer (10 mM) 1 µl 
 45S BSP Reverse Primer (10 mM) 1 µl 
 Bisulfite DNA    1 µl 
 ddH2O     14.7 µl 
 Taq Polymerase    0.3 µl 
 
Thermal cycler condition for 45S BSP primers is as follows: initial denaturation at 95°C 
for 5 minutes, 45 cycles of denaturation (30 seconds at 95°C), annealing (30 seconds at 
56°C) and extension (30 seconds at 72°C) and PCR was finished with a final extension at 
72°C for 5 minutes. At the end of the BSP PCR, 5 µl of 6X DNA loading dye (Thermo 
Scientific) was added into PCR products and all samples were loaded into 1.5% agarose 
gel. Agarose gel was briefly visualized with AxioCam MRc5 image capture device. 
 
2.3.5.3 Gel extraction, ligation and transformation 
 
45S BSP PCR bands at correct size (436 bp) were quickly excised from the gel under UV 
light. PCR products were extracted from the gel by using QIAquick Gel Extraction kit 
(Qiagen). Purified products were cloned into pGEM-T Easy vector by using pGEM-T 
Easy vector system (Promega, USA). Ligation mixture was prepared for each PCR 
product and for controls described in Table 2-7. 
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Table 2-7. Preparation of ligation mixture 
 
Standard 
Reaction 
Positive 
Control 
Background 
Control 
2X Rapid Ligation 
Buffer 5 µl 5 µl 5 µl 
pGEM - T Easy Vector 1 µl 1 µl 1 µl 
PCR product 3 µl - - 
Control Insert DNA - 2 µl - 
T4 DNA Ligase 1 µl 1 µl 1 µl 
Deionized water -  1 µl 3 µl 
 
Ligation mixtures were allowed to stand at room temperature for 1 hour then placed into 
+4°C for overnight before transformation.  
The transformation protocol was performed according to the pGEM-T Easy vector 
system manual using competent E. coli DH5%. Bacteria plated on LB-agar containing 100 
µg/ml Ampicillin (Applichem, Germany), 0.5 mM IPTG (Fermentas) and 80 µg/ml X-
Gal (Fermentas). 
 
2.3.5.4 Selection and sequencing of the bisulfite clones 
 
Five colonies from each cell line and 10 colonies from tissue samples (positive, white 
colonies) were randomly selected from the plates and inoculated in 3ml LB with 
Ampicillin (100 µg/ml) at 37°C in a shaker incubator overnight. 
Small-scale isolation of plasmid DNA (mini-prep) was performed with Nucleospin 
Plasmid Isolation (Macherey Nagel) kit according to the manufacturer’s instructions. 
Plasmids containing the cloned inserts confirmed with PCR using T7 and SP6 universal 
primers.  
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PCR reaction mixture for T7 and SP6 primers was prepared as follows: 
 
10X Taq Buffer   2.5 µl 
 MgCl2 (25 mM)   1µl 
 dNTP (10 mM)   1 µl 
 T7 Primer (10 mM)   1 µl 
 SP6 Primer (10 mM)   1 µl 
 Plasmid DNA     1 µl 
 ddH2O     17.3 µl 
 Taq Polymerase    0.2 µl 
 
 
PCR was placed into a thermal cycler and conditions were set as follows; initial 
denaturation at 95°C for 5 minutes, 30 cycles of denaturation (30 seconds at 95°C), 
annealing (30 seconds at 47°C) and extension (30 seconds at 72°C) and PCR was 
finished with a final extension at 72°C for 5 minutes. At the end of the PCR, 5 µl of 6X 
DNA loading dye (Thermo Scientific) was added into PCR products and 15 µl from each 
plasmid PCR product was loaded into 1.5% agarose gel. Agarose gel was visualized with 
the AxioCam MRc5 image capture device. Positive clones with the correct insert size 
were selected and sequenced with SP6 primers using dideoxy chain termination method 
(by Iontek Company, Turkey). 
 
2.3.6 RNA Isolation and cDNA synthesis 
2.3.6.1 RNA isolation from frozen tissue samples 
 
4-5 slices from frozen tumor samples and 20-25 slices for normal tissue samples were 
dissected into 60-µm-thick sections and RNA isolation was performed. Tissue samples 
were homogenized with a homogenizer in 1 ml TRI Reagent RT (Molecular Research 
Center, USA) and a 21-gauge needle was used for fine homogenization of the samples. 
Samples were incubated at room temperature for 5 minutes and 50 µl of 4-Bromoanisole 
(Molecular Research Center) was added for every ml of TRI reagent used. Samples were 
vigorously shaken for 15 seconds using vortex and allowed to stand at room temperature 
for 2-3 minutes. Centrifugation of the samples was performed at 12000xg for 15 min at 
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4°C and then the upper aqueous phase was collected into a new eppendorfa tube. 0.5 ml 
of isopropanol was added into the RNA containing clear phase. After 10 minutes of 
incubation at room temperature, the mixture was centrifuged at 12000xg for 15 min at 
4°C for to recovery of the RNA. The supernatant was discarded without disturbing the 
pellet. The pellet was washed twice with 75% ethanol and centrifuged at 7500xg for 5 
min at 4°C. Lids of the tubes left open in the fume to air-dry the pellets for 10 minutes. 
RNA pellets were dissolved in 30-50 µl (depending on the visibility of the RNA pellet) of 
Diethylpyrocarbonate (DEPC) treated H2O. RNA concentrations were determined with 
the Nanodrop Spectrophotometer. 
 
2.3.6.2 RNA isolation from cell lines 
 
RNA isolation was performed from collected breast cancer cells using NucleoSpin RNA 
(Macherey Nagel, Germany) kit following manufacturer’s instructions. 
 
2.3.6.3 DNase I treatment of RNA samples 
 
DNase I treatment was performed with MessageClean Kit (GenHunter, USA) in order to 
eliminate DNA contamination of total RNA that are obtained from tissue samples. 10 µg 
of total RNA diluted in 5.7 µl of 10X reaction buffer, 1 µl of DNaseI I added and volume 
increased to 56.7 µl with nuclease free water. Samples were mixed and incubated at 37°C 
for 30 minutes. Then, RNA was cleaned with phenol: chloroform: isoamyl alcohol 
extraction. 
An equal volume of phenol: chloroform: isoamyl alcohol (25: 24: 1) mixture was added 
into the incubated mixture and vortexed for 30 seconds. The sample was incubated on ice 
for 10 minutes and centrifuged 5 minutes at 13000 rpm at +4°C. Aqueous phase was 
transferred into a new 1.5 ml tube, an equal volume of chloroform was added and 
vortexed for 30 seconds. The sample was again incubated on ice for 10 minutes and 
centrifuged for 5 minutes at 13000 rpm at +4°C. The aqueous phase was transferred into 
a new 1.5 ml Eppendorf tube and 5 µl of 3M NaoAc pH: 5.2 and 200 µl of ice-cold 
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ethanol added. The samples were incubated at -80°C overnight. Samples were 
centrifuged 20 minutes at 13000rpm at +4°C after overnight incubation and supernatant 
was discarded. The pellet was washed with 1 ml of 70% EtOH and centrifuged for 5 
minutes at 13000 rpm at room temperature. EtOH was removed and the pellet was air-
dried. The pellet was resuspended with 10-20 µl DEPC treated water. 
 
2.3.6.4 Random primed cDNA synthesis from RNA samples 
 
500 ng of total RNA from the tissue samples and 1 µg of total RNA from the cell lines 
were used in random primed cDNA synthesis with RevertAid First Strand cDNA 
Synthesis Kit (Fermentas). 
The specified amount of RNAs (500 ng for tissues and 1 µg for cell lines) was taken and 
prepared in two different tubes (1 tube for +RT and 1 tube for – RT). 1 µl of random 
hexamer primers were added and mixture is completed to 12 µl with DEPC H2O. 
Samples were mixed, spun down, incubated at 65°C for 5 minutes in a thermal cycler and 
then samples chilled on ice. 4 µl of 5X reaction buffer, 1 µl of RiboLock RNase Inhibitor 
and 2 µl of 10 mM dNTP mix added in both of the tubes. 1 µl of RevertAid RT is added 
only to +RT tubes. Samples are mixed, spun down, incubated at 25°C for 5 minutes, 
followed by 42°C for 60 minutes and reaction was terminated at 70°C for 5 minutes in a 
thermal cycler. cDNA products were kept at -80°C for long-term storage. 
 
2.3.7 Real-Time PCR 
2.3.7.1 Real-Time PCR 
 
Real-time PCR was performed with primers targeting 45S ETS, 18S, 28S and 5.8 rRNA 
transcripts. All primer sequences were listed in Table 2-4. Random primed cDNAs from 
both cell lines and frozen tissue samples were diluted at 1/5 ratio. 1µl of diluted cDNA 
was used in every reaction containing 10 µl of Dynamo SYBR Green qPCR Kit (Thermo 
Scientific) and 10 pmol of forward and reverse primers in 20 µl of final volume. Thermal 
cycling conditions are as follows: initial denaturation 5min at 95°C, 40 cycles of 30 s at 
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95°C, 30 s at 60°C and 30 s at 72°C followed by melting curve. All reactions were set as 
duplicates. The Stratagene Mx3005P Real-Time PCR System (Agilent, USA) was used 
for real-time PCR experiments.  
 
2.3.7.2 Real-Time PCR data analysis 
 
The Stratagene Mx3005P Real-Time PCR System automatically calculates the threshold 
line and cycle threshold (Ct) values are calculated depending on the threshold line. We 
used the logarithmic scaling to manually determine the threshold line to increase the 
sensitivity of each run. The automatic and manual threshold lines were presented for 5.8S 
rRNA as an example (Figure 2.1). New threshold lines enabled us to determine more 
subtle changes between samples while eliminating the noise signal.  
  
 
Figure 2.1. The threshold line of qRT-PCR results were changed from automatically 
calculated threshold line (A) to manually determined threshold line (B) by using log 
transformed Ct values for more sensitive analysis. 
 
The average of the duplicates were calculated if the duplicates are consistent with each 
other. Relative expression levels of rRNAs (18S, 28S, 5.8S and 45S ETS) were evaluated 
using Log2 (2-'Ct) calculation.  
TBP, ACTB and ACTB&TBP genes were used as reference genes for cell lines and TBP 
was used as a reference gene in breast tumor and paired normal tissue samples to assess 
the amount of cDNA. However both genes are known to be fluctuating between breast 
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tumor and normal samples, we purposed the use of geometric mean of rRNA transcripts 
(GM-rRNAs) to identify relative changes of rRNAs in the rRNA pool. Accordingly, we 
also used GM-rRNA values to determine relative rRNA expression values again using the 
Log2 (2-'Ct) calculation method. 
 
2.3.8 Statistical Analyses 
2.3.8.1 Statistical analyses of methylation data 
 
Raw bisulfite sequencing data were aligned with genomic DNA sequence of amplified 
region (rDNA promoter region from -380 to +53 bp) using Quantification of Methylation 
Analysis (QUMA) tool which is a web-based quantification tool for methylation analysis 
(http://quma.cdb.riken.jp) (Kumaki et al. 2008). Raw data was trimmed with reference to 
genomic DNA sequence using QUMA. Analysing the unconverted cytosine residues in 
non-CG sites in raw sequencing data used to determine the bisulfite conversion rate of the 
clones. A 95% bisulfite conversion rate was determined as the threshold and clones with 
lower conversion rates were excluded. Clones from each sample were displayed as 
lollipop graphs using QUMA program.  
The Wilcoxon signed rank test was used to test paired differences between breast tumor 
and matched normal methylation levels instead of the Mann-Whitney U test offered by 
the QUMA tool. 
 
2.3.8.2 Pattern similarity analyses in tissue samples 
 
We used methylation percentages of every CpG position in a tissue sample and correlated 
it with its pair to identify whether there is a correlation in the methylation pattern of pairs. 
We performed the same analysis with unmatched tumor and normal pairs to find out 
whether the methylation pattern is patient specific or tissue specific. We used Pearson 
correlation to test the pattern similarity analysis. 
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2.3.8.3 Analyses of clinical variables with methylation difference values 
 
Methylation difference in each CpG was calculated as methylation % tumor sample - 
methylation % of matched normal sample as shown in Table 2-8. Only 12 CpGs from 
two paired samples were shown. 
 
Table 2-8 Calculation of percent methylation difference in each CpG 
CpG 
Number 1 2 3 4 5 6 7 8 9 10 11 12… 
113N 40 70 60 70 90 40 60 60 70 70 40 50 
113T 40 40 30 50 30 50 60 60 50 40 40 40 
Meth Dif. 
(T-N) 0 -30 -30 -20 -60 10 0 0 -20 -30 0 -10 
146N 20 20 10 60 50 10 10 30 30 10 20 40 
146T 100 90 90 100 90 90 80 100 100 90 70 70 
Meth Dif. 
(T-N) 80 70 80 40 40 80 70 70 70 80 50 30 
Green and squares indicate less and more methylated CpGs in tumors compared to normal tissue 
pair, respectively. 
 
 
Percent methylation differences of 54 CpGs of all the clones for each sample were used 
to generate Figure 3.6 and Figure 3.7. Both CpG positions and samples were grouped by 
their methylation pattern using Cluster 3.0 program.  
Cluster 3.0 is a publicly available program 
(http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm), generally used in the 
analysis of expression arrays. We used unsupervised hierarchical clustering of Cluster 3.0 
program with breast tumor and normal paired samples based on their methylation 
differences to group the patient samples. Java Treeview program 
(http://jtreeview.sourceforge.net/) was used to visualization of the clustering data. 
Two groups (methylated and unmethylated) were identified. Fisher’s exact test was used 
to identify any association between these groups and clinical variables (categorical 
variables).  
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2.3.8.4 Correlation analyses of clinical variables and methylation levels 
 
Methylation differences might not be reflected in the patient characteristics. We used 
only methylation levels (%) of the tumor and normal samples to test the association with 
patient features: age, ER, PR, distant metastasis, lymph node and metastasis status. 
Spearman correlation was performed this time since it is better at testing different types 
of data (methylation and clinical variables in our case) by using a ranking system 
compared to Pearson that can evaluate linear relationships. 
 
2.3.8.5 Relationship between methylated CpGs and clinical variables  
 
Multivariate analysis of variance (MANOVA) is a statistical test used for comparing 
mean values of multiple variables in different groups. We used MANOVA to determine 
the effect of the independent variables (clinical variables) on methylation levels of each 
CpG position (dependent variable).  
 
2.3.8.6 Expression analyses of rRNA genes  
 
We used ACTB, TBP, ACTB&TBP and GM-rRNA normalization methods to test the 
effect of normalization on expression changes in rRNA transcripts. Expression 
differences of rRNAs between treated and untreated cell lines or tumor and matched 
normal samples were performed using paired t-test. 
 
2.3.8.7 Analysis of clinical variables and rRNA expression levels 
 
Multiple regression analysis was used to predict clinical variables based rRNA 
expression values. We also used Spearman correlation to identify the association between 
rRNA levels and clinical features of the patients.  
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2.3.8.8 Correlation analyses of rRNA expression and rDNA methylation levels 
 
rDNA methylation levels and rRNA gene expression levels were tested using Spearman 
correlation to determine whether rDNA promoter methylation has an effect on rRNA 
gene expression in breast cancer cell lines as well as in tissue samples. The same 
correlation analysis is also used to identify the correlation between CpG methylation 
levels and rRNA gene expression.  
Ct values of rRNA species (18S, 28S, 5.8S and 45S ETS) were used in Spearman 
correlation test to see whether there is a correlation between spliced rRNA products in 
tissue samples.   
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3 RESULTS 
3.1 Methylation Analysis of 45S rDNA Promoter Region in Breast Cancer 
3.1.1 Methylation Analysis of 45S rDNA Promoter Region in Breast Cancer Cell 
Lines 
 
Bisulfite sequencing primers targeting a 434 bp region spanning both Upstream Control 
Element (UCE) and core promoter (CP) region (from -381 bp to +53 bp) were used to 
amplify bisulfite treated DNA from ten breast cancer cell lines (MCF7, MDA-MB-231, 
MDA-MB-453, MDA-MB-468, BT-474, ZR-75-1, BT-20, MDA-MD-361, SKBR-3 and 
CAL-51) and a non tumorigenic breast cell line (MCF-10A). Five clones were randomly 
selected and sequenced using SP6 primers. Raw data was aligned, trimmed and analysed 
using the QUMA tool (Kumaki et al. 2008).  
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Figure 3.1. The methylation status of the 45S rDNA promoter in breast cancer cell lines and 
a non-tumorigenic breast cell line (MCF-10A). A total of 54 CpGs in a region spanning -381 
bp to +53 bp was analysed by the bisulfite sequencing method. Each row corresponds to the 
sequence analysis of one clone and each column represents the CpG positions. The filled 
and empty circles stand for methylated and unmethylated CpGs respectively. Average 
methylation percentages of the clones for each sample are indicated at the right of the 
graph.  
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45S rDNA promoter region was heavily methylated (ranging from 74% to 96%) in all 
breast cancer cell lines (Figure 3.1). 
 
3.1.2 Methylation Analysis of 45S rDNA Promoter in Breast Tumor and Matched 
Normal Tissue Samples 
 
Nineteen breast cancer tissue and matched normal tissues (Table 2-6) were used to 
analyse 45S rDNA promoter methylation status with the same bisulfite sequencing 
method. Randomly selected ten clones were sequenced for each sample.  
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Figure 3.2. Methylation levels of the 45S rDNA promoter region in clinical breast cancer are 
significantly higher than their matched normal tissue samples in thirteen pairs. Ten 
randomly selected clones were sequenced from each sample. Wilcoxon Signed-Rank test 
was used to identify methylation differences between paired samples. (** for p<0.0001 and * 
for p<0.05).  
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Thirteen breast tumor samples (68.4%) have significantly higher methylation levels than 
their matched normal samples at the 45S rDNA promoter region (Figure 3.2). 
 
 
Figure 3.3. Methylation levels of the 45S rDNA promoter region in normal breast tissues are 
significantly higher than their matched breast tumor tissue samples in three pairs. Ten 
randomly selected clones were sequenced from each sample. Wilcoxon Signed-Rank test 
was used to identify methylation differences between samples. (** for p<0.0001 and * for 
p<0.05). 
 
Three normal breast samples have significantly higher methylation levels than their 
matched tumor tissue at the 45S rDNA promoter region (Figure 3.3). 
 
 
Figure 3.4. Methylation status of the 45S rDNA promoter region in clinical breast cancer 
and matched normal tissues are at similar levels in three pairs. Ten randomly selected 
clones were sequenced from each sample. Wilcoxon Signed-Rank test was used to identify 
methylation differences between samples.  
 
No significant methylation difference was observed between three pairs of tissue samples 
(Figure 3.4). 
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Our results revealed that 13 out of 19 (68.4%) breast cancer tissue samples had higher 
methylation levels at 45S rDNA promoter region (Figure 3.2). On the other hand, three 
samples (15.8%) showed significantly higher methylation levels in normal samples 
compared to their tumor pairs (Figure 3.3), whereas there was no significant difference 
between promoter methylation levels of breast tumor and matched normal tissues in the 
remaining three samples (15.8%)  (Figure 3.4). Normal samples were not fully 
unmethylated and instead showed a mosaic methylation pattern, a relatively common 
observation for human rDNA promoters (Ghoshal et al. 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 53 
 
 
 
Figure 3.5. Methylation levels of every CpG in clones from breast tumor and paired normal tissues were compared to determine 
differentially methylated CpGs. Methylation percentages of every CpG are presented as a pie chart. Significantly (p<0.05) methylated 
CpGs in tumor samples compared to normal samples were indicated with “*”. 
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The analysis of individual CpGs in all tumor and normal tissue samples using Wilcoxon 
matched pairs signed rank test, revealed significant methylation differences at certain 
CpGs (Figure 3.5). 
 
3.1.3 Methylation Pattern Similarity Between Breast Tumor and Matched Normal 
Tissues 45S rDNA Promoter Region 
 
We used methylation levels in all CpGs of a tumor and its normal pair in order to see 
whether a patient (individual) specific methylation pattern exists in this region.  
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Table 3-1. Correlation of methylation between tumor 
and matched normal samples 
 Pearson r Pearson p Significant 
96 0.199 0.149  
113 0.328 0.015 * 
115 0.352 0.009 * 
116 0.335 0.013 * 
133 0.339 0.012 * 
137 0.196 0.156  
146 0.346 0.010 * 
148 0.474 <0.0001 * 
154 0.398 0.003 * 
159 0.300 0.028 * 
161 0.552 <0.0001 * 
164 0.204 0.138  
166 0.121 0.382  
168 0.511 <0.0001 * 
170 0.201 0.145  
173 0.081 0.561  
176 0.272 0.047 * 
177 0.348 0.010 * 
181 0.259 0.058  
Pearson r: Pearson correlation coefficient, Pearson p: 
Pearson correlation significance, *Significant correlation 
p<0.05 
 
Twelve pairs out of nineteen pairs (63%) showed significant correlation for their 
methylation patterns (Table 3-1). Unmatched tumor and normal samples were also 
analysed to ensure that this pattern similarity is patient specific but not tissue specific. 
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Table 3-2. A representative of Pearson correlation between unmatched tumor and 
normal breast tissue samples 
  
96T 113T 115T 116T 133T 
96N Pearson r 0.199 0.497 0.316 0.163 0.435 
 
Pearson p 0.149 p<0.001* 0.02* 0.24 0.001* 
113N Pearson r 0.346 0.328 0.501 0.179 0.412 
 
Pearson p 0.01* 0.015 p<0.001* 0.195 0.002* 
115N Pearson r 0.226 0.343 0.352 0.039 0.611 
 
Pearson p 0.1 0.011* 0.009 0.778 p<0.001* 
116N Pearson r 0.303 0.279 0.324 0.335 0.421 
 
Pearson p 0.026* 0.041* 0.017* 0.013 0.002* 
133N Pearson r 0.004 0.233 0.422 0.239 0.339 
 
Pearson p 0.978 0.09 0.001* 0.081 0.012 
Pearson r: Pearson correlation coefficient, Pearson p: Pearson correlation significance, 
*Significant correlation p<0.05 
 
All unmatched tumor and normal tissue samples were evaluated with Pearson correlation 
test. Table 3-2 shows correlation results between a few tumors and normal samples. 
Significantly (p<0.05) correlated methylation levels between unmatched tumor and 
normal samples were indicated with “*”. Unpaired tumor and normal samples were 
analysed with Pearson correlation and 48.8% (167/342) of the unpaired samples showed 
significant correlation. This data indicates that pattern similarity might be tissue specific 
rather than patient specific. 
 
3.2 Analysis of Clinical Variables with Promoter Methylation Levels 
 
3.2.1 Classifying Patients According to Methylation Difference 
 
Cluster 3.0 program was used for unsupervised hierarchical clustering of breast tumor 
and normal paired samples based on their methylation differences. 
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Figure 3.6. CpG methylation differences were calculated (tumor methylation % - normal methylation %) in each pair and unsupervised 
hierarchical clustering was performed using Cluster 3.0 program and Treeview program. Reddish squares indicated the CpG positions 
with higher methylation in tumor samples whereas greenish squares showed CpG position with higher methylation in normal pairs.  
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Figure 3.7. CpG methylation differences were calculated (tumor methylation % - normal methylation %) in each pair (including sample 
115) and unsupervised hierarchical clustering was performed using Cluster 3.0 program and Treeview program. Reddish squares 
indicated the CpG positions with higher methylation in tumor samples whereas greenish squares showed CpG position with higher 
methylation in normal pairs.  
.  
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Unsupervised hierarchical cluster images were generated using percent methylation 
differences in each CpG of tumor and normal paired samples. Dendogram divided 
patients into two main groups depending on their methylation patterns.  
Samples were grouped by their methylation differences using the values given in Table 2-
8 upper part of the Figure 3.6 includes highly methylated tumor samples 96, 146, 148, 
164, 166, 170 and 168 (Group 1, more methylated in tumors compared to matched 
normal tissues) whereas the lower part contains lower methylation of tumor samples 
including 159, 137, 154, 116, 113, 161, 176, 177 and 181 (Group 2, less methylated in 
tumors compared to matched normal tissues). This grouping of the samples by their 
methylation differences can be used for further analysis with their ER (Estrogen 
Receptor) and PR (Progesterone Receptor) status. Samples 133 and 173 were excluded 
from this analysis since we do not have any patient information for these two samples 
and sample 115 was excluded from the first clustering in Figure 3.6  since we do not have 
its ER and PR information of the patient 115.  
When sample 115 was included in hierarchical clustering, the picture did not change 
significantly much as seen in Figure 3.7 but sample 115 was grouped with more 
methylated in tumor samples group (Group 1). 
The cluster image in Figure 3.7 is similar to the cluster in Figure 3.6, but sample 115 was 
clustered with highly methylated tumor samples. This grouping of the samples by their 
methylation differences can be used for further analysis with distant metastasis and 
pathological lymph node status of the patient samples. 
 
3.2.2 Analysing Clinical Characteristics of the Patients with Methylation 
Difference Classifications 
 
Methylation data can be linked to the clinical variables and it can be statistically tested 
whether methylation differences or methylation patterns can explain any of the clinical 
features. 
In the Figure 3.6 two groups were identified depending on their methylation differences. 
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Group 1, methylated in tumors, including samples 96, 146, 148, 164, 166, 170 and 168. 
Group 2, unmethylated in tumors, including samples 159, 137, 116, 113, 161, 176, 177 
and 181. 
Patterns of methylation differences between tumor and normal pairs grouped the patients 
into two groups as explained above and this data could be used to analyse association 
between methylation groups and the clinical variables of the patients. A simple statistical 
test known as Fisher’s exact test was used to examine the association (contingency) 
between the two kinds of classification. We generated the contingency tables using 
hierarchical clustering groups and ER, PR, metastasis and lymph node status. 
 
Table 3-3. Contingency table is generated using hierarchical clustering groups 
and ER status of the patients 
 ER +                ER- 
ER - 
Total 
Group 1 3 4 7 
Group 2 2 7 9 
 5 11 16 
 
No statistically significant (p=0.5962) association was found between hierarchical 
clustering groups of methylation (group 1 and group 2) and ER status (+,-). 
 
Table 3-4. Contingency table is generated using hierarchical clustering groups 
and PR status of the patients 
   PR +               PR- 
ER - 
Total 
Group 1  5 2 7 
Group 2 4 5 9 
 9 7 16 
 
No statistically significant (p=0.3575) association was found between hierarchical 
clustering groups of methylation (group 1 and group 2) and PR status (+,-). 
As shown in Figure 3.7 sample 115 was included and hierarchical clustering was 
performed again, sample 115 was identified in the Group 1. 
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Table 3-5. Contingency table is generated using hierarchical clustering groups and 
distant metastasis status of the patients 
 Metastasis + Metastasis - Total 
    Group 1 1 7 8 
Group 2 3 6 9 
  4 13 17 
 
No statistically significant (p=0.5765) association was found between hierarchical 
clustering groups of methylation (group 1 and group 2) and the distance metastasis status. 
 
Table 3-6. Contingency table is generated using hierarchical clustering groups and 
lymph node involvement of the patients 
 Lym. Node + Lym. Node - Total 
    Group 1 5 3 8 
Group 2 6 3 9 
  11 6 17 
 
No statistically significant (p=0.600) association was found between hierarchical 
clustering groups of methylation (group 1 and group 2) and the lymph node status. 
Methylation differences based hierarchical clustering has generated two groups, these 
two groups analysed with Fisher’s exact test in order to find a relation between clinical 
parameters and methylation levels yet no significant result was obtained. 
 
3.2.3 Correlation Analysis Between Clinical Variables and 45S rDNA Promoter 
Methylation Levels in Breast Cancer Tissues 
 
Analysis using methylation differences between tumor and paired normal samples did not 
identify any significant association with the clinical variables using Fisher’s exact test. So 
we used using Spearman correlation (two-tailed) analysis to determine whether DNA 
methylation levels of 45S rDNA promoter in tissue samples have a more direct 
association with the clinical variables (Table 3-7). 
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Table 3-7. Spearman correlation analysis of methylation levels and clinical features of 
the tumor and normal samples 
!! !!
Age ER PR Dist. Met. 
Lym. 
Node Grade Stage 
M
et
hy
la
tio
n 
of
 
N
or
m
al
 
Sa
m
pl
es
 Spear
man ! -0.368 -0.12 0.346 0.084 0.139 -0.096 -0.031 
Spear
man p 0.24 0.726 0.297 0.796 0.666 0.779 0.924 
N 12 11 11 12 12 11 12 
M
et
hy
la
tio
n 
of
 
T
um
or
 
Sa
m
pl
es
 Spear
man ! -0.091 0.12 0.289 -0.084 0.251 0.064 -0.047 
Spear
man p 0.778 0.726 0.389 0.796 0.432 0.852 0.885 
N 12 11 11 12 12 11 12 
?; Spearman correlation coefficient, p Spearman correlation significance!!!
None of the clinical variables showed correlation with rDNA promoter methylation levels 
of breast tumor and matched normal pairs. 
 
3.2.4 Analysis of Methylation Differences at Certain CpG Positions and their 
Relation to Clinical Parameters by Using MANOVA 
 
In the previous analysis, total methylation percentage of each sample was used to analyse 
the effect of total methylation at the rDNA promoter region. Multiple ANOVA 
(MANOVA) test was used to analyse the effect of clinical variables on methylation levels 
of each CpG position. 
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Table 3-8. CpG positions showing significant methylation difference 
depending on clinical parameters. 
  Dependent 
Variable 
Mean 
Square 
F Sig. 
ER  CpG10 4439.264 7.35 0.017 
CpG13 3114.409 4.709 0.048 
CpG15 2753.059 6 0.028 
CpG18 4597.878 13.228 0.003 
CpG19 3178.7 4.862 0.045 
     PR    CpG4 4145.589 6.58 0.022 
Distant 
Metastasis  
  CpG7 3204.935 7.861 0.013 
CpG30 4626.812 6.069 0.026 
CpG36 1748.355 4.853 0.044 
CpG43 1921.188 4.724 0.046 
CpG45 3201.889 5.448 0.034 
CpG46 3553.622 5.939 0.028 
CpG51 1980.609 4.643 0.048 
CpG52 3390.332 7.71 0.014 
CpG55 2317.119 5.093 0.039 
Lymph Node    No CpG 
F: Representative of the degree of difference in the dependent variable 
generated by the independent variable, it also considers covariance of the 
variables. Sig: Significance 
  
Sequential CpGs CpG 10, 13, 15, 18 and CpG 19 can be important and can be analysed 
further to see whether this part of the promoter contains any estrogen responsive 
elements. 
Distant metastasis status was also found to be associated with several CpG positions, 
some of them are sequential, such as: CpG 43, 45 and CpG 46 or CpG 51, 52 and CpG 
55. 
ER status and distant metastasis status was found to be associated with more than one 
CpG position (almost all found to be sequential) whereas PR was found to be related to 
only one CpG position (CpG 4) and there was no relationship found between lymph node 
status and differential methylation of CpG positions. 
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3.3 Transcription Factor Binding Site Analysis of 45S rDNA Promoter with 
Promo 3.0 
 
Transcription factor binding site prediction tool PROMO 3.0 was used in order to see 
whether any of the CpGs in the analysed 45S rDNA promoter region is important for the 
binding of potential transcription factors.  
PROMO is a virtual laboratory for the identification of putative transcription factor 
binding sites (TFBS) in DNA sequences from a species or groups of species of interest. 
TFBS defined in the TRANSFAC database are used to construct specific binding site 
weight matrices for TFBS prediction (Messeguer et al. 2002; Farré et al. 2003). 
 
0 GR-alpha 1 Pax-5  2 GCF 3 ER-alpha  
4 GATA-1 5 NF-1 6 C/EBPbeta  7 TFII-I  
8 AP-2alphaA  9 YY1      
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Figure 3.8. Promo 3.0 program is used to predict potential transcription factor binding sites 
at the 45S rDNA promoter region. 
 Nine different types of transcription binding sites were identified in this region. All sites 
predicted have a dissimilarity rate less or equal to 1%. 
 
Some of the TFBS predicted to have more than one binding site (GR-alpha, Pax-5, TFII-I 
and AP-2 alpha A).  
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Table 3-9. Transcription binding sites in 45S promoter sequence predicted by 
PROMO 3.0 
TFBS Sequence Start bp End bp CpG Status 
GR-alpha  
AGAGG 38 42 No CpG 
AGAGG 215 219 No CpG 
ACAGG 265 269 No CpG 
CCTCT 395 399 No CpG 
CCTGT 405 409 No CpG 
AGAGG 416 420 No CpG 
Pax-5  
GGGCCGG 90 96 CpG 15 
GGGCCGG 131 137 CpG 20 
CCGGCCC 134 140 CpG 20 
CCGGCCC 175 181 CpG 26 
GGGCCGG 291 297 CpG 41 
CCGGCCC 322 328 CpG 47 
GCF  GCCCGGCGC 178 186 CpG 27 and CpG 28 
ER-alpha TGACC 210 214 No CpG 
GATA-1 TATCTT 340 345 No CpG 
NF-1 TTGGGCCG 364 371 CpG 52 
C/EBPbeta TTGC 380 383 No CpG 
TFII-I 
GGACAG 263 268 No CpG 
CTGTCC 391 396 No CpG 
AP-2 alpha A 
GCCTGG 47 52 No CpG 
GCCTGG 287 292 No CpG 
YY1 ATGG 247 250 No CpG 
Significantly methylated CpGs in tumor samples were shown with bold characters. 
 
Predicted transcription binding sites may contain CpGs (such as Pax-5, GCF and NF-1) 
and CpG methylation at these sites might play a key role in the expressional regulation. 
As shown in Table 3-9, Pax-5 TFB sites overlap with 5 CpG positions; 3 of them (CpG 
20, 26 and 41), written with bold characters, were found to be significantly methylated in 
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tumor samples compared to normal pairs. GCF sites overlap with two CpG positions and 
only one of them was identified as significantly methylated in tumors whereas the NF-1 
binding site contains one CpG position (CpG 52), which is significantly methylated in 
tumor samples compared to normal samples. 
 
3.4 Expression Analysis of rRNA Transcripts in Breast Cancer 
 
There are three ribosomal RNAs (18S, 28S and 5.8S) synthesized from the 45S rDNA 
promoter. They are synthesized as a long precursor 45S pre-RNA including ETS 
(external transcribed spacer) and ITS (internal transcribed spacer) regions and then 
rapidly processed, modified and assembled into respective ribosome subunits. Expression 
analyses of 18S, 28S, 5.8S rRNAs and 45S ETS region (which has a relatively short half 
life) was performed with the qRT-PCR primers listed in Table 2-4. 
 
3.4.1 Expression Analysis of rRNA Transcripts in Breast Cancer Cell Lines 
 
It is known that promoter DNA methylation has a repressive effect, especially on Pol II 
transcribed genes in cancer and increased methylation levels are implicated in decreased 
levels of rRNA transcription (M Esteller 2007; Esteller et al. 2001; Ghoshal et al. 2004; 
Raval et al. 2012). Thus we hypothesized that rRNA transcription levels might also be 
down regulated in these breast cancer cell lines with the hypermethylated 45S rDNA 
promoter (Figure 3.1). Total RNA was analysed with primers targeting Pol I products; 
18S, 28S, 5.8S and 45S ETS region in cell lines by qRT-PCR. 
TBP, ACTB and ACTB&TBP genes were used as reference genes for cell lines to assess 
the amount of cDNA. We also used the geometric mean of rRNA transcripts (GM-
rRNAs) to identify relative changes of rRNAs in the rRNA pool. 
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Figure 3.9. rRNA transcript levels in breast cancer cell lines normalized with reference 
genes (A) ACTB transcript level (B) TBP transcript level (C) geometric mean of 
ACTB&TBP (D) GM-rRNA. 
 
All of the rRNA transcripts were expressed at different levels among cell lines when 
normalization was performed with ACTB, TBP and ACTB&TBP expression values 
(Figure 3.9 A, B and C). Similar results were obtained when we used GM-rRNA to 
determine changes in the ratio of rRNA transcripts (Figure 3.9 D). 
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3.4.2 Expression Analysis of rRNA Transcripts in Breast Cancer Cell Lines 
Treated with Epigenetic Drugs 5-AZA and/or TSA 
 
To further establish the relationship between 45S rDNA promoter methylation and rRNA 
expression levels, we used the hypomethylating agent, 5-Aza-2’deoxycytidine (5-AZA), 
which prevents DNA methylation by inhibiting DNA methyltransferases and leads to 
increased RNA transcription (Ballestar & Esteller 2008). Expression analyses of rRNA 
transcripts were determined using ACTB, TBP, geometric mean of ACTB&TBP 
(ACTB&TBP) or geometric mean of rRNAs (GM-rRNA). 
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Figure 3.10. rRNA transcript levels in 5-AZA and DMSO (control) treated cell lines. 
Expression levels of rRNA transcripts in the 5-AZA or DMSO treated breast cell lines were 
normalized to (A) ACTB transcript level (B) TBP transcript level (C) geometric mean of 
ACTB&TBP (D) GM-rRNA. Box plots indicate relative expression levels of rRNA 
transcripts in DMSO and 5-AZA treated cell lines. Significant (* p<0.05) rRNA expression 
differences between DMSO and 5-AZA treated cell lines were determined using paired t-
test. 
 
ACTB, TBP and ACTB&TBP normalized expression levels of 5.8S and 45S ETS 
transcripts were significantly decreased upon 5-AZA treatment (Figure 3.10 A, B and C). 
However, proportion of rRNA transcripts did not exhibit significant differences between 
5-AZA treated and DMSO treated samples (normalization with GM-rRNA) (Figure 3.10 
D).  
TSA is a non-specific histone deacetylase (HDAC) inhibitor. TSA treatment of cells 
affects the acetylation status of H3 and H4 and thus TSA indirectly upregulates gene 
expression by dispersion of the chromatin structure (Ballestar & Esteller 2008). 
Therefore, TSA was used to determine whether other mechanisms (such as histone 
acetylation) were involved in rRNA synthesis besides DNA methylation. 
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TSA treatment alone did not significantly alter the expression levels or the relative 
proportions of rRNA transcripts when normalized with ACTB, TBP, ACTB&TBP or 
GM-rRNA, respectively (Figure 3.11 A, B, C and D).  
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Figure 3.11. rRNA transcript levels in TSA and DMSO (control) treated cell lines. 
Expression levels of rRNA transcripts in the TSA or DMSO treated breast cell lines were 
normalized to (A) ACTB transcript level (B) TBP transcript level (C) geometric mean of 
ACTB&TBP (D) GM-rRNA. Box plots indicate relative expression levels of rRNA 
transcripts in DMSO and TSA treated cell lines. Significant (* p<0.05) rRNA expression 
differences between DMSO and TSA treated cell lines were determined using paired t-test. 
 
In order to identify whether these two epigenetic mechanisms (DNA methylation and 
histone acetylation) work together to regulate the rRNA expression, 5-AZA and TSA 
were used together to treat cell lines. 
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Figure 3.12. rRNA transcript levels in 5-AZA+TSA and DMSO (control) treated cell lines. 
Expression levels of rRNA transcripts in the 5-AZA+TSA or DMSO treated breast cell lines 
were normalized to (A) ACTB transcript level (B) TBP transcript level (C) geometric mean 
of ACTB&TBP (D) GM-rRNA. Box plots indicate relative expression levels of rRNA 
transcripts in DMSO and 5-AZA+TSA treated cell lines. Significant (* p<0.05) rRNA 
expression differences between DMSO and 5-AZA+TSA treated cell lines were determined 
using paired t-test. 
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Treatment with 5-AZA and TSA together (5-AZA+TSA) did not significantly effect the 
ACTB or TBP normalized expression levels of rRNA transcripts (Figure 3.12 A, B), but 
it significantly increased 18S rRNA expression when normalization was performed with 
ACTB&TBP (Figure 3.12 C). However, the 5.8S proportion of rRNAs was significantly 
decreased in 5-AZA+TSA treated samples compared to DMSO treated samples (Figure 
3.12 D). 
 
3.4.3 Expression Analysis of rRNA Genes in Breast Tumor and Matched Normal 
Tissue Samples 
 
TBP, GAPDH and ACTB have been used as reference genes to determine rRNA 
expression levels in many studies (Raval et al. 2012; Uemura et al. 2011; Brown & Szyf 
2008) but these RNA Polymerase II (Pol II) transcribed genes are variably expressed in 
many cancer types (Guo, Liu & Sun 2013; Guo, Liu, Wang, et al. 2013).  
We performed an expression analysis with the potential reference genes using Oncomine 
expression database (https://www.oncomine.org/resource/main.html) to be able to choose 
the most stably expressed reference gene between breast tumor and normal samples. 
There were 10-13 available breast cancer tissue datasets in Oncomine acquired through 
microarray or next-generation sequencing technology, we showed only 2 of them (the 
most variable datasets). 
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Figure 3.13. Expression analysis of ACTB expression levels in Oncomine datasets. (A) 
ACTB expression analysis using Ma Breast (Ma et al. 2009) dataset in Oncomine (B) ACTB 
expression analysis using Curtis Breast (Curtis et al. 2012) dataset in Oncomine. No value: 
Normal breast tissue samples. 
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As shown in Figure 3.13 ACTB levels were variably expressed between normal breast 
tissue and breast cancer samples. The difference of ACTB levels was statistically 
significant between normal and cancer in different studies. The ACTB gene is therefore 
not a suitable reference gene to normalize breast tumor-normal tissues. 
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Figure 3.14. Expression analysis of GAPDH expression levels in Oncomine datasets. (A) 
GAPDH expression analysis using Curtis Breast (Curtis et al. 2012) dataset in Oncomine 
(B) GAPDH expression analysis using Perou Breast (Perou et al. 2000) dataset in Oncomine. 
No value: Normal breast tissue samples. 
 
The variability of GAPDH expression levels was more significant than of ACTB levels. 
GAPDH was therefore not the most suitable reference gene. 
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Figure 3.15. Expression analysis of SDHA expression levels in Oncomine datasets. (A) 
SDHA expression analysis using Ma Breast (Ma et al. 2009) dataset in Oncomine (B) SDHA 
expression analysis using Zhao Breast (Zhao et al. 2004) dataset in Oncomine. No value: 
Normal breast tissue samples. 
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SDHA expression levels were more stable than ACTB and GAPDH but SDHA was still 
significantly lower in normal breast tissue samples compared to breast cancer tissues in 
both studies. 
 
 
 
 84 
 
 
Figure 3.16. Expression analysis of TBP expression levels in Oncomine datasets. (A) TBP 
expression analysis using Sorlie Breast (Sørlie et al. 2001) dataset in Oncomine (B) TBP 
expression analysis using Perou Breast (Perou et al. 2000) dataset in Oncomine. No value: 
Normal breast tissue samples. 
 
As we can see from Figure 3.16 TBP levels were very stable between normal breast and 
breast cancer tissues in different studies especially compared to the other reference gene 
candidates.  
 
3.5 Expression Analysis of rRNA genes in Breast Tumor and Matched 
Normal Tissue Samples using TBP as a Reference Gene 
 
Since, we found that TBP gene is relatively stable compared to other reference genes 
between breast tumor tissues and normal breast tissue samples we used TBP as a 
reference gene to identify absolute rRNA expression levels. 
We tested whether increased levels of methylation of the 45S promoter in tumor samples 
led to repressed expression levels of rRNA transcripts. RNA isolation was performed 
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from the same tissue samples used in methylation analysis (only 14 of 19 paired tissue 
samples had enough tissue for RNA isolation).  
 
 
 
Figure 3.17. Expression analysis of rRNA transcripts in clinical breast tumor and normal 
tissue pairs relative to TBP transcript levels. Relative expression levels of rRNA transcripts 
are shown with box plots for clinical breast cancer and matched normal samples. 
Significant (* p<0.05) expression differences between normal and tumor samples were 
determined using paired t-test. 
 
Expression levels did not differ between tumors and corresponding normal tissues for any 
of the rRNA transcripts when expression was analysed using TBP as seen in Figure 3.17. 
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3.5.1 Multiple Regression Analysis of rRNA Expression Levels (TBP 
normalization) and Clinical Variables in Breast Cancer Tissue Samples 
 
Ribosome biogenesis and rRNA synthesis are implicated in cancer progression. Thus 
rRNA expression levels were used to predict clinical variables in breast cancer tissue 
samples. 
 
A multiple regression was run to predict clinical variables (age, ER, PR, lymph node, 
distant metastasis status, grade and stage of the tumors in patients) from rRNA expression 
values (TBP normalized) of tumor samples.  
 
Table 3-10. Multiple regression analysis of clinical variables and expression values of 
rRNAs in tumor samples 
Dependent 
variable 
Independent 
variable 
Mean 
Square 
ANOVA 
F 
ANOVA 
Sig. 
Age TBP nor. 269.88 2.645 0.124 
ER TBP nor. 0.281 1.188 0.404 
PR TBP nor. 0.06 0.146 0.958 
Distant Metastasis TBP nor. 0.024 0.077 0.987 
Lymph Node TBP nor. 0.214 1.075 0.436 
Grade TBP nor. 0.505 1.876 0.234 
Stage TBP nor. 0.105 0.173 0.945 
ER; estrogen receptor, PR; progesterone receptor, nor; normalization, ANOVA F; 
representative of the degree of difference in the dependent variable generated by the 
independent variable, it also considers covariance of the variables  
 
(Note: Stages were merged due to low number of samples. For example; IIA and IIB 
samples were analysed as stage II). 
None of the variables significantly predicted clinical characteristics of the tumors 
samples. 
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3.5.2 Correlation Analysis of rRNA Expression Levels (TBP normalization) and 
Clinical Variables in Breast Cancer Tissue Samples 
 
We have performed Spearman correlation to identify whether there are any correlation 
between rRNA expression levels and clinical variables of the patients. 
 
Table 3-11. Spearman correlation analysis of clinical variables and expression levels of 
rRNA genes (rRNA/TBP) 
    Normal Tumor 
    18S 28S 5.8S 
45S 
ETS 18S 28S 5.8S 
45S 
ETS 
ER 
! -0.418 0.06 -0.179 -0.538 0.239 -0.418 -0.06 -0.478 
p 0.2 0.861 0.598 0.088 0.479 0.2 0.861 0.137 
N 11 11 11 11 11 11 11 11 
PR 
! -0.289 0.173 -0.115 -0.289 0.058 0.115 0.404 -0.115 
p 0.389 0.611 0.735 0.389 0.866 0.735 0.218 0.735 
N 11 11 11 11 11 11 11 11 
Dist. 
met 
! -0.195 0.028 0.028 -0.195 -0.028 0.084 -0.084 -0.028 
p 0.543 0.931 0.931 0.543 0.931 0.796 0.796 0.931 
N 12 12 12 12 12 12 12 12 
Lym. 
node 
! 0.084 0.195 0.139 -0.028 0.307 -0.195 -0.084 -0.084 
p 0.796 0.543 0.666 0.931 0.332 0.543 0.796 0.796 
N 12 12 12 12 12 12 12 12 
Grade 
! 0.554 0.011 0.107 0.650 -0.32 0.384 0.235 -0.043 
p 0.077 0.975 0.755 0.03* 0.338 0.244 0.488 0.901 
N 11 11 11 11 11 11 11 11 
Stage 
! 0.008 -0.331 0.023 -0.171 0.202 0.132 0.019 0 
p 0.981 0.294 0.943 0.595 0.528 0.682 0.952 1 
N 12 12 12 12 12 12 12 12 
?; Spearman correlation coefficient, p; Spearman correlation significance, N; Sample size. * 
Significant correlations (p<0.05) 
 
45S ETS expression levels (relative to TBP) in normal pairs of the tumor were positively 
correlated with the tumor grade.  
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3.6 Expression Analysis of rRNA genes in Breast Tumor and Matched 
Normal Tissue Samples using GMrRNA as a Reference Value 
 
Several studies advise against using rRNA levels to determine mRNA levels (Gur-
Dedeoglu et al. 2009; Tricarico et al. 2002), since they are variable between breast and 
normal tissue samples. Accordingly, using mRNA levels to normalize rRNA levels have 
a similar drawback as shown in Figure 3.13, Figure 3.14 and Figure 3.15. But TBP gene 
is the most suitable gene among the other candidates. Therefore we used TBP as 
reference gene for rRNA expression analyses in tissue samples. 
In this study, the geometric mean of expression from an rRNA pool (18S, 28S, 5.8S and 
45S ETS) synthesized by Pol I, GM-rRNA, was also used to analyse the relative changes 
of rRNAs with respect to each other between tumor and normal samples. 
TBP normalization and GM-rRNA normalization have helped us to identify two different 
aspects of the rRNA expression levels. TBP normalization is used to find absolute rRNA 
expression levels and GM-rRNA normalization is used to assess whether rRNA transcript 
ratios were affected within rRNA pool. 
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Figure 3.18. Expression analysis of rRNA transcripts in clinical breast tumor and normal 
tissue pairs relative to GM-rRNA value. Relative expression levels of rRNA transcripts are 
shown with box plots for clinical breast cancer and matched normal samples. Significant (* 
p<0.05) expression differences between normal and tumor samples were determined using 
paired t-test. 
 
When normalized with GM-rRNA the proportion of 5.8S rRNA was significantly 
increased in tumor samples whereas that of 18S was significantly decreased (Figure 
3.18). This indicates a dysregulation of the spliced rRNA products in tumor rRNA pool. 
 
3.6.1 Multiple Regression Analysis of rRNA Expression Levels (GMrRNA 
normalization) and Clinical Variables in Breast Cancer Tissue Samples 
 
A multiple regression was run to predict clinical variables (age, ER, PR, lymph node, 
distant metastasis status, grade and stage of the tumors in patients) from rRNA expression 
values (GM-rRNA normalized) of tumor samples.  
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Table 3-12. Multiple regression analysis of clinical variables and expression values of 
rRNAs in tumor samples 
Dependent 
variable 
Independent 
variable 
Mean 
Square 
ANOVA 
F 
ANOVA 
Sig. 
Age GM-rRNA nor. 94.935 0.47 0.757 
ER GM-rRNA nor. 0.352 1.861 0.237 
PR GM-rRNA nor. 0.082 0.206 0.926 
Distant Metastasis GM-rRNA nor. 0.116 0.456 0.766 
Lymph Node GM-rRNA nor. 0.256 1.459 0.31 
Grade GM-rRNA nor. 0.57 2.52 0.15 
Stage GM-rRNA nor. 0.294 0.59 0.681 
ER; estrogen receptor, PR; progesterone receptor, nor; normalization, ANOVA F; 
representative of the degree of difference in the dependent variable generated by the 
independent variable, it also considers covariance of the variables  
 
(Note: Stages were merged due to low number of samples. For example; IIA and IIB 
samples were analysed as stage II). 
None of the variables significantly predicted clinical characteristics of the tumors 
samples. 
 
3.6.2 Correlation Analysis of rRNA Expression Levels (GMrRNA normalization) 
and Clinical Variables in Breast Cancer Tissue Samples 
 
We have performed Spearman correlation to identify whether there are any correlation 
between rRNA expression levels and clinical variables of the patients. 
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Table 3-13. Spearman correlation analysis of clinical variables and expression levels of 
rRNA genes (rRNA/GM-rRNA) 
    Normal Tumor 
    18S 28S 5.8S 
45S 
ETS 18S 28S 5.8S 
45S 
ETS 
ER 
! 0 0.359 0.12 -0.418 0.538 -0.418 0 -0.239 
p 1 0.279 0.726 0.2 0.088 0.2 1 0.479 
N 11 11 11 11 11 11 11 11 
PR 
! -0.231 0.173 0.115 0 0.058 0.231 0.289 -0.346 
p 0.494 0.611 0.735 1 0.866 0.494 0.389 0.297 
N 11 11 11 11 11 11 11 11 
Dist. 
met 
! -0.084 0.307 0.084 -0.362 0.139 -0.084 0.028 0.139 
p 0.796 0.332 0.796 0.247 0.666 0.796 0.931 0.666 
N 12 12 12 12 12 12 12 12 
Lym. 
node 
! -0.195 0.418 -0.195 -0.418 0.53 -0.53 -0.418 -0.307 
p 0.543 0.176 0.543 0.176 0.077 0.077 0.176 0.332 
N 12 12 12 12 12 12 12 12 
Grade 
! 0.181 -0.437 -0.213 0.33 -0.0714 0.725 0.586 -0.107 
p 0.594 0.179 0.529 0.321 0.014* 0.012* 0.058 0.755 
N 11 11 11 11 11 11 11 11 
Clin. 
Stage 
! 0.342 -0.148 0.089 -0.288 0.245 -0.012 0.074 -0.043 
p 0.276 0.647 0.782 0.364 0.443 0.971 0.819 0.895 
N 12 12 12 12 12 12 12 12 
!; Spearman correlation coefficient, p; Spearman correlation significance, N; Sample size. * 
Significant correlations (p<0.05) 
 
 
28S/GM-rRNA ratio of tumor samples was positively correlated while the 18S/GM-
rRNA ratio was negatively correlated with the grade of the tumors. 
 
3.7 Correlation Analysis of rDNA methylation levels and rRNA expression 
levels in breast cancer 
 
rDNA methylation levels as well as rRNA expression levels were determined in both 
breast cancer cell lines and breast cancer and matched normal tissue samples. Since 
rDNA methylation levels were implicated in decreased rRNA expression levels we 
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performed Spearman correlation analysis between rDNA methylation levels and rRNA 
expression levels. 
 
3.7.1 Correlation Analysis of rDNA Methylation Levels and rRNA Expression 
Levels in Breast Cancer Cell Lines 
 
Both 45S rDNA promoter methylation levels and rRNA expression levels were 
determined in ten breast cancer cell lines and MCF-10A. Total rDNA methylation levels 
and rRNA expression levels (normalized with ACTB, TBP, ACTB&TBP or GM-rRNA) 
were analysed with Spearman correlation analysis.  
 
Table 3-14. Spearman correlation analysis of 45S rDNA promoter methylation levels 
and rRNA expression levels (ACTB normalization) in breast cancer cell lines 
 18S rRNA 28S rRNA 5.8S rRNA 45S ETS 
Spearman ! -0.5012 -0.1058 -0.2299 -02805 
Spearman p 0.1078 0.7261 0.4680 0.3768 
?; Spearman correlation coefficient, p: Spearman correlation significance 
 
Table 3-15. Spearman correlation analysis of 45S rDNA promoter methylation levels 
and rRNA expression levels (TBP normalization) in breast cancer cell lines 
 18S rRNA 28S rRNA 5.8S rRNA 45S ETS 
Spearman ! -0.0413 0.4736 0.5564 0.0299 
Spearman p 0.8744 0.1432 0.0794 0.9308 
?; Spearman correlation coefficient, p: Spearman correlation significance 
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Table 3-16. Spearman correlation analysis of 45S rDNA promoter methylation levels 
and rRNA expression levels (ACTB and TBP Normalization) in breast cancer cell lines 
 18S rRNA 28S rRNA 5.8S rRNA 45S ETS 
Spearman ! -0.4368 -0.0505 -0.2207 -0.3678 
Spearman p 0.1652 0.8530 0.4854 0.2461 
?; Spearman correlation coefficient, p: Spearman correlation significance 
 
Table 3-17. Spearman correlation analysis of 45S rDNA promoter methylation levels 
and rRNA expression levels (GM-rRNA Normalization) in breast cancer cell lines 
 18S rRNA 28S rRNA 5.8S rRNA 45S ETS 
Spearman ! 0.0459 0.1885 0.1793 0.3035 
Spearman p 0.8960 0.5773 .5965 0.3615 
?; Spearman correlation coefficient, p: Spearman correlation significance 
 
No significant correlation was identified between rDNA promoter methylation levels and 
rRNA expression levels in breast cancer cell line panel. This indicates that rRNA 
expression levels are independent from the 45S rDNA methylation status in cell lines. 
 
3.7.2 Correlation Analysis of rDNA Methylation Levels and rRNA Expression 
Levels in Breast Cancer and Matched Normal Tissue Samples 
 
Even though no significant correlation was identified between 45S rDNA promoter 
methylation levels and rRNA expression levels in breast cancer cell lines, a correlation 
analysis was also performed for tissue samples since cell lines and actual cancer cells 
might act differently. 
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Table 3-18. Spearman correlation analysis of 45S rDNA promoter methylation levels 
and rRNA expression levels (TBP Normalization) in primary breast tumor and 
matched normal samples 
  18S rRNA 28S rRNA 5.8S rRNA 45S ETS 
N
or
m
al
 Spearman ! -0.0901 0.3582 0.1253 0.1473 
Spearman p 0.7616 0.2090 0.6706 0.6158 
T
um
or
 Spearman ! 0.3011 -0.2352 -0.2044 -0.0725 
Spearman p 0.2951 0.4175 0.4827 0.8083 
?; Spearman correlation coefficient, p: Spearman correlation significance 
 
No correlation was identified between rDNA promoter methylation levels and rRNA 
expression levels with TBP normalization.  
 
Table 3-19. Spearman correlation analysis of 45S rDNA promoter methylation levels 
and rRNA expression levels (GM-rRNA Normalization) in primary breast tumor and 
matched normal samples 
  18S rRNA 28S rRNA 5.8S rRNA 45S ETS 
N
or
m
al
 Spearman ! -0.6571 0.3495 -0.3099 -0.1473 
Spearman p 0.0128* 0.2210 0.2806 0.6158 
T
um
or
 Spearman ! 0.3934 -0.3055 -0.3451 -0.1253 
Spearman p 0.1652 0.2878 0.2272 0.6706 
?; Spearman correlation coefficient, p: Spearman correlation significance 
Significant (p<0.05) correlations were shown with “*”. 
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The rDNA promoter methylation levels and 18S/GM-rRNA ratio was found to be 
negatively correlated in normal breast tissues but no correlation was identified in matched 
tumor samples.  
 
 
 
Figure 3.19. Correlation graph of 45S rDNA promoter methylation levels and 18S rRNA 
ratios (18S/GM-rRNA) in breast tumor and matched normal tissue samples. !; Spearman 
correlation coefficient, p: Spearman correlation significance. Spearman correlation analysis 
results are given in the chart below. * Significant correlation p<0.05 
 
Significant correlation between rDNA promoter methylation levels and 18S/GM-rRNA 
ratio is more visible in Figure 3.19. 
3.7.3 Correlation Analysis of CpG DNA Methylation and Expression Levels in 
Breast Cancer and Matched Normal Tissue Samples 
 
In the previous analysis we identified a negative correlation between 18S/GM-rRNA 
ratio and 45S rDNA promoter methylation levels in normal breast tissue samples. We 
performed a correlation analysis with methylation levels of CpG positions and 
rRNA/GM-rRNA ratio in breast tumor and matched normal tissue samples in order to see 
whether methylation levels in any CpG position contribute to this correlation. 
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Table 3-20. Spearman correlation analysis of CpG methylation levels and rRNA 
proportions in normal breast tissues samples 
 
18S rRNA 28S rRNA 5.8S rRNA 45S ETS 
Correlation ! p ! p ! p ! p 
CpG1 -0.619 0.018* 0.445 0.111 -0.485 0.079 -0.16 0.584 
CpG2 -0.603 0.023* 0.421 0.134 -0.417 0.138 -0.119 0.686 
CpG3 -0.461 0.097 0.206 0.48 -0.359 0.208 -0.089 0.763 
CpG4 -0.790 0.001** 0.521 0.056 -0.402 0.154 -0.184 0.529 
CpG5 -0.521 0.056 0.389 0.169 -0.23 0.429 -0.382 0.177 
CpG6 -0.525 0.054 0.372 0.191 -0.523 0.055 -0.092 0.753 
CpG7 -0.261 0.367 0.167 0.569 0.029 0.921 -0.239 0.411 
CpG8 -0.403 0.153 0.101 0.732 -0.356 0.212 0.02 0.946 
CpG9 -0.269 0.353 0.091 0.757 -0.631 0.016* 0.089 0.763 
CpG10 -0.613 0.02* 0.339 0.236 -0.435 0.12 -0.085 0.773 
CpG11 -0.509 0.063 0.291 0.313 -0.504 0.066 0.051 0.862 
CpG12 -0.484 0.08 0.233 0.423 -0.417 0.138 -0.002 0.994 
CpG13 -0.269 0.353 -0.053 0.856 -0.36 0.206 0.193 0.508 
CpG14 -0.415 0.14 0.033 0.91 -0.368 0.196 0.178 0.542 
CpG15 -0.428 0.127 0.105 0.72 -0.372 0.19 0.072 0.808 
CpG16 -0.371 0.192 0.002 0.994 -0.545 0.044* 0.269 0.352 
CpG17 -0.528 0.052 0.172 0.556 -0.164 0.576 -0.013 0.964 
CpG18 -0.385 0.174 0.069 0.815 -0.047 0.874 0.06 0.838 
CpG19 -0.317 0.269 0.114 0.698 -0.042 0.885 -0.089 0.761 
CpG20 -0.527 0.053 0.346 0.225 -0.206 0.481 -0.154 0.599 
CpG21 -0.525 0.054 0.215 0.46 -0.072 0.806 -0.061 0.836 
CpG22 -0.461 0.097 0.193 0.509 -0.002 0.994 -0.172 0.555 
CpG23 -0.393 0.165 0.153 0.601 -0.166 0.569 -0.087 0.769 
CpG24 -0.749 0.002** 0.44 0.115 -0.257 0.375 -0.212 0.466 
CpG25 -0.691 0.006** 0.425 0.129 -0.223 0.444 -0.068 0.819 
CpG26 -0.44 0.116 0.217 0.457 -0.161 0.583 -0.1 0.733 
CpG27 -0.678 0.008** 0.418 0.137 -0.342 0.231 -0.209 0.474 
CpG28 -0.615 0.019* 0.384 0.175 -0.313 0.276 -0.177 0.546 
CpG29 -0.656 0.011* 0.409 0.147 -0.184 0.528 -0.28 0.332 
CpG30 -0.691 0.006** 0.573* 0.032 -0.098 0.739 -0.439 0.116 
CpG31 -0.459 0.098 0.183 0.532 -0.283 0.327 -0.018 0.952 
CpG32 -0.616 0.019* 0.362 0.204 -0.281 0.33 -0.192 0.511 
CpG33 -0.414 0.141 0.209 0.473 -0.313 0.277 0.06 0.839 
CpG34 -0.680 0.007** 0.395 0.163 -0.314 0.274 -0.172 0.557 
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CpG35 -0.625 0.017* 0.293 0.31 -0.293 0.31 -0.129 0.661 
CpG36 -0.567 0.035* 0.376 0.186 -0.398 0.159 -0.1 0.734 
CpG37 -0.358 0.209 0.121 0.681 0.143 0.626 -0.358 0.209 
CpG38 -0.376 0.185 0.19 0.515 -0.514 0.06 -0.005 0.988 
CpG39 -0.733 0.003** 0.458 0.1 -0.28 0.332 -0.193 0.508 
CpG40 -0.505 0.065 0.186 0.524 -0.425 0.13 0.133 0.651 
CpG41 -0.691 0.006** 0.421 0.134 -0.236 0.416 -0.252 0.385 
CpG42 -0.687 0.007** 0.472 0.088 -0.389 0.169 -0.277 0.337 
CpG43 -0.533 0.05* 0.349 0.221 -0.029 0.921 -0.309 0.283 
CpG44 -0.568 0.034* 0.455 0.102 -0.277 0.337 -0.259 0.371 
CpG45 -0.478 0.084 0.236 0.417 -0.26 0.369 -0.024 0.934 
CpG46 -0.423 0.132 0.248 0.394 -0.331 0.248 -0.054 0.855 
CpG47 -0.644 0.013* 0.35 0.22 -0.155 0.597 -0.144 0.624 
CpG48 -0.595 0.025* 0.281 0.331 -0.308 0.284 -0.049 0.868 
CpG49 -0.550 0.041* 0.398 0.158 -0.107 0.715 -0.177 0.546 
CpG50 -0.488 0.076 0.355 0.214 -0.185 0.526 -0.156 0.594 
CpG51 -0.605 0.022* 0.468 0.092 -0.029 0.922 -0.315 0.273 
CpG52 -0.539 0.047* 0.395 0.162 0.142 0.629 -0.423 0.132 
CpG53 -0.361 0.204 0.301 0.296 -0.164 0.576 -0.323 0.26 
CpG54 -0.585 0.028* 0.438 0.118 -0.107 0.715 -0.411 0.145 
 ?; Spearman correlation coefficient, p: Spearman correlation significance. ** Correlation is 
significant at the 0.01 level, * correlation is significant at the 0.05 level (2-tailed). 
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Table 3-21. Spearman correlation analysis of rRNA proportions with CpG methylation 
levels in breast tumor tissue samples 
 
18S rRNA 28S rRNA 5.8S rRNA 45S ETS 
Correlation ! p ! p ! p ! p 
CpG1 0.016 0.956 0.002 0.994 0.051 0.863 -0.223 0.444 
CpG2 0.177 0.546 -0.034 0.908 -0.104 0.723 -0.242 0.404 
CpG3 -0.09 0.759 -0.016 0.957 -0.023 0.939 -0.127 0.666 
CpG4 0.098 0.739 -0.155 0.597 -0.002 0.994 -0.255 0.378 
CpG5 0.224 0.441 -0.22 0.451 -0.358 0.208 -0.096 0.743 
CpG6 0.308 0.284 -0.315 0.273 -0.256 0.377 -0.278 0.335 
CpG7 0.37 0.193 -0.516 0.059 -0.297 0.302 -0.043 0.883 
CpG8 0.013 0.964 -0.148 0.613 -0.027 0.927 0.034 0.909 
CpG9 0.469 0.091 -0.373 0.189 -0.42 0.135 -0.186 0.524 
CpG10 0.504 0.066 -0.052 0.861 -0.193 0.509 -0.600 0.023* 
CpG11 0.246 0.397 0.025 0.932 0.084 0.775 -0.403 0.153 
CpG12 0.542 0.045* -0.176 0.546 -0.167 0.567 -0.342 0.232 
CpG13 0.171 0.56 0.023 0.938 -0.228 0.432 -0.404 0.152 
CpG14 0.115 0.695 0.217 0.456 -0.389 0.169 -0.109 0.712 
CpG15 0.209 0.474 0.155 0.597 -0.025 0.933 -0.254 0.381 
CpG16 0.048 0.871 -0.154 0.598 -0.098 0.74 -0.143 0.626 
CpG17 0.195 0.503 0.076 0.795 -0.088 0.766 -0.002 0.994 
CpG18 0.105 0.72 0.004 0.988 0.04 0.891 0.094 0.749 
CpG19 -0.09 0.759 0.174 0.552 0.213 0.466 -0.038 0.896 
CpG20 0.301 0.296 0.124 0.672 -0.383 0.177 -0.179 0.541 
CpG21 0.427 0.127 -0.22 0.451 -0.392 0.166 -0.241 0.407 
CpG22 0.521 0.056 -0.265 0.36 -0.505 0.065 -0.123 0.674 
CpG23 0.273 0.344 -0.031 0.916 -0.411 0.144 -0.116 0.694 
CpG24 0.278 0.335 -0.083 0.778 -0.321 0.263 -0.166 0.57 
CpG25 0.145 0.62 0.105 0.721 -0.018 0.952 -0.246 0.396 
CpG26 0.025 0.934 0.178 0.542 0.087 0.768 -0.35 0.22 
CpG27 0.082 0.78 -0.049 0.868 -0.049 0.868 -0.151 0.606 
CpG28 0.061 0.835 -0.045 0.877 -0.023 0.939 -0.161 0.582 
CpG29 0.331 0.248 -0.34 0.235 -0.631 0.015* 0.034 0.908 
CpG30 0.447 0.109 -0.385 0.174 -0.519 0.057 0.002 0.994 
CpG31 0.507 0.064 -0.471 0.089 -0.518 0.058 -0.129 0.66 
CpG32 0.205 0.482 -0.339 0.236 -0.288 0.318 0.111 0.707 
CpG33 0.027 0.927 -0.321 0.264 -0.408 0.147 0.419 0.136 
CpG34 0.112 0.704 -0.344 0.229 -0.172 0.557 0.248 0.393 
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CpG35 -0.007 0.982 -0.129 0.659 -0.163 0.578 0.105 0.721 
CpG36 -0.273 0.346 -0.016 0.957 -0.038 0.897 0.207 0.477 
CpG37 0.333 0.245 -0.353 0.216 -0.211 0.468 0.007 0.982 
CpG38 -0.212 0.467 -0.119 0.684 -0.068 0.818 0.178 0.543 
CpG39 0.257 0.376 -0.199 0.496 0.029 0.922 -0.159 0.588 
CpG40 0.273 0.346 -0.216 0.458 -0.437 0.118 0.167 0.569 
CpG41 0.065 0.825 -0.155 0.597 -0.249 0.39 0.11 0.708 
CpG42 -0.145 0.621 -0.071 0.808 0.317 0.269 0.134 0.648 
CpG43 0.313 0.275 -0.127 0.666 -0.242 0.405 -0.053 0.857 
CpG44 0 1 -0.286 0.322 -0.021 0.944 0.16 0.585 
CpG45 0.332 0.247 -0.011 0.97 -0.369 0.194 -0.089 0.762 
CpG46 0.048 0.871 -0.485 0.079 -0.082 0.781 0.43 0.125 
CpG47 0.321 0.263 -0.303 0.292 -0.222 0.447 -0.009 0.976 
CpG48 0.498 0.07 -0.550 0.042* -0.289 0.316 0.044 0.88 
CpG49 0.542 0.045* -0.296 0.305 -0.36 0.206 -0.191 0.513 
CpG50 0.054 0.854 -0.169 0.563 0.056 0.848 -0.005 0.988 
CpG51 0.545 0.044* -0.392 0.166 -0.22 0.451 -0.267 0.356 
CpG52 0.128 0.663 -0.516 0.059 -0.146 0.618 0.158 0.59 
CpG53 -0.196 0.503 -0.04 0.891 0.121 0.679 0.236 0.417 
CpG54 0.351 0.219 -0.535 0.049* -0.207 0.477 -0.034 0.908 
?; Spearman correlation coefficient, p: Spearman correlation significance. ** Correlation is 
significant at the 0.01 level, * correlation is significant at the 0.05 level (2-tailed). 
 
As we can see in Table 3-20, methylation levels in several CpGs (CpG 1, 2, 4, 10, 24, 25, 
27, 28, 29, 30, 32, 34, 35, 36, 39, 41, 42, 43, 44, 47,48, 49, 51, 52, 54) were found to 
negatively correlate with the 18S rRNA/GM-rRNA ratio in normal breast tissue samples, 
yet methylation levels of only two CpGs (CpG 9 and 16) were correlated with the 5.8S 
rRNA/GM-rRNA ratio. Other rRNA proportions (28S/GM-rRNA and 45S ETS/rRNA) 
did not show any correlation with methylation levels of CpGs. In the tumor samples, only 
three CpGs (CpG 12, 49 and 51) were positively correlated with the 18S/GM-rRNA ratio. 
Two CpGs (CpG 48 and 54) were negatively correlated with the 28S/GM-rRNA ratio, 
CpG 29 negatively correlated with the 5.8S/GM-rRNA ratio. CpG 10 was also negatively 
correlated with the 45S ETS/GM-rRNA ratio in breast tumor tissue samples (Table 3-21). 
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3.7.4 Correlation Analysis of rRNA Species Expression Levels in Breast Tumor 
and Matched Normal Tissue Samples 
 
rRNA species are transcribed as 45S rRNA precursor and spliced into 18S, 28S and 5.8S 
rRNA transcripts. If they were spliced simultaneously, one would expect them to be 
expressed relatively equally. However, as shown in Figure 3.18, rRNA proportions were 
dysregulated in tumor samples, which indicates possible disruption of rRNA maturation 
mechanism. Spearman correlation analysis was performed to see whether expression of 
rRNA species were correlated with each other in breast tumor and matched normal tissue 
samples.  
 
Table 3-22. Spearman correlation analysis between rRNA transcripts in tumor and 
normal samples  
  28S rRNA 5.8S rRNA 45S ETS 
N
or
m
al
 18S rRNA 0.837 (p<0.01*) 0.824 (p<0.01*) 0.818(p<0.01*) 
28S rRNA  0.833 (p<0.01*) 0.674(p=0.012*) 
5.8S rRNA   0.57 (p=0.033*) 
T
um
or
 18S rRNA 0.042 (p=0.887) -0.051 (p=0864) 0.288 (p=0.318) 
28S rRNA  0.521 (p=0.056) 0.349 (p=0.221) 
5.8S rRNA   0.543 (p=0.045*) 
Shown are Spearman correlation coefficients ? and p values in brackets 
 
Expressions of rRNA transcripts were significantly correlated with each other in normal 
breast tissue samples whereas this correlation was lost in matched tumor samples. Only 
Ct values of 5.8S rRNA and 45S ETS transcripts were correlated with each other in 
tumor samples whereas all rRNA transcripts were correlated with each other in normal 
samples Table 3-22. 
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4 DISCUSSION 
 
Ribosome biogenesis is the essential requirement for a cell to grow and divide but it is 
limited to the transcription of rRNA genes. Highly proliferative cancer cells are expected 
to increase rRNA expression and thus ribosome biogenesis, but there are only a limited 
number of studies analysing the rRNA expression levels (only 18S rRNA) in breast 
cancer tissues and matched normal samples. These previous studies tested the variation in 
18S rRNA expression in breast cancer and paired normal tissues to use it as a reference 
gene (Gur-Dedeoglu et al. 2009; Tricarico et al. 2002). One of these studies found that 
18S rRNA was expressed at higher levels in breast tumors compared to matched normal 
tissues and the other study found just the opposite but none of them identified whether 
this expression difference of 18S rRNA was the result of the 45S rDNA promoter 
methylation (Gur-Dedeoglu et al. 2009; Tricarico et al. 2002). They also did not use any 
other rRNA transcripts (28S, 5.8S or 45S ETS) to see whether these rRNAs are also 
differentially expressed within the tumor or between tumor and normal pairs.  
DNA methylation of the CpG islands in promoter regions is known to repress 
transcription by interrupting the binding of Pol II to the promoter; considering both Pol I 
and Pol II have common features and transcription factors 45S rDNA promoter 
methylation may interfere with rRNA gene expression from the promoter by Pol I 
(Sentenac 1985; Sharp 1992; Comai et al. 1992; Eden & Cedar 1994).  
In this study, we investigated 45S rDNA promoter methylation levels and expression 
levels of rRNA transcripts (18S, 28S, 5.8S and 45S ETS) together with their relation to 
each other in both breast cancer cell lines and clinical breast cancer tissues. We used ten 
breast cancer cell lines (MCF7, MDA-MB-231, MDA-MB-453, MDA-MB-468, BT-474, 
ZR-75-1, BT-20, MDA-MD-361, SKBR-3 and CAL-51) and a non-tumorigenic breast 
cell line (MCF-10A). The investigated region (-381 bp to +53 bp) was profoundly 
methylated (74%-96% methylation) in all cell lines (Figure 3.1). In accordance with our 
results, transformed cell lines with different origins (Jurkat, CEM, HeLa, KB, NIH 3T3, 
HEK293 were also found to exhibit high levels of 45S rDNA promoter methylation in the 
literature (Kochanek et al. 1996; Németh et al. 2008; Brown & Szyf 2007). Another 
possible explanation for the high levels of methylation in rDNA promoter of breast 
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cancer cell lines is long-continued culturing after all rDNA gene locus was identified to 
be one of the loci sensitive to accumulate methylation with aging in rat liver cells and 
spermatozoa (Oakes et al. 2003). Some studies in the literature identified rDNA promoter 
methylation clones to consist of two populations: one with hypermethylated and one with 
hypomethylated promoter (Ghoshal et al. 2004; Raval et al. 2012; Uemura et al. 2011; 
Gagnon-Kugler et al. 2009), nevertheless we were unable to identify these two 
populations in breast cancer cell lines. However this result might be due to low number of 
bisulfite sequencing clones (five clones from each cell line) analysed in cell lines.  
In order to further analyse 45S rDNA promoter methylation levels in breast cancer we 
used frozen breast tumor and matched normal tissue samples collected and immediately 
frozen during surgery. We used 19 breast tumor and matched normal tissue samples, 
clinical characteristics of tissues were detailed in Table 2-6 45S rDNA promoter 
methylation levels were significantly higher in most of the breast tumor samples (13/19) 
compared to their normal counterparts (Figure 3.2). We also identified many consequent 
CpG sites in the 45S rDNA promoter to be significantly methylated in tumor samples 
compared to normal pairs (Figure 3.5). 45S rDNA promoter region was analysed with a 
transcription factor binding prediction tool (PROMO 3.0) to find overlapping sequences 
between PROMO and sequentially methylated CpG sites. Methylation at certain CpG 
sites in 45S rDNA promoter region may affect the bindings of transcription factors to 
their predicted binding sites. GCF, is a repressor of GC-rich promoters (Tohgi et al. 
1999), which binds to GCF transcription factor binding site also found in 45S rDNA 
promoter and overlaps with two CpG position one of them (CpG 28) was significantly 
methylated in tumor samples. Nuclear factor-1 binding site also found to be located in 
45S promoter and contains one CpG (CpG 52), which is also identified as significantly 
methylated in tumor samples compared normal samples. However, methylation at NF-1 
site and its effect on methylation has not been studied yet. Pax-5 is TFBS located in 45S 
promoter known to require unmethylated CpG to be bound by Pax-5 transcription factor 
(Maier et al. 2003). Pax-5 TFB sites overlap with five CpG positions in the 45S rDNA 
promoter; three of them (CpG 20, 26 and 41), were significantly methylated in tumor 
samples compared to normal pairs. No relationship has been shown between Pax-5 
binding to 45S promoter or whether it is required for transcription by RNA polymerase I 
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but it should be considered as a regulatory mechanism. Before further analysing Pax-5 
binding to rDNA promoter we wanted to make sure that 45S rDNA promoter methylation 
has a significant effect on rRNA transcription.  
Normal breast tissue samples exhibited a mosaic methylation pattern, which is rather 
frequently observed at 45S rDNA promoters (Ghoshal et al. 2004; Uemura et al. 2011). 
Analysis of methylation patterns between breast tumor and normal pairs revealed that 
63% of the tumor-normal pairs methylation patterns were significantly correlated with 
each other (Table 3-1) that indicates a possible individual specific methylation pattern at 
45S rDNA promoter in breast. To make sure that this correlation is individual specific 
rather than tissue specific, we performed the same correlation analysis with unmatched 
tumor and normal samples, many of the (48.8%) unmatched tumor and normal samples 
showed significant correlation as well (a representative of the results were given in Table 
3-2). Determining the methylation pattern of 45S rDNA promoter region in different 
tissues may help to reveal whether it is tissue specific or not, considering different loci 
are differentially methylated in different tissues (Muangsub et al. 2014).  
rDNA methylation levels were implied to have relationship with different clinical 
characteristics in different cancer types (Chan et al. 2005; Powell et al. 2002; Yan et al. 
2000), so we sought a relationship between 45S rDNA promoter methylation levels and 
clinical features of breast cancer samples used in our study. In order to take advantage of 
using paired samples, we took into account the methylation differences between paired 
breast tumor and normal samples in each CpG and used this methylation difference to 
cluster (unsupervised hierarchical clustering) samples in to two groups (Group 1: 
methylated in tumors, Group 2: unmethylated in tumors). We used Fisher’s exact test to 
analyse these two categorical groups with other categorical variables; ER, PR, lymph 
node status and metastasis status. However, no statistically significant association was 
found between hierarchical clustering groups of methylation (group 1 and group 2) and 
ER, PR, lymph node status and metastasis status. This method uses the methylation 
difference between paired samples but maybe clinical parameters associate with tumor 
rDNA promoter methylation levels of the tissues rather than paired methylation 
difference. To test this hypothesis we used Spearman correlation analysis and tested the 
correlation between clinical variables (including grade and stage) and 45S rDNA 
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promoter methylation levels (%) of tumor and normal samples separately. As seen in 
Table 3-7, this approach also failed to identify any association between 45S rDNA 
methylation levels and clinical variables of the patients. Similar to our findings, another 
study on paired breast tumor and normal tissue samples also failed to identify any 
significant correlation between rDNA promoter, 5’ regions of 18S and 28S rDNA 
methylation levels and any clinicopathological features, except nuclear size and grade 
(Bacalini et al. 2014). Using a larger sample size might be more effective for identifying 
an association between rDNA methylation and clinical parameters in breast cancer, if 
there is any.  
Our initial motivation to analyse 45S rDNA methylation level was to identify its effect on 
rRNA gene expression, so we performed expression analysis of rRNA transcripts (18S, 
28S, 5.8S and 45S ETS) in both breast cancer cell lines, non-tumorigenic breast cell line 
(MCF-10A) and breast tumor and matched normal tissue samples. To identify rRNA 
expression levels in cancer, different studies used different housekeeping genes for 
normalization; the most commonly used ones are ACTB, GAPDH and TBP (Raval et al. 
2012; Uemura et al. 2011; Brown & Szyf 2008). ACTB, TBP and ACTB&TBP levels 
were used as reference genes to analyse expression levels in cell lines. We used TBP 
(RNA polymerase II transcribed genes) as a reference gene for tissue samples since it was 
the most stably expressed reference gene between breast normal and breast cancer tissues 
among other reference genes (ACTB, SDHA and GAPDH) according to the Oncomine 
analysis (Figure 3.13, Figure 3.14, Figure 3.15 and Figure 3.16). We also propose that 
using the geometric mean (GM) of rRNAs (18S, 5.8S, 28S and 45S ETS) to normalize 
rRNA expression might be useful in identifying relative changes of rRNAs within the 
rRNA pool. GM-rRNA is calculated from the rRNA transcripts synthesized by Pol I and 
it might be less susceptible to alterations compared to genes transcribed by Pol II. 
Normalization of rRNA expression with reference genes (ACTB, TBP, ACTB&TBP in 
cell lines, TBP in tissue samples) enabled us to identify relative change of rRNAs 
compared to mRNA levels whereas using GM-rRNA (geometric mean of 18S, 28S, 5.8S 
and 45S ETS) for normalization has helped us to identify relative changes of rRNA 
transcripts within their own rRNA pool. 
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As we have seen in Figure 3.1 all breast cancer cell lines as well as non-tumorigenic 
MCF-10A cell line were hypermethylated at the 45S rDNA promoter region. Breast 
cancer cell lines with hypermethylated 45S rDNA promoter expressed rRNA transcripts 
at different levels (Figure 3.9) and independent from 45S rDNA promoter methylation 
levels (Table 3-14, Table 3-15, Table 3-16 and Table 3-17). These results imply that 
expression from 45S rDNA promoter might not be the major determinant of rRNA 
expression in breast cancer cell lines. Consistent with our results, Xenopus leavis oocytes 
are able to transcribe rRNA from transfected fully methylated (Xenopus leavis sperm 
DNA) and unmethylated rDNA promoter constructs equally efficient (Macleod & Bird 
1983). 
To further investigate whether rRNA transcription is really independent of 45S rDNA 
promoter methylation, we treated breast cancer cell lines with 5-Aza-2’-deoxycytidine (5-
AZA), which is a cytosine analogue, incorporated into DNA during replication and 
blocks DNA methylation by inhibiting DNMTs (Christman et al. 1983; Creusot et al. 
1982; Taylor & Jones 1982). 5-AZA treatment of cell lines is expected to decrease CpG 
methylation in all genome along with CG rich 45S rDNA promoter and increase 
expression of rRNA genes. Surprisingly, all rRNA transcripts were relatively 
downregulated in 5-AZA treated group compared to control group and the 
downregulation of 5.8S and 45S ETS rRNA transcripts were significant (normalization 
with reference genes). Nonetheless no change was observed in the relative rRNA 
transcript ratios (GM-rRNA normalization) (Figure 3.10 D). Consistent with our results, 
another study used 5-AZA treatment in HCT116 (colon cancer) cell line and identified a 
downregulation in rRNA synthesis, which was caused by cryptic transcription via RNA 
Pol II from unmethylated 45S rDNA promoter that prevents proper processing and 
stability of rRNA transcripts (Gagnon-Kugler et al. 2009). Decreased methylation of 45S 
rDNA promoter in breast cancer cell lines upon 5-AZA treatment might have decreased 
the stability of rRNA transcripts and we found significant downregulation of both 5.8S 
rRNA and 45S ETS products in these cell lines compared to the control group. This 
cryptic transcription by RNA polymerase II, which acts similar to a negative feedback 
mechanism, might be a way for cell to achieve a fine balanced expression of these 
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essential rRNA genes and also a mechanism to protect cell from energy loss in the 
absence of CpG methylation at 45S rDNA promoter. 
We used another epigenetic drug Trichostatin A (TSA) to determine whether other 
regulatory mechanisms such as histone acetylation play a more determinant role in the 
regulation of rRNA gene expression. TSA is a potent HDAC inhibitor (Vigushin et al. 
2001), treating cell lines with TSA indirectly increases H3 and H4 lysine acetylation by 
inhibiting HDACs, which also leads to dissociation of the chromatin hence upregulation 
of many genes in the genome (Ballestar & Esteller 2008). Treatment of breast cancer cell 
lines only with TSA did not significantly alter the rRNA expression or the ratio of rRNA 
transcripts but a significant increase in 18S rRNA/ACTB&TBP level and a significant 
decrease in 5.8S/GM-rRNA ratio was observed in 5-AZA+TSA treatment group 
compared to the control (DMSO treated) group. It is plausible that transcription of rRNAs 
might be mainly regulated by other mechanisms (PIC formation, initiation, promoter 
escape, elongation, termination, re-initiation, RNA processing and post-transcriptional 
modifications) instead of epigenetic modifications in breast cancer cell lines. It is also 
critical to acknowledge that using epigenetic drugs affect hundreds of genes at once in the 
genome along with rDNA genes. The variation between mRNA normalization and rRNA 
normalization might be due to the fact that mRNA genes are subjected to the direct or 
indirect effects of these drugs. 
We had already identified a significant difference in rDNA promoter methylation levels 
between breast tumors and matched normal tissue samples, and we also analysed 
expression levels of rRNA genes in these tissue samples to see whether the significant 
methylation of rDNA promoter in breast tumor samples was reflected in rRNA 
expression levels. TBP normalization analysis did not reveal a significant difference 
between breast tumors and matched normal samples (Figure 3.17). When we used GM-
rRNA for normalization, we found that 18S and 5.8S rRNA ratios were significantly 
down- and up -regulated, respectively, in breast tumor samples compared matched 
normal pairs (Figure 3.18). These results demonstrate that 18S and 5.8S rRNA 
proportions shift in the reverse direction within the same total rRNA pool even though 
total rRNA amounts might be rather equal. Supportingly, normal breast tissue samples 
exhibited a perfect correlation between rRNA transcripts but this correlation was 
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vanished in breast tumor tissue samples (Table 3-22). To identify whether rRNA 
expression levels or ratios are correlated with promoter methylation levels we performed 
a correlation analysis and found that TBP normalized expression levels were not 
significantly correlated with 45S rDNA promoter methylation levels in breast tumor and 
matched normal samples (Table 3-18). However, rDNA promoter methylation levels of 
normal samples (which display varied methylation pattern) and 18S/GM-rRNA ratio 
were negatively correlated in normal breast tissues but this correlation was disappeared in 
matched tumor samples (Figure 3.19). As far as we know, this is the first study to show 
that methylation status of the promoter might affect the expression of one or more rRNA 
transcripts but not all of them.  
rRNA expression levels were also used to predict clinical variables in breast cancer tissue 
samples. None of the variables significantly predicted clinical characteristics of the 
tumors with multiple regression analysis. Using spearman correlation analysis identified 
45S/TBP and 28S/GM-rRNA to be positively correlated with the grade of the tumors. 
Breast cancer grading uses nuclear pleomorphism as a criteria that groups breast cancer 
according to the size and shape of the nucleoli (Egner 2010). Increased expression or 
ratio of certain rRNA transcripts might be responsible for the morphological 
abnormalities observed in the nucleoli of higher-grade breast tumor samples.  
Post-transcriptional modifications are also important players in gene regulation. In some 
cases, promoter-sharing polycistronic mRNAs and miRNAs were shown to exist at 
unequal levels due to post-transcriptional regulation in plants (Jia & Rock 2013; Malik 
Ghulam et al. 2013). As reported by other studies, promoter-sharing genes might be 
differentially expressed by other mechanisms not only by basal transcription machinery. 
Mixed methylation patterns observed in normal tissues (moderate methylation levels) 
might still be coordinating the expression of 18S rRNA but high methylation levels 
observed in tumor samples lost this coordination, as seen in Figure 3.19. On the other 
hand, methylation of promoter indirectly influences splicing, modification and 
stabilization of rRNA transcripts (Gagnon-Kugler et al. 2009). Correlation between 
rRNA transcripts (Table 3-22) observed in normal tissue samples were lost in tumor 
samples indicating that hypermethylated promoter of 45S rDNA might influence the 
processing of rRNAs. 
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Ribosome maturation is a multistep and complex process facilitated through orchestration 
of many factors (∼200) (Kiss et al. 2006; Terns & Terns 2006). Splicing, processing and 
modification of rRNAs are mainly coordinated by snorNAs and changes in snoRNA 
levels might be reflected in the rRNA ratios. Special modifications are required for 
proper folding and stabilization of rRNAs. Two specific sites in 28S RNA should be 
modified with 2’-O-methylation modification via U50 (box C/D snoRNA). U50 was 
found to be altered through mutations, deletions and somatic rearrangements in various 
cancer types such as prostate cancer, breast carcinoma, B-cell lymphoma and colon 
cancer (Dong et al. 2008; Dong et al. 2009; Tanaka et al. 2000; Pacilli et al. 2013). 
Decreased expression of GAS5 and/or its snoRNAs have been displayed in head and 
neck squamous cell carcinoma, glioblastoma multiforme and breast cancer (Gee et al. 
2011; Lee et al. 2006; Mourtada-Maarabouni et al. 2009). It is hard to interpret the exact 
role of rDNA promoter methylation in rRNA expression as there are many players in 
rRNA gene regulation but increased methylation seems to affect rRNA modification and 
processing as well, which requires further studies.  
Finally, rRNA transcription in breast cancer cell lines was found to be independent of 
hypermethylation at the 45S rDNA promoter region. Yet tissue samples did not support 
this result, as the 18S rRNA/GM-rRNA ratio was significantly correlated with 
methylation of the 45S rDNA promoter region in normal breast tissue samples. As 
indicated earlier, both breast cancer cell lines and breast cancer tissue samples have 
heavily methylated 45S rDNA promoter regions and promoter methylation of 45S rDNA 
promoters might have a different role than regulating rRNA gene expression. It might for 
example be required for protecting these essential genes in all conditions. Like many 
repeats in the genome, rDNA repeats have also been implicated in stability of the genome 
and decreased genomic stability has also been associated with 45S rDNA promoter 
hypomethylation (Kobayashi 2014; Peng & Karpen 2007; Kobayashi 2008). 
Hypermethylation of 45S rDNA promoter in tumors might be a strategy used by the cell 
to restore the disrupted genomic integrity. Further research is required to unravel the 
possible cause of dysregulation in rRNA transcripts in cancer as well as its association 
with rDNA promoter methylation.  
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5 FUTURE PERSPECTIVES 
 
In order to, better establish the relationship between 45S rDNA promoter methylation and 
rRNA expression levels in breast cancer sample size should increase. 
rRNA gene expression is tightly regulated since it codes for one of the most essential 
genes in the genome and these genes exist in all forms of life, even the most primitive. 
There are many regulatory mechanisms that are evolved for the optimal rRNA gene 
expression starting with tandemly repeated rDNA genes and continues with PIC 
formation, initiation, promoter escape, elongation, termination, re-initiation, RNA 
processing and post-transcriptional modifications.  
We focused on the effect of the rDNA methylation on rRNA gene expression in breast 
cancer but transcriptional and post-transcriptional regulation of rRNAs should be 
molecularly dissected to be able to better comprehend the whole regulatory mechanism of 
rRNA gene expression.  
Transcription factors binding to the 45S rDNA promoter region (GR-alpha, Pax-5, GCF, 
ER-alpha, GATA-1, NF-1, C/EBPbeta, TFII-I, AP-2, alpha A YY1) can be further 
analysed using chromatin immunoprecipitation (ChIP). Artificially methylated (Sss1 
methyltransferase treated) and unmethylated (DNA from 5-AZA treated or DNMT 
knockout cells) rDNA products can also be used in immnuoprecipitation with these 
transcription factors to identify whether there is a difference in binding efficiencies of 
transcription factors to methylated and unmethylated rDNA promoter. 
Active and inactive histone marks can be used in order to further identify the effect of 
45S rDNA promoter methylation on rRNA gene expression. Chromatin 
immunoprecipitation with active histone marks (such as H3K9me3, H4K20 and 
H3K27me3) and inactive histone marks (such as acetylated histones H4, H3 and 
H3K4me3) followed by a bisulfite sequencing targeting 45S rDNA promoter can reveal 
the true nature of DNA methylation states of active and inactive rDNA promoter. 
Promoter associated RNA (pRNA) is a non-coding DNA transcribed from the intergenic 
spacer ~2 kb upstream of the rRNA transcription start site and is associated with rRNA 
gene silencing (Mayer et al. 2008; Mayer et al. 2006). pRNA levels could be determined 
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to see whether it has any effect on dysregulation of rRNAs in cancer cells compared to 
normal cells.  
Post-transcriptional modifications of rRNAs play a major role in maturation, ribosome 
assembly and accuracy of the decoding. There are three major types of rRNA 
modifications; 2’-O-methylation (Nm), pseudouridylation (!) and base methylation at 
various positions (Smith & Dunn 1959; Davis & Allen 1957; Cohn 1960; Wagner et al. 
1967). Detection of changes in post-transcriptional modifications using chromatography 
and mass spectrophotometry based methods is vital for understanding the deregulated 
expression of rRNA genes in cancer.  
Until recently, the only known epigenetic mark of DNA itself was 5-methylcytosine 
(5mC). Hydroxymethylation of cytosine residues at 5th position was first characterized in 
Purkinje neurons and embryonic stem cells (Kriaucionis & Heintz 2009; Ficz et al. 2011). 
5-hydroxymethylcytosine (5-hmC) is generated through the oxidization of 5-mC by TET 
family of enzymes (Ito et al. 2010; Tahiliani et al. 2009). These reports provided new 
insights into the mechanism of active DNA demethylation, suggesting that a 
hydroxylated methyl group could be an intermediate for oxidative demethylation. 
Recently, it has been shown that hydroxymethylation levels are also altered in various 
types of cancer including breast cancer (Kroeze et al. 2014; Kraus et al. 2012; Ko et al. 
2010; Haffner et al. 2011). Furthermore, many standard methods used for detecting 
methylated DNA, such as bisulfite conversion, cannot distinguish between 5-mC and 5-
hmC. 45S rDNA promoter hydroxymethylation status could also be analyzed to identify 
if the region contains any 5-hmC along with 5mC. 
New technologies such as whole genome bisulfite sequencing and next generation 
sequencing methods (instead of Sanger sequencing) can be used to unravel the complete 
picture of the DNA methylation states of 45S rDNA. 
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Appendix B 
MIQE: Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments Check List 
ITEM TO CHECK IMPORTANCE CHECKLIST 
EXPERIMENTAL DESIGN     
Definition of experimental and 
control groups E ! 
Number within each group E 14 
Assay carried out by core lab or 
investigator's lab? D Investigator's lab 
Acknowledgement of authors' 
contributions  D ! 
SAMPLE     
Description E Total RNA from tissue 
• Volume/mass of sample 
processed 
D 
60-µm-thick sections (4-5 slice from 
tumor and 20-25 slices from normal 
tissues) 
• Microdissection or 
macrodissection E Macrodissection 
Processing procedure E Snap frozen with liquide nitrogen 
• If frozen - how and how 
quickly? E Immediately, during surgery 
• If fixed - with what, how 
quickly? E NA 
Sample storage conditions and 
duration (especially for FFPE 
samples) E -80°C, 4-6 years 
NUCLEIC ACID EXTRACTION     
Procedure and/or 
instrumentation E Trizol  
• Name of kit and details 
of any modifications E 
TRI Reagent RT (Molecular 
Research Center), no modification  
• Source of additional 
reagents used  D Sigma 
Details of DNase or RNAse 
treatment E MessageClean Kit (GenHunter) 
Contamination assessment 
(DNA or RNA) E -RT 
Nucleic acid quantification  E ! 
• Instrument and method 
E 
Nanodrop Spectrophotometer 
(Thermo Scientific) 
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• Purity (A260/A280)  D 1.7-2.1 
• Yield D 500-2000 ng 
RNA integrity 
method/instrument E Agilent RNA 6000 Nano Kit 
• RIN/RQI or Cq of 3' and 
5' transcripts  E RIN: 4-7 
• Electrophoresis traces D NA 
 Inhibition testing (Cq dilutions, 
spike or other)  E NA 
REVERSE TRANSCRIPTION     
Complete reaction conditions E ! 
• Amount of RNA and 
reaction volume E 500 ng and 20µl 
• Priming oligonucleotide 
(if using GSP) and 
concentration E 
Random hexamer primer and 24 µg 
at 100 µM concentration 
• Reverse transcriptase 
and concentration E 
RevertAid Reverse Transcriptase 
(200 U/µL) 
• Temperature and time E 1 hour at 42°C 
• Manufacturer of 
reagents and catalogue 
numbers D Thermo Scientific (K1691) 
Cqs with and without RT D* 8-10 and 30-32 
Storage conditions of cDNA D '-80°C 
qPCR TARGET 
INFORMATION     
If multiplex, efficiency and 
LOD of each assay. E NA 
Sequence accession number E ! 
Location of amplicon D ! 
• Amplicon length E ! 
• In silico specificity 
screen (BLAST, etc) E ! 
• Pseudogenes, 
retropseudogenes or 
other homologs? D Identical repeated genes 
• Sequence alignment D ! 
• Secondary structure 
analysis of amplicon D ! 
Location of each primer by 
exon or intron (if applicable) E ! 
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• What splice variants are 
targeted? E No splice variants 
qPCR OLIGONUCLEOTIDES     
Primer sequences E ! 
RTPrimerDB Identification 
Number  D NA 
Probe sequences D** NA 
Location and identity of any 
modifications E None 
Manufacturer of 
oligonucleotides D Iontek Company (Turkey) 
Purification method D Standard desalination 
qPCR PROTOCOL     
Complete reaction conditions E ! 
• Reaction volume and 
amount of cDNA/DNA E ! 
• Primer, (probe), Mg++ 
and dNTP 
concentrations E ! 
• Polymerase identity and 
concentration  E ! 
• Buffer/kit identity and 
manufacturer  E 
DyNAmo qPCR kit, Thermo 
Scientific  
• Exact chemical 
constitution of the buffer D ! 
• Additives (SYBR Green I, 
DMSO, etc.) E ! 
Manufacturer of plates/tubes 
and catalog number D Bioplastics, B70501 
Complete thermocycling 
parameters E ! 
Reaction setup 
(manual/robotic) D Manual 
Manufacturer of qPCR 
instrument E Stratagene 
qPCR VALIDATION     
Evidence of optimisation (from 
gradients)  D ! 
Specificity (gel, sequence,  
melt, or digest) E Gel 
For SYBR Green I, Cq of the 
NTC E 35-No Cq 
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Standard curves with slope and 
y-intercept E ! 
• PCR efficiency 
calculated from slope E ! 
• Confidence interval for 
PCR efficiency or 
standard error D NA 
• r2 of standard curve E ! 
• Linear dynamic range E ! 
• Cq variation at lower 
limit E 0.9 Cq 
• Confidence intervals 
throughout range D NA 
Evidence for limit of detection  E NA 
If multiplex, efficiency and 
LOD of each assay. E NA 
DATA ANALYSIS     
qPCR analysis program (source, 
version) E Excel for Mac 2011, Version 14.5.3 
• Cq method 
determination E Delta Ct  
• Outlier identification 
and disposition E NA 
Results of NTCs  E ! 
Justification of number and 
choice of reference genes E ! 
Description of normalisation 
method E TBP and Geometric Mean of rRNAs 
Number and concordance of 
biological replicates D NA 
Number and stage (RT or 
qPCR) of technical replicates E 2 
Repeatability (intra-assay 
variation) E NA 
Reproducibility (inter-assay 
variation, %CV) D NA 
Power analysis D NA 
Statistical methods for result 
significance E p<0.05 
Software (source, version) E IBM SPSS Statistics, Version 21 
Cq or raw data submission 
using RDML D NA 
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MIQE checklist for authors, reviewers and editors. All essential information (E) must be 
submitted with the manuscript.  Desirable information (D) should be submitted if 
available. If using primers obtained from RTPrimerDB, information on qPCR target, 
oligonucleotides, protocols and validation is available from that source. 
   *: Assessing the absence of DNA using a no RT assay is essential when first extracting 
RNA. Once the sample has been validated as 
 RDNA-free, inclusion of a no-RT 
control is desirable, but no longer 
essential. 
 
   **: Disclosure of the probe sequence is highly desirable and strongly encouraged. 
However, since not all commercial pre-designed assay 
 vendors provide this information, it cannot be an essential requirement. Use of such 
assays is advised against. 
   NA: Not Available 
  
   ✓ : Either given in the thesis or 
performed 
   
ONCOLOGY REPORTS  33:  3131-3145,  2015
Abstract. Ribosomal RNA (rRNA) expression, one of the most 
important factors regulating ribosome production, is primarily 
controlled by a CG-rich 45S rDNA promoter. However, the 
DNA methylation state of the 45S rDNA promoter, as well 
as its effect on rRNA gene expression in types of human 
cancers is controversial. In the present study we analyzed the 
methylation status of the rDNA promoter (-380 to +53 bp) as 
well as associated rRNA expression levels in breast cancer cell 
lines and breast tumor-normal tissue pairs. We found that the 
aforementioned regulatory region was extensively methylated 
(74-96%) in all cell lines and in 68% (13/19 tumor-normal 
pairs) of the tumors. Expression levels of rRNA transcripts 
18S, 28S, 5.8S and 45S external transcribed spacer (45S ETS) 
greatly varied in the breast cancer cell lines regardless of their 
methylation status. Analyses of rRNA transcript expression 
levels in the breast tumor and normal matched tissues showed 
??????????????????????????????????????????????????????????
other hand, using the geometric mean of the rRNA expression 
???????????????????????????????????????????????????????????-
cant changes in the relative expression of rRNAs in the tissue 
samples. We propose GM-rRNA normalization as a novel 
strategy to analyze expression differences between rRNA 
transcripts. Accordingly, the 18S rRNA/GM-rRNA ratio 
??????????????????????????????????????????????????????
??????????????????????? ?????? ?????????? ?????????????? ?????
this ratio in the matched normal samples. Moreover, the 18S 
rRNA/GM-rRNA ratio was negatively correlated with the 45S 
rDNA promoter methylation level in the normal breast tissue 
???????????????????????????????????????????????????????????????
observed between the expression levels of rRNA transcripts 
in the normal samples were lost in the tumor samples. We 
showed that the expression of rRNA transcripts may not be 
based solely on promoter methylation. Carcinogenesis may 
cause dysregulation of the correlation between spliced rRNA 
expression levels, possibly due to changes in rRNA processing, 
which requires further investigation.
Introduction
??????????????????? ???????????????????????????????? ??????
was also the primary and secondary cause of cancer-related 
deaths among women living in less developed (14.3% of all 
cancer-related deaths) and more developed regions (15.4% 
after lung cancer) in 2012, respectively (1). Familial or somatic 
????????????????????????????????????????????????????????
known high risk factors for breast cancer formation while 
?????????????????????????????????????????????????
have been estimated to have moderate or weak effects (2).
Contrary to mutations that modify the DNA sequence 
itself, epigenetic alterations affect gene expression via DNA 
methylation, histone modifications and chromatin remod-
eling. DNA methylation, the frequently studied epigenetic 
??????????????????????????????????????????????????????????
inactivation and imprinting (3-5), is also important for the 
protection of genome integrity and hence cancer. Global hypo-
methylation of the genome, commonly observed in multiple 
cancers, increases genome instability and activates proto-
oncogenes while hypermethylation of promoter CpG islands 
silences the expression of tumor suppressor genes (6-8). 
???????????????????????????????????????????????????????????
of many genes, contributes to breast tumorigenesis; however, 
DNA methylation of the rDNA region has been overlooked in 
DNA methylation studies related to breast cancer.
Ribosome synthesis is closely related to the cell metabo-
lism involved in cell growth and proliferation, and is tightly 
correlated with ribosomal RNA (rRNA) synthesis (9). The 
Relative expression of rRNA transcripts and 45S rDNA 
promoter methylation status are dysregulated in tumors in 
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human genome contains ~300-400 copies of rRNA genes 
but only a fraction of these genes are actively transcribed 
depending on the cell type, external signals and the cell stage, 
while the rest of the genes remain inactive (10). rRNA genes 
are organized in tandem repeated arrays within nucleolar 
???????????????????????????????????????????????????????????
human acrocentric chromosomes: chromosome 13, 14, 15, 
21 and 22 (11). rRNA genes (except 5S, which is transcribed 
by RNA polymerase III) are transcribed from the 45S rDNA 
promoter by RNA polymerase I (Pol I). Since ~60% of the 
total RNA of a cell consists of Pol I products (12), rRNA 
genes are regulated tightly at different levels that include 
pre-initiation complex (PIC) formation, initiation, promoter 
escape, elongation, termination, re-initiation, RNA processing 
????????????????????????? ?????????????????
The entire promoter region of rRNA genes is contained 
in an intergenic spacer region (IGS) between rDNA units. 
The promoter region of rDNA repeating unit consists of 
two important elements: the core promoter and upstream 
control element (UCE). The core promoter is located between 
-50 to +20 bp and is essential for basal transcription, whereas 
the UCE is located 150-200 bp upstream of the transcription 
???????????????????????????????????????????????????????????????
formation (14) (Fig. 1A). Cooperative binding of the HMG1 
??????????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????????????
for Pol I recruitment (15,16). rRNA genes are transcribed as 
long precursors known as 45S pre-RNA which are then rapidly 
spliced into the 18S, 28S and 5.8S rRNA transcripts (17). 
??????????????????????????????????????????????????????????
respective ribosomal subunits in the nucleolus (18,19).
The association between the nucleolus and cancer has long 
been known. Abnormal morphology of the nucleolus in cancer 
cells has drawn the attention of tumor pathologists since 
the 19th century. However, only recently has the molecular 
biology of rRNA synthesis and ribosome biogenesis in cancer 
cells begun to be explored.
CpG island methylation at the promoters of tumor 
suppressor genes is known to be an important factor in the 
formation and progression of many types of cancer (20). The 
promoter and transcribed regions of rRNA genes are rich in 
CG dinucleotide yet they are longer than regular 1 to 2 kb CpG 
islands (21). A limited number of studies analyzing the DNA 
methylation status of the rDNA promoter region in cancer have 
focused on the relationship between rDNA promoter methyla-
tion and the expression levels of rRNA genes.
Methylation at the 45S rDNA promoter region decreased 
the expression of rRNA genes in hepatocellular carci-
noma (22) and in CD34+ cells of patients with myelodysplastic 
syndromes (23). On the other hand, other studies have shown 
no relationship or a positive correlation between promoter 
methylation and rRNA transcription (24,25).
Although rRNA genes and particularly 18S RNA are 
frequently used in qRT-PCR as housekeeping genes, recent 
studies have shown that 18S is differentially expressed in breast 
tumor and normal samples (26-28). Furthermore, changes in 
the relative amount of spliced rRNA products from 45S have 
not been tested in the context of breast cancer.
????????????????????????????????????????????????????-
nostic factor in ovarian, endometrial and breast cancer (29-31). 
A recent study also revealed that the 45S rDNA promoter as 
well as the 5' regions of 18S and 28S rDNA are hypermeth-
ylated in breast cancer tissues compared to paired normal 
tissues. Notably, methylation levels of these regions exhibited 
a correlation with nuclear grade and nuclear size values (32). 
However, none of the previous breast cancer studies examined 
the ratio of rRNA transcript levels and rDNA promoter meth-
ylation levels in tumors and normal tissues comparatively.
In the present study, we analyzed the methylation levels of 
the 45S rDNA promoter in breast cancer cell lines as well as 
in primary breast tumor tissues and matched normal samples. 
We also determined the expression levels of rRNA transcripts 
in the same samples in order to understand the role of rDNA 
promoter methylation on rRNA gene expression in breast 
???????? ????????????????????????????????????????????????????????
ratio of 18S and 5.8S rRNA was differentially modulated in 
tumors in comparison to adjacent normal tissues. In addition, 
????????????????????????????????????????????????????????????
and negatively correlated with the methylation status but this 
was not observed in the breast tumors. Furthermore, the high 
correlation between expression of rRNA transcripts in normal 
?????????????? ??????????????????? ???????????????????????????-
cant dysregulation of relative rRNA expression in conjunction 
with promoter methylation.
Materials and methods
Cell culture, 5-aza-2'-deoxycytidine (5-AZA) and trichostatin A 
(TSA) treatments. ??????????????????????????????
??????????????????????????????????????????????? ??????
????? ?????? ??? ???? ?????? ??????? ?????? ?????? ??????????
????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????
??????????????????????????????? ??????????????????????????
USA) supplemented with RPMI-1640 medium (HyClone). 
????????????????? ???????????????????????????????????????????
ml insulin (Sigma-Aldrich) supplemented with low glucose 
????????????????? ??????????????? ????? ???????????
???????????????????? ??????????????????????????????????????
USA) and 1% P/S supplemented with low glucose DMEM. 
?????????????????????????????????????????????????????????
1 mM sodium pyruvate supplemented with RPMI-1640 medium. 
???????????????????????????????????????????????????????
20 ng/ml EGF and 0.5 mg/ml hydrocortisone (both from Sigma-
Aldrich) supplemented with DMEM/Ham's F-12 (1:1) medium 
???????????? ????? ?????????? ?????????????????????????? ???
????????????????????????????????????????? ???? ??????????
medium (HyClone). CAL-51 cell line was propagated in 20% 
??????????????????????????????????????????????????????????
cells were grown in 5% CO2???????????????????????????????????????
incubator. All cell lines except MCF-10A and CAL-51 cells were 
purchased from the American Type Culture Collection (ATCC; 
Rockville, MD, USA). MCF-10A and CAL-51 were kindly 
provided by Assistant Professor Dr A. Elif Erson (Middle East 
?????????? ????????????????????????????????????????? ???????????
verify the authenticity of all cell lines.
?????????????????????????????????????????????????????
????? ??????????? ???????????????????????????????????
????????????????????????????????????????????????-
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??????????????????????????????????????????????????????????
or TSA. Cells seeded at a density of 750,000/100 mm were 
???????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????
Drugs were changed every day along with the medium, and 
cells were collected on day 5. 400 nM TSA or DMSO (same 
amount used to solubilize TSA) was administered to the cells 
24 h after cell plating, and the cells were collected after 48 h.
???????????????????????????????? ??????????? ?????? 
????? ???????????? ???????? ????????? ??????? ????????
?????????????????????????????????????????????????????
???????????????????????????????????????????????????????
the day of seeding and 400 nM TSA was added 72 h later in 
????????????????????????????????????????????????????????????
on day 5.
Patients and tissue samples. Primary breast tumors and 
matched normal tissues were obtained from 19 patients at 
Ankara Numune Research and Teaching Hospital (Table I). 
Clinical tissue samples were used with the approval of the 
Research Ethics Committee of Ankara Numune Research and 
Teaching Hospital, and consent was obtained from the patients 
according to the Helsinki Declaration.
Tissues acquired from patients during surgery were 
????????????????????????????????????????????????????????????
until RNA or DNA extraction was performed. Pathological 
examinations were carried out with hematoxylin and eosin 
???????????????????????????????????????????????????????????
examination consisting of >80-90% tumor cells were included 
in the present study.
???????????????????????????????????????Genomic DNA was 
extracted from the breast cancer cell lines as well as the clin-
ical breast cancer and matched normal tissue samples using 
the NucleoSpin Tissue DNA extraction kit (Macherey-Nagel, 
Germany) following the manufacturer's instructions.
????????????????????????????? ???? ???????????????????
thylated cytosine residues to uracil leaving methylated cytosine 
?????????????????????????????????????????????????????????
???????????????????????????????????????? ????????????????? ???
????????????????????????????????????????
??????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????
with Taq??????????????????????????????????????????????
???????????????????????????????????????????????????????????
???????????????????????????????????????????????????????
reverse primer sequences are listed in Table II). PCR products 
?????????????????????????????????????? ???????? ??????????????
???????????????????????????????????????????????????????????
Easy Vector using the pGEM-T Easy Vector system (Promega, 
USA). The transformation protocol was performed according 
to the pGEM-T Easy Vector system manual using competent 
E. coli DH5??????????????????????????????????????????????
??????????? ?????????????????????? ??????????????? ??????
????????????????????????????????????????????????????????????
lines and 10 colonies from tissue samples) were randomly 
selected.
Small-scale isolation of plasmid DNA (mini-prep) 
was performed with the NucleoSpin Plasmid Isolation kit 
(Macherey-Nagel) according to the manufacturer's instruc-
????????????????????????????????????????????????????????????
with PCR using T7 and SP6 universal primers. The insert-
containing plasmids were sequenced with SP6 primers using 
the dideoxy chain-termination method (Iontek, Turkey).
Methylation analysis. Raw bisulfite sequencing data were 
????????? ?????? ???? ??????????????? ????? ???? ????????????
?????????? ???????? ?? ?????????? ??????????????? ????? ????
???????????????????????????????????????????????????????????????
conversion rates of raw sequencing data were determined 
by analyzing unconverted cytosine residues in non-CG sites. 
??????? ??????????????????????????????????????? ??????????????
Clones from each sample were trimmed, aligned and displayed 
??????????????????????????????
???? ?????? ???? ???? ????? ?????????? ? The f rozen 
tumor (4-5 slices for each sample) and normal (20-25 slices 
?????????????????????????????????????????????????????????????
and used for RNA isolation. Tissue samples were lysed in 
1 ml TRI reagent RT (Molecular Research Center, USA) with 
a homogenizer and passed through a 21-gauge needle several 
??????????????????????????????????????????????????????????????
4-bromoanisole (Molecular Research Center) was added/ml of 
TRI reagent. Tubes were vortexed for 15 sec and incubated at 
room temperature for 2-3 min. After incubation, the mixture 
?????????????????????????????????????????????????????????????
aqueous phase was collected into a clean tube. Isopropanol 
(0.5 ml) was added to the aqueous phase/1 ml of TRI reagent 
used. The mixture was incubated at room temperature for 
????????????????????????????????????????????????????????????
to recover the RNA. The supernatant was removed, and the 
pellet was washed with 75% ethanol twice and centrifuged 
????????????????????????????????????????????????????????????
dissolved in diethylpyrocarbonate (DEPC)-treated H2O. In 
order to avoid DNA contamination of the total RNA acquired 
from the tissue samples, DNase I treatment was performed 
with the Message Clean kit (GenHunter, USA) according to 
the manufacturer's instructions. Total RNA (500 ng) was used 
in random primed cDNA synthesis with the RevertAid First 
Strand cDNA Synthesis kit (Fermentas).
RNA isolation from the cell lines was performed using 
the NucleoSpin RNA II RNA isolation kit (Macharey-Nagel) 
????????????????????????????????????????????????????????????
used in random primed cDNA synthesis with the RevertAid 
First Strand cDNA Synthesis kit.
???????????????Real-time PCR was performed with primers 
targeting 45S ETS, 18S, 28S and 5.8 rRNA transcripts. All 
primer sequences are listed in Table II. Randomly primed 
cDNAs from both cell lines and frozen tissue samples were 
??????????????????????????????????????????????????????????????
????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
????????????????????????????????????????????????????????-
???????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????
followed by melting curve. All reactions were set as duplicates. 
The Stratagene Mx3005P Real-Time PCR System (Agilent, 
USA) was used for real-time PCR experiments.
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The relative expression levels of rRNAs were evaluated 
using log2 (2?Ct?????????????????????????????????????????????
gene both for cell lines and clinical tissue samples to assess 
the amount of cDNA. The geometric mean of the rRNA 
expression values (GM-rRNAs) (18S, 28S, 5.8S and 45S ETS) 
was also used as a reference gene in tissue samples in order 
to understand the relative changes of rRNAs with respect to 
each other.
Statistical analysis. Raw bisulfite sequencing data were 
??????????????????????????????????????????? ??????????????
graphs and pie charts of the methylation status were also gener-
?????????????????????????? ?????????????????????????????
rank test was used to assess both sample-wise and CpG-wise 
????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
were determined using the paired t-test. Correlations between 
45S rDNA promoter methylation and rRNA expression levels, 
as well as rRNA transcripts with each other were analyzed 
using Spearman correlation.
The association of rDNA promoter methylation and 
rRNA expression with clinical variables was evaluated with 
???????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????
??? ??????????????????????????????? ????????????????????????
SPSS software version 21.0 or GraphPad Prism 6.0.
Results
?????????????????? ??????????????????????????????????????
cell lines. To identify the methylation levels of the 45S rDNA 
promoter region in breast cancer in vitro, we performed 
bisulfite genomic sequencing for the 45S rDNA promoter 
region in 10 breast cancer cell lines and a non-tumorigenic 
??????? ????? ????? ????????????????????? ???????????????????
?????????????????????????????????????????????????????????
a 434-bp region spanning two important elements: UCE and 
??????????????????????????????????????????????????????????????
lines were treated with sodium bisulfite reagent, allowing 
for integration of epigenetic information (DNA methylation) 
into genetic information. Five randomly selected clones from 
each cell line were sequenced, aligned and analyzed using 
??????????? ??????????????????????????????????????????????????
cell line, MCF-10A, exhibited very high levels of methylation 
(varying between 74 and 96%) in their 45S rDNA promoter 
regions (Fig. 2).
Breast tumors are heavily methylated compared to their 
??????????????????????????????????????????????????????. 
We analyzed 19 breast tumor and matched normal frozen 
?????????????????????????????????????????????????????????????
method to test whether methylation levels of the 45S rDNA 
promoter region in patient samples were similar to those of 
the cell lines. Ten randomly selected clones were sequenced, 
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
pointing arrows. IGS, intergenic spacer; UCE, upstream control element; CP, core promoter; ETS, external transcribed spacer; ITS, internal transcribed 
????????????????????????????????????????????????????????????????????????????????????????????? ??????????????????????????????????????????????????????????????
are 54 CpGs in the 434-bp region analyzed; the transcription start site is indicated with a curved arrow. Primers are shown with italicized characters and 
CG-dinucleotides are indicated with bold characters. rDNA, ribosomal DNA.
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aligned and analyzed from each of the breast tumor and 
??????????????????? ?????????? ??????????? ???????????????
rank test for testing the paired differences instead of the 
????? ????????????????????????????????????????????????????
revealed that 13 out of 19 (68%) breast cancer tissue samples 
had higher methylation levels of the 45S rDNA. On the other 
hand, three samples showed significantly higher methyla-
tion levels in normal samples compared to their tumor pairs, 
????????????????????????????????????????????????????????????
methylation levels in breast tumor and matched normal tissues 
Table I. Clinicopathological characteristics of the patients.
Patient Age    Path  Clinical  -DM
no. (years) ER PR Diagnosis lymph node Grade grade DM month
???? ??? ?? ?? ???? ?? ?? ????????? ?? ??
115 57   Papillary carcinoma - 3 Grade 2A - 
  96 39 - + IDC - 2 Grade 2A - 
116 74 - - IDC + 2 Grade 2A - 
???? ??? ?? ?? ?????????? ?? ?? ????????? ??
???? ??? ?? ?? ???? ?? ? ????????? ??
148 70 + - IDC + 2 Grade 3A + 15
???? ??? ?? ?? ???? ?? ?? ????????? ??
159 30 - + Metaplastic - 2 Grade 2A - 
???? ??? ?? ?? ???? ?? ?? ????????? ?? ??
???? ??? ?? ?? ???? ?? ?? ????????? ??
166 55 - + IDC + 2 Grade 2A - 
???? ??? ?? ?? ???? ?? ?? ????????? ??
???? ??? ?? ?? ???? ?? ?? ????????? ??
176 49 + + IDC + 2 Grade 2A - 
177 47 - + IDC + 2 Grade 3A + 48
181 44 - - IDC + 2 Grade 1 - 
133a         
173a         
a???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
lymph node, pathological lymph node status; DM, distant metastasis status.
Table II. Primers used in the present study.
? ? ? ????????????? ?????????
Primer Sequence (bp) value
???????????????????????????????? ???????? ????????????????????????????? ???? ?
???????????????????????????????? ???????? ??????????????????????????
18S rRNA Forward 5'-AAACGGCTACCACATCCAAG-3' 154 1.95
18S rRNA Reverse 5'-CCTCCAATGGATCCTCGTTA-3'
28S rRNA Forward 5'-CAGGGGAATCCGACTGTTTA-3' 151 1.85
28SS rRNA Reverse 5'-ATGACGAGGCATTTGGCTAC-3'
5.8S rRNA Forward 5'-CTCTTAGCGGTGGATCACTC-3' 155 2.00
5.8S rRNA Reverse 5'-GACGCTCAGACAGGCGTAG-3'
45S ETS Forward 5'-CGATCTGAGAGGCGTGCCTT-3' 87 1.93
45S ETS Reverse 5'-GGCAGCGCTACCATAACGGA-3'
???? ???????? ?????????????????????????????? ???? ????
???? ???????? ??????????????????????????
rRNA, ribosomal RNA; ETS, external transcribed spacer.
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in the remaining three samples (Fig. 3A). Normal samples were 
not fully unmethylated and instead showed a mosaic meth-
ylation pattern, a relatively common observation for human 
rDNA promoters (22). Methylation patterns of tumor and 
??????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
methylation of rDNA promoters, we performed a correla-
tion analysis between randomly selected tumor and normal 
samples; and these showed similar degrees of correlation (data 
not shown). In addition, the analysis of individual CpGs in 
??????????????????????????????????????????? ??????????????????
????????????????????????????????????? ??????????????????????
???????????????????????????
?????????????????????????????????????????????????????
promoter methylation levels and patient clinical variables.
?????????????????????????????????????????????????????????????
????????????????????????????????? ???????????????? ???
determine rRNA expression levels in several studies (23,24,35) 
but these RNA polymerase II (Pol II) transcribed genes are 
variably expressed in numerous types of cancer (36,37). 
However, several studies advise against using rRNA levels to 
determine mRNA levels (26,27). Accordingly, using mRNA 
levels to normalize rRNA levels may have a similar drawback. 
Herein, we propose that GM-rRNA, the geometric mean of 
expression from an rRNA pool (18S, 28S, 5.8S and 45S ETS) 
Figure 2. The methylation status of the 45S rDNA promoter in breast cancer cell lines and a non-tumorigenic cell line. A total of 54 CpGs in a region spanning 
??????????????????????????????????????????????????????? ?????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????? ??????????????????????????? ??????????????????? ??????? ??????????????????????????????????????????????
sample are indicated at the right of the graph. UCE, upstream control element.
ONCOLOGY REPORTS  33:  3131-3145,  2015 3137
synthesized by Pol I, can be used to analyze relative changes in 
rRNAs with respect to each other between tumor and normal 
samples, as well as in cell lines. We performed our analyses 
??????????????????? ????????????????????????????????????????
of normalization on expression changes in rRNA transcripts.
????????????????????????????????????????????????????????????
cancer cell lines. It is known that promoter DNA methylation 
has a repressive effect, particularly on Pol II transcribed 
genes in cancer (20,38) and increased methylation levels are 
implicated in decreased levels of rRNA transcription (22,23). 
Thus, we hypothesized that rRNA transcription levels may 
also be downregulated in these breast cancer cell lines with a 
hypermethylated 45S rDNA promoter. Total RNA was isolated 
and tested in cell lines with qRT-PCR using primers targeting 
Figure 3. Methylation status of the 45S rDNA promoter region in clinical breast cancer and matched normal tissues. (A) The methylation status of each CpG 
dinucleotide in the region spanning -381 to +53 bp was analyzed in 19 breast cancer and normal pairs. Ten randomly selected clones were sequenced from each 
????????????????????**?????????????*???????? ???????????????????????????????????????? ??????????????????????????? ??????????????????????????????????????
tumor clones and normal clones were compared to determine differentially methylated CpGs. Methylation percentages of every CpG are presented as a pie 
?????????????????????*???????? ???????????????????????????????????????????????????????????
Figure 4. rRNA transcript levels in breast cancer cell lines (A) Relative expression levels of rRNA transcripts in the breast cancer cell line panel, normalized 
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
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Pol I products 18S, 28S, 5.8S and 45S external transcribed 
spacer (ETS) region.
All of the rRNA transcripts were expressed at varying 
levels among the cell lines when normalization was performed 
???????????????????????????????????????????????????????????
when we used GM-rRNA to determine changes in the ratio of 
???????????????????????????????
??????????? ?????? ?????? ???? ?????????? ?????????
??????????? ??? ????? ???????????. To further establish the 
relationship between 45S rDNA promoter methylation and 
rRNA expression, we used the hypomethylating agent, 
????????????????????????????????????????????????????????
methyltransferases (39) and leads to increased RNA transcription. 
???? ?????????? ????????????????? ?? ???? ??? ??? ???????????????
????????????????????????????????????????????????????????????
However, proportion of rRNA transcripts did not exhibit 
????????????????????????????????????????????????????????
??????????????????????? ???? ??????????????????
?????????????????????????????????????????????????????-
itor. TSA treatment of cells affects the acetylation status of 
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????? ????????????????????????????????????????????????????????????????????? ?????????????????? ??????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????*????????????????????????????????????????????????????????????????????
??????????? ???????????????????????????????????????????????????????????????????????????????????????????? ????????????????????????? ??????????????????
mean of rRNA expression values.
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H3 and H4 and thus TSA indirectly upregulates gene expres-
sion by dispersion of the chromatin structure (39). Therefore, 
TSA was used to determine whether other mechanisms (such 
as histone acetylation) are involved in the rRNA synthesis 
besides DNA methylation. TSA treatment alone did not 
???????????????????????????????????????????????????????????????-
??????????????????????????????????????????????????????????
GM-rRNA, respectively (data not shown). Treatment with 
????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????-
scripts (Fig. 6A). However, the 5.8S proportion of rRNAs was 
????????????????????????????????????????????????????????
???????????????????????????????????????????????
???????????????????????????????????????????????????????????
altered in breast tumors. Next, we tested whether increased 
levels of methylation of the 45S rDNA promoter in tumor 
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????*????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????-
statin A; DMSO, dimethyl sulfoxide; GM-rRNA, geometric mean of the rRNA expression values.
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samples led to repressed expression levels of rRNA transcripts. 
RNA isolation was performed from the same tissue samples 
used in the methylation analysis (only 14 of 19 paired tissue 
samples had enough tissue for RNA isolation). Expression 
?????????????????????????????????????????????????????????????
differ between the tumors and corresponding adjacent normal 
tissues for any of the rRNA transcripts (Fig. 7A). However, 
when normalized with GM-rRNA, the proportion of 18S was 
????????????????????????????????????????????????????????????
???????????????????????????????????????????????
?????????????????????????????????????????????????????????
promoter methylation levels in breast cancer cell lines. There 
?????????????????????????????????????? ?????????????????? ????
rRNA expression levels or rRNA ratios in the breast cancer 
cell lines or in the MCF10A cells (non-tumorigenic cell line). 
Figure 7. Expression analysis of rRNA transcripts in clinical breast cancer and normal pairs. Relative expression levels of rRNA transcripts are shown with 
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????*????????????????????????????????????????????????????????
samples were determined using paired t-test. rRNA, ribosomal RNA; GM-rRNA, geometric mean of the rRNA expression values.
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rRNA expression levels, as well as relative rRNA proportions 
in cell lines were found to be independent of their promoter 
methylation levels (data not shown). These results indicate 
that rRNA transcripts were expressed even in the presence of 
heavy methylation at the 45S rDNA promoter.
Correlation between 45S rDNA promoter methylation 
?????????????????????????????????????????????????????. Next, 
Spearman's correlation analysis was performed to test whether 
the 45S rDNA promoter methylation levels in the breast tumor 
and matched normal samples were correlated with either rRNA 
expression levels or rRNA proportions in the rRNA pool. 
????????????????????? ????????????????????????????????
expression, no correlation between expression and methylation 
was observed (data not shown). The increase in methylation 
of the rDNA promoter levels in the normal samples was 
inversely correlated with the 18S rRNA/GM-rRNA expres-
sion ratio (Spearman r=-0.6571 and p=0.0128), yet promoter 
hypermethylation did not exhibit any correlation with 18S 
rRNA/GM-rRNA ratios in the tumor samples (Fig. 8).
Furthermore, Ct values of rRNAs transcribed from the 
45S rDNA promoter were highly correlated with each other in 
the normal samples, yet this correlation was lost in the tumor 
samples (Table III).
?????????????????????????????????????????????????????????
breast cancer?? ????????????????????? ?????????????????????-
ization) in tumor samples (n=11) was positively correlated 
with the grade of breast cancer (Spearman r=0.650, p=0.03). 
Additionally, the 28S/GM-rRNA ratio of tumor samples was 
also positively correlated (Spearman r=0.725, p=0.012) while 
the 18S/GM-rRNA ratio was negatively correlated with the 
grade (Spearman r=-0.714, p=0.014).
Discussion
A high expression of rRNA transcripts characterizes cancer 
cells but only a few studies have analyzed the expression of 18S 
rRNA in breast cancer tissues and matched normal samples. 
Previous studies have mostly focused on testing whether 
rRNA genes are suitable as reference genes (26,27). One of 
these studies found that 18S rRNA was expressed at lower 
levels in breast tumors compared to matched normal tissues in 
contrast to the general acceptance of higher rRNA expression 
in tumors (26). None of the studies, however, investigated 
whether the expression difference between breast cancer 
and normal pairs was due to rDNA promoter methylation or 
whether the ratios of spliced products of the 45S precursor 
were differentially expressed between tumor and normal pairs 
in breast cancer.
DNA methylation is a well-known phenomenon that inac-
tivates transcription by interfering with Pol II binding to the 
Table III. Correlation analysis between rRNA transcripts in tumor and normal samples.
Sample Transcript 28S rRNA 5.8S rRNA 45S ETS
??????? ????????? ??????????????a? ??????????????a? ??????????????a
? ????????? ? ??????????????a 0.674 (p=0.012)a
 5.8S rRNA   0.57 (p=0.033)a
Tumor 18S rRNA 0.042 (p=0.887) -0.051 (p=0864) 0.288 (p=0.318)
 28S rRNA  0.521 (p=0.056) 0.349 (p=0.221)
 5.8S rRNA   0.543 (p=0.045)a
????????????????????????a???????? ??????????????????????????????????????????????????????????????????????rRNA, ribosomal RNA; ETS, external 
transcribed spacer.
????????????????????????????????????????????????? ?????????????????????????????????????????????????????????? ???????????????????????????????????????????
correlation (*??????????????????????????????????????????????????????????
??????? et al:  DYSREGULATION OF rDNA PROMOTER METHYLATION AND r????????????????????3142
promoter (40); since Pol I and Pol II share common features 
and transcription factors (41-43), DNA methylation in the 45S 
rDNA promoter may have a similar effect on expression of 
rRNA genes.
We used both breast cancer cell lines and clinical breast 
cancer tissues to investigate the methylation levels of rDNA 
promoters and expression differences of rRNA transcripts, 
as well as their relationship with each other in breast cancer. 
We found that breast cancer cell lines were hypermethyl-
ated (74-96% methylation) at the 45S rDNA promoter 
region (Fig. 2). High methylation levels of rDNA promoters are 
????????????????????????????????????????????????????????????
???????? ???? ????? ???????? ???????????????? ????????????
A genome-wide analysis of aberrant methylation changes with 
????????????????????????????????????????????????????????
methylation levels increased age-dependently in both sperma-
tozoa and rat liver cells (47). If the rDNA locus is sensitive to 
accumulating random methylation over time, the high methyla-
tion levels found in breast cancer cell lines may be explained 
with long-continued culturing, a common characteristic of 
cancer cell lines.
We could not identify two populations of alleles (one popu-
lation with a hypermethylated promoter, the other population 
with a hypomethylated promoter; Fig. 2) in breast cancer cell 
lines as proposed earlier by other studies (22-25). Considering 
the repetitive nature of rRNA genes, this result may be due 
to the low number of clones (5 clones) analyzed for each 
?????????????????????????????????????????????????????????????
rDNA promoters did not repress or alter the ratio of rRNA 
transcripts (Fig. 4). rRNA expression levels and proportions of 
rRNA transcripts were found to be independent of the rDNA 
promoter methylation levels; this result may indicate that the 
methylation of the 45S rDNA promoter may not be solely 
responsible for rRNA expression or proportion changes in 
breast cancer cell lines. Completely methylated (Xenopus leavis 
sperm DNA) and unmethylated rDNA constructs were found 
???????????????????????????????????????????????????????????
Xenopus leavis oocytes (48). This is consistent with our results 
in which expression of rRNA transcripts was found to be rela-
tively independent of their rDNA promoter methylation levels.
????? ??????????????? ?? ?????? ?????? ??????????? ??????????
of some forms of mature rRNA transcripts (significant 
for 5.8S RNA and 45S ETS) unexpectedly decreased 
compared to the DMSO-treated group when normalized with 
????????????????????????????????????????????????????????????
???????? ??????? ???? ????? ????? ?????? ????? ?? ??????? ??????
demonstrated that the loss of CpG methylation of the rDNA 
????????????????????????????????????????????????????????
regions caused cryptic transcription of RNA polymerase II 
from 45S rDNA promoters. Cryptic transcription from rDNA 
????????????????????????????????????????????????????????????
???????? ????????????????????????????????????????????????????
Loss of CpG methylation at rDNA promoter regions in 
????????????????????????????????? ?????????????????????????
this cryptic RNA polymerase II transcription, which explains 
the downregulation of 5.8S and 45S ETS rRNA transcripts 
????????????????????????????????????????????????????????????
as a negative feedback loop, may be a strategy developed by 
cells to achieve a balanced expression of rRNA transcripts and 
prevent energy loss in cells in the absence of CpG methylation.
Gene expression is usually regulated by a combination of 
????????????????????????????????????????????????????????????
chromatin remodeling complexes (49). TSA treatment alone 
?????????????? ?????????????????? ??????? ??? ?? ????????????
increase in rRNA levels (Fig. 6A), yet the 5.8S rRNA ratio 
????????????????????????????????????????????????????????
rRNA transcription may predominantly be regulated by other 
transcriptional or post-transcriptional mechanisms rather than 
epigenetic regulatory processes (at least DNA methylation and 
histone acetylation) in breast cancer cell lines.
????????????????????????????????????????????????????
????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????-
ment. The change may also be due to some indirect effect of 
the drugs through other genes as both drugs affect several 
other genes along with the rDNA genes.
Further analysis of rDNA promoter methylation with the 
Wilcoxon matched-pairs signed rank test in tissues showed 
???????????????????????????????????????????????????????????????
methylation levels than their normal counterparts (Fig. 3A). 
???????????? ???????????????????????????????????????????????
within tumors and between tumor and adjacent normal tissues, 
indicating tissue- and/or locus-specificity of methylation. 
Methylation analysis of the same region in different tissues and 
types of cancer may reveal whether the methylation pattern of 
????????????????????????????????????????????????????????????????
different tissues display different methylation patterns at 
different loci (50).
??????????????????????????????????????????????????????
prognostic factor in some cancer types (31,51) including breast 
cancer (30). However, the correlation analysis of methylation 
levels with clinicopathological characteristics (as described in 
Table I) of the patients used in the present study did not show 
?????????????????????????????????? ?????????????????????????????
study on 45 paired breast tumor and normal samples could 
?????????????????????????????????????????????????????????????
of rDNA promoters, 5' regions of 18S and 28S rDNA and 
ER, PR, grade and other clinicopathological features, except 
nuclear size and grade (32). The use of larger sample sizes 
may help clarify the clinical importance of rDNA methylation 
??????????????????????????????????????????????????????????
28S/GM-rRNA) in tumors on the other hand showed a positive 
correlation with the grade of the tumor. Nuclear pleomorphism 
is one of the criteria used in the grading of breast cancer, which 
??????????????????????????????????????????????????????????????
the nucleoli (52). An increase in the expression or the ratio of 
rRNA transcripts may be responsible for the abnormal appear-
ance of nucleoli in higher grade breast cancer samples.
?????????????????????????????????????????????????????
GM-rRNA normalizations revealed different sides of the same 
coin. While the former enables measurement of expression 
??????????????????????????????????????????????????????????????
changes in the relative ratios of rRNA transcript levels. Our 
data accordingly revealed that 5.8S and 45S rRNA transcripts 
????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
line results, expression analysis of rRNA genes in the breast 
tumor and matched normal tissues showed no significant 
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????????????????????????????????????????????????????????
and 5.8S rRNAs were proportionally altered in the breast 
?????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????
the fact that they analyze separate aspects of rRNA expression.
??????????????? ????????????????????????????????????????-
strated that two rRNA forms (5.8S and 45S precursors) were 
??????????????????????????????????????????????????????????????
tissues compared to matched-benign tissues. However, meth-
ylation levels of the 45S rDNA promoter in the same prostate 
?????????????????????????????????????????????????????????????
Another study showed that loss of CpG methylation at the 
rDNA promoter surprisingly decrease rRNA transcript levels 
by disrupting rRNA synthesis and processing via activating 
cryptic transcription of rRNA genes by Pol II (25).
?????????????????????????????????????????????????????????
??????????????? ?????? ????????? ???????? ?????????????
????????????????????????????????????????????? ??????????????
RNA polymerase II transcribed gene) to normalize rRNA 
????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????
failed to identify such differences in our cohort (data not 
shown). We propose that the geometric mean (GM) of rRNAs 
synthesized by RNA polymerase I (18S, 5.8S, 28S and 45S 
ETS) to normalize rRNA expression can be used to detect 
relative changes in rRNAs with each other. GM-rRNA may 
be less prone to changes than Pol II gene transcripts since it 
is calculated from the rRNA transcripts synthesized by Pol I. 
When GM-rRNA was used for normalization, 5.8S and 18S 
?????????????????????????????????????????????????????????
downregulated, respectively, in the tumor samples compared 
??? ???? ??????? ?????? ?????? ????????? ????? ????????? ????? ????
proportion of 18S and 5.8S rRNA in the total rRNA pool 
changed in the opposite direction while total rRNA levels 
may be relatively constant. We found that methylation levels 
of normal samples (which exhibit mixed methylation patterns) 
showed a negative correlation with the 18S rRNA/GM-rRNA 
expression level but this correlation was disrupted in the tumor 
?????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
expression of one or more rRNA transcripts but not all.
Some forms of polycistronic mRNAs and miRNAs that 
are expressed from the same promoter have been shown to be 
post-transcriptionally regulated and exist at different levels in 
plants (53,54). The SNRPN-SNURF gene, possessing a biscis-
tronic structure and sharing a common promoter, for example, 
is differentially expressed, as identified by both northern 
blot and microarray analysis in mammalian cells (55,56). As 
reported in other studies, genes that are expressed from the 
same promoter can be differentially expressed by other mech-
anisms apart from the effect of basal transcription machinery.
The maturation of ribosomes is a complex process assisted 
by multiple factors (~200) that need to be orchestrated in 
harmony (57,58). Alteration in the methylation levels of 
rDNA promoters may have an effect on rRNA stabilization, 
which could leads to this non-proportional change in rRNA 
transcripts. Moderate levels of rDNA promoter methylation 
(as observed in normal samples) may still be regulating 18S 
rRNA levels but this correlation is disrupted in tumor samples, 
possibly due to the high methylation levels found in the 
45S rDNA promoter. Another possibility is that methylation 
levels can indirectly affect splicing, post-transcriptional modi-
??????????????????????????????????????????????????????????????
that normal samples showed a higher correlation between rRNA 
transcript expression while this correlation was disrupted in 
tumor samples supported this possibility (Table III), indicating 
that the methylated promoter of 45S rDNA in tumors may have 
an effect on the processing of rRNAs.
?????????????????????????? ????????????????????????????-
dent on snoRNAs, any change in snoRNA levels globally may 
?????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????
28S rRNA and was shown to be altered by somatic rearrange-
ments, mutations and deletions in prostate cancer (59), breast 
????????????????????????????????????????????????????????????
Another snoRNA, GAS5, was also found to be downregulated 
in breast cancer (63). Increased methylation levels of rDNA 
??????????????????????????????????? ??????????????????????????
need to be better analyzed in future studies.
In conclusion, we found that rRNA transcripts were 
expressed independently of the hypermethylated 45S rDNA 
promoter region in breast cancer cell lines. However, the 
18S rRNA/GM-rRNA ratios were significantly correlated 
with methylation levels in the normal samples but not in the 
tumor samples. Promoter methylation of rDNA promoters 
appears to have a different role than regulating the expres-
sion of rRNA transcripts in breast cancer. It may be used as a 
mechanism to stabilize and protect these essential genes under 
any circumstances. rDNA repeats have been proposed to be 
responsible for genomic stability (64) and hypomethylation 
of rDNA promoter has been implicated in decreased genomic 
stability (65,66). Increased methylation of the rDNA promoter 
in tumor cells may be an indicator of the tumor cell effort to 
restore impaired genomic stability. Future research is needed 
to evaluate the cause of relative expression changes observed 
among rRNA transcripts in tumors and their relationship with 
rDNA promoter methylation.
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